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Abstract:  
Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting 
for 30% of all deaths. Coronary artery disease (CAD - narrowing of arteries), most common 
type of CVD, results in altered shear stress that can affect platelets and endothelial cells 
(EC). Activated platelets and EC can express/secrete adhesion ligands, and inflammatory 
molecules, further promoting CVD. Previous functional studies utilized constant shear 
stress to activate either platelets or EC without considering EC/platelet communication. 
These conditions are not physiological. Therefore, we exposed platelets and EC together 
to physiological dynamic shear stress to study platelet and EC responses and signal 
pathway activation. Our results indicated that platelets showed increased PECAM-1 and 
decreased GPIbα and GPIIb expression, whereas EC showed increased soluble vWF 
expression and EMP generation in response to dynamic shear stress. We also found 
signaling pathway (MAPK and NF-κB) activation. Our results demonstrated that platelets 
enhance shear induced EC activation, which in turn leads to platelet-EC crosstalk that 
returns the activation level towards equilibrium by modulating platelet activation. 
Arteriogenesis (remodeling of collateral arteries), a natural defense mechanism, 
attempts to preserve blood flow during CAD. Placental growth factor (PLGF) is a key 
arteriogenic growth factor. Diabetes is known to inhibit arteriogenesis, but how diabetes 
affects platelet uptake/release of PLGF, EC PLGF expression, and the underlying 
molecular mechanisms regulating PLGF has not been studied. Our results demonstrated 
that 1) platelets can take up PLGF; 2) simulated acute hyperglycemia (glucose treatment) 
and chronic hyperglycemia (AGE treatment) are the major contributors to impaired PLGF 
expression in cardiac and skeletal muscle cells; 3) elevated dynamic shear stress increases 
PLGF production by EC, and AGE can negatively modulate this effect; and 4) Western 
diet consumption can increase AGE levels in mouse skeletal muscle. We conclude that 
inhibition of PLGF expression by AGE contributes to impaired arteriogenesis in diabetes. 
Findings from this study have advanced our knowledge of how platelets and EC 
interact in various physiological and pathophysiological settings, suggesting their 
contribution to CAD development. We also identified a possible mechanism for impaired 
arteriogenesis in diabetic patients. Thus, our study has the potential to lead to therapeutic 
innovations. 
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CHAPTER I 
 
 
INTRODUCTION 
 
Cardiovascular diseases (CVD) are the number one cause of death around the world. 
According to the statistics from American Heart Association, in the USA, CVD accounted for about 
31.3% of total deaths and affected approximately 86 million people in 20111. Every year, over $320 
billion is spent on direct and indirect medical care costs of CVD treatment and prevention in the 
USA alone2. Coronary artery disease (CAD) is the most common type of CVD and is characterized 
by localized narrowing (or stenosis) of the coronary arteries, resulting in decreased blood supply to 
different regions of the heart. Narrowing of arteries mainly occurs by the accumulation of lipids 
and fats in the inner lining of the endothelium of the blood vessels, induction of inflammatory 
responses, and formation of localized plaques. The plaques stiffen the blood vessel wall, which is 
widely known as “hardening of the arteries” or atherosclerosis. Atherosclerotic plaque can form in 
both large (macro-vessels involving arteries and veins) and small (micro-vessels involving 
capillaries and collaterals) blood vessels. Macrovascular plaque formation can lead to CAD, 
peripheral artery disease (PAD), and cerebrovascular diseases, whereas microvascular 
complications lead to disease conditions such as diabetic retinopathy, and neuropathy. Major 
determining factors for atherosclerotic plaque formation are 1) the location and 2) the geometry of 
the blood vessels. In the coronary circulation, the left coronary artery, especially areas near the 
bifurcation of the left anterior descending artery and the left circumflex artery, are vulnerable to 
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plaque formation due to their complex geometrical structure. In these regions, altered blood flow 
generates low recirculatory shear stress or oscillatory shear stress, which are considered to be 
atherogenic3.  
Peripheral artery disease (PAD) is another chronic circulatory disorder during which fatty 
substances deposit under the endothelium of the peripheral arteries limiting blood flow in the upper and 
lower limbs of the body. It is the leading cause of critical limb ischemia and amputation, as PAD often 
remains undiagnosed until the late stage. PAD affected around 18 million US people in 2010, which is 
predicted to reach 21 million by the year 20204;5. Diabetic people are predisposed to develop 
cardiovascular diseases (such as CAD, PAD), at least 2-3 times more, and suffer greater complications. 
Currently, above 29 million US people have diabetes, and around 40% of them are diagnosed with 
PAD6-8.  
During both PAD and CAD development, endothelial cells (EC) and platelets, two major cell 
types of our body, become dysfunctional and undergo activation, further promoting disease 
progression. EC are the innermost layer of the arteries and platelets are circulating blood cells. Thus, 
both of these cell types are continuously exposed to blood flow. Hence, any changes in blood flow 
induced shear stress can greatly affect the normal functions of EC and platelets. Activated EC, 
stimulated by biochemical or biomechanical changes, express many adhesion ligands, secrete numerous 
cytokines, inflammatory molecules, and growth factors, and interact with circulating blood cells 
including platelets. Interaction between activated EC and platelets can induce platelets to secrete 
different biochemical substances which can further activate EC or nearby quiescent platelets, leading 
to thrombosis9. Studies have demonstrated that local shear stress conditions play a major role in EC 
and platelet activation, as well as cardiovascular and peripheral disease progression10;11. Although many 
in vitro studies have been conducted characterizing functional changes of platelet and EC in response 
to shear stress, most of these studies used constant shear stress to activate platelets and EC, which is 
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not physiologically relevant12-14. Also, most of these studies have investigated the effect of constant 
shear stress only on either platelet or EC without considering the effect of platelet-EC communication 
on modulation of their responses. Therefore, in our studies, we have exposed platelet and EC under 
physiologically relevant dynamic shear stress, found in healthy and diseased left coronary artery, using 
a cone-plate shearing device in vitro and investigated post shear platelet responses through platelet 
surface glycoproteins PECAM-1, GPIb, GPIIb expression, and platelet microparticle generation. EC 
responses were also assessed through vWF and TF expression, and endothelial microparticle 
generation. Physiological relevance was further enhanced through an ex vivo study where freshly 
harvested rat aortas were exposed to dynamic shear stress for quantification of EC activation (vWF and 
ICAM-1) and inflammatory (TF) responses. Since, variation in shear stress can be transmitted from EC 
cell surface to nucleus via different signaling pathways to change functional responses, we also have 
investigated the effect of dynamic shear stress on MAPK and NF-κB pathway activation.    
Activation and interaction of EC and platelets can narrow arteries through formation of plaques, 
decreasing oxygen and nutrient supply to distal tissues, which in acute conditions can lead to 
myocardial infarction (MI) or heart attack. However, the body has a natural defense mechanism that 
attempts to preserve blood flow in the downstream regions of the occluded blood vessels. This is a 
bypass mechanism known as arteriogenesis or radial enlargement of small pre-existing interconnecting 
collateral arteries, which under normal conditions carry little blood due to their high resistance. In the 
presence of an occlusion in the upstream regions of a main artery, collateral arteries remodel to carry 
an increased amount of blood, thus reducing ischemic tissue damage. Unfortunately, the extent of 
arteriogenesis varies greatly among people, and is negatively affected by disease conditions like 
diabetes. Surgical intervention to reopen or replace blocked arteries is not always feasible in many 
people with CAD and PAD, due to physical condition or age. Also, statistics show that 25 – 30% of 
CAD patients fail to revascularize even after coronary or femoral artery bypass surgery and have a 
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higher occurrence of restenosis15. Therefore, therapeutic stimulation of collateral artery growth is 
potentially a valuable and more desirable treatment for these patients than surgical intervention.  
EC and platelets can contribute to arteriogenesis through the production/transportation of 
growth factors and modulation of growth factor receptor expression. During PAD or CAD 
development, the pressure gradient across the collateral arteries increases, elevating blood flow induced 
shear stress on the vessel wall and thus affecting cellular activities. Since shear stress has been shown 
to be a primary modulator of arteriogenesis, numerous studies have investigated the role of shear stress 
in activating EC and stimulating arteriogenesis through the release of growth factors16;17. However, 
most studies have focused on vascular endothelial growth factor-A (VEGF-A), which primarily 
promotes capillary proliferation, not arteriogenesis. Therefore, in our studies, we focused on placental 
growth factor (PLGF), a growth factor which is more specific for arteriogenesis. We have studied for 
the first time, how platelets can take up or release PLGF in response to physiologically relevant dynamic 
changes in shear stress. Our study also investigated how PLGF expression is modulated in different cell 
types (endothelial cells, cardiac muscle cells, and skeletal muscle cells) by diabetes-associated 
metabolic dysfunction. Diabetes, a serious metabolic disorder, can cause dysregulated expression of 
growth factors and receptors18. Diabetes is characterized by several metabolic dysfunctions such as 
hyperglycemia, hyperlipidemia, hyperinsulinemia, and oxidative stress. Sustained hyperglycemia leads 
to production of advanced glycation end products (AGE), and persistent hyperlipidemia increases low 
density lipoprotein (LDL) levels. Both of these compounds can greatly affect normal functions of EC 
and platelets19.  
Results from in vivo studies previously conducted in our lab have demonstrated that metabolic 
dysfunctions induced through 6 mo of Western diet feeding reduces tissue level PLGF expression in 
mice. Therefore, another goal of this study was to factor out which specific metabolic parameters have 
the greatest impact on cellular level PLGF expression, and to begin identifying the underlying 
mechanisms by which these parameters act to reduce PLGF in tissue levels. In addition, we asked 
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whether metabolic dysfunction would influence shear stress mediated PLGF expression at the 
molecular level, and which pathways would be involved. 
In summary, the major goals of this study were to investigate the effects of physiologically 
relevant dynamic shear stress, cell-cell communication, and diabetes-associated metabolic factors on 
platelet and EC activities, and to understand how the changes in their behavior can contribute to 1) 
CAD progression and 2) arteriogenesis. Signaling pathways involved in modulation of cellular 
functions were also studied. Findings obtained from this study have provided insight into how dynamic 
shear stress and diabetes-associated metabolic dysfunction can modulate EC and platelet behavior, and 
may lead to potential therapeutic approaches to treat CAD progression or diabetic CAD/PAD. 
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CHAPTER II 
 
 
SPECIFIC AIMS AND SIGNIFICANCE 
 
The global hypothesis of this study was that blood flow induced pathological dynamic 
shear stress can regulate platelet and endothelial cell activities and lead to the progression of certain 
types of cardiovascular disease (CVD). CVD progression in turn can cause increased blood velocity 
through narrowed vessels, resulting in altered shear stress that can trigger compensatory collateral 
vessel remodeling (arteriogenesis) through further modulation of platelet and endothelial cell 
behavior. Presence of disease conditions such as diabetes can inhibit arteriogenesis. Therefore, we 
further hypothesized that presence of diabetes associated metabolic dysfunction and cell-cell 
interactions play important roles both in CVD development and in compensatory mechanisms for 
CVD. These hypotheses were tested through the following specific aims. 
Specific aim 1: The goal of this aim was to measure platelet and endothelial cell (EC) 
responses under physiologically relevant dynamic shear stress conditions in vitro, and to 
determine whether the presence of one cell type affects the responses of the other to shear. In 
addition, the effects of dynamic shear stress on endothelial cell responses ex vivo, in a rat 
aorta model, was also investigated. Dynamic shear stress was applied on platelets in 
absence/presence of EC using a cone-plate shearing device in vitro. Post-shear, platelet responses 
were assessed by measuring cell surface PECAM-1, GPIb, and GPIIb expression, as well as 
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platelet microparticle generation. EC responses were assessed by measuring cell surface and 
released von Willebrand factor (vWF) levels and tissue factor (TF) expression, as well as EC 
microparticle generation. ex vivo study was conducted by exposing freshly harvested rat aorta to 
dynamic shear stress in a perfusion flow chamber, followed by measurement of EC activation and 
inflammatory responses through vWF, ICAM-1, and TF protein expression.  
Specific aim 2: The goal of this aim was to study signaling pathways involved in endothelial 
cell responses to dynamic shear stress. EC were exposed to dynamic shear stress and MAPK 
pathway activation was assessed through quantification of p38, JNK, and ERK1/2 protein 
phosphorylation. NF-κB pathway activation was measured through NF-κB p65 protein 
phosphorylation. 
Specific aim 3: The goal of this aim was to characterize the uptake/release of endothelial 
growth factors by platelets, and to test the effect of dynamic shear stress on these processes. 
Platelets were incubated with different concentrations of recombinant human placental growth 
factor (PLGF) or vascular endothelial growth factor (VEGF-A), after which PLGF and VEGF-A 
uptake by platelets was quantified. The effect of shear stress, hyperglycemia, or calcium ion 
chelation on uptake/release of PLGF and VEGF-A was also assessed after exposing platelets to 
these conditions in the presence of recombinant human PLGF or VEGF-A.  
Specific aim 4: The goal of this aim was to quantify the effect of diabetes-associated major 
metabolic dysfunction on the expression level of PLGF and vascular endothelial growth 
factor receptor 1 (VEGFR1, the receptor for PLGF) in mouse and human cell. Coronary artery 
EC, cardiac muscle cells, and skeletal muscle cells from both mouse and human were treated with 
low density lipoprotein (LDL), oxidized LDL, advanced glycation end products (AGE), and 
hydrogen peroxide, followed by quantification of PLGF level and cell surface VEGFR1.  
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Specific aim 5: The goal of this aim was to investigate the effects of glucose, advanced 
glycation end products (AGE), and the presence of smooth muscle cells (SMC) on dynamic 
shear stress-stimulated EC PLGF expression, and to identify the signaling pathways involved. 
EC-SMC co-cultures were exposed to dynamic shear stress in the presence or absence of glucose 
or AGE, followed by quantification of EC produced PLGF expression levels. Involvement of 
signaling pathways was investigated by assessing EC RAGE, Nox2 and Nox4, HO-1, MCP-1, and 
TNF-α levels.   
Specific aim 6: The goal of this aim was to discover the key underlying molecular mechanisms 
by which a Western diet induces dysfunctional PLGF expression in mouse skeletal muscle. 
Thigh (quadriceps femoris, QF) and calf (gastrocnemius/plantaris/soleus, G-P-S) muscles of 
control diet (CD) and Western diet (WD) fed C57/BL6J and ApoE-/- mice were collected. Tissue 
AGE levels were quantified, and the activity of associated signaling pathways was assessed through 
measuring tissue RAGE, Nox2 and Nox4, HO-1, MCP-1, and TNF-α expression.  
Many studies have investigated the effects of shear stress on platelets and EC20;21. The 
major limitations of these studies include 1) use of simplified constant shear stress and 2) lack of 
consideration of platelet-EC or EC-SMC communication/interaction. In the current studies, we 
addressed these limitations by exposing cells to physiological and pathological dynamic shear 
stress. We also tested the effect of cell-cell interaction on platelet and EC activities. In addition, we 
assessed the effect of Type 2 diabetes associated metabolic dysfunction on modulation of platelet 
and EC behavior. The physiological relevance of our research was further enhanced through the 
inclusion of ex vivo animal studies. The results obtained from this study have advanced our 
understanding of how shear stress, cell-cell interactions, and metabolic parameters influence both 
CVD development and adaptive responses (such as arteriogenesis) to CVD, and may lead to 
potential therapeutic solutions.  
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CHAPTER III 
 
 
REVIEW OF LITERATURE 
 
This study had two sections. In the first section, we have characterized changes in platelet 
and EC activation responses (through quantification of adhesion ligands and inflammatory 
molecules expression) under dynamic shear exposure to understand how they can contribute to 
CAD progression. The second section focused on how the key arteriogenic growth factor 
uptake/release, production, and growth factor receptor expression by platelet and EC are modulated 
in presence of diabetes associated metabolic parameters to understand the role of platelet and EC 
in arteriogenesis during diabetic CAD/PAD. Therefore, the literature review of these two sections 
are presented separately referring as study 1 and study 2. 
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3.1 Study 1 
Atherosclerosis, a chronic inflammatory disease of the vasculature, is the underlying cause 
of coronary artery disease, peripheral artery disease, stroke, and heart attack. Arteriosclerosis is a 
type of atherosclerosis that refers to thickening and stiffening of the arteries. Under normal healthy 
conditions, the endothelium (the inner lining of the arteries) maintains vascular permeability and 
provides an atheroprotective environment. During atherosclerosis, this atheroprotective state is 
disrupted by EC dysfunction, which is characterized by increased permeability of the endothelium 
to macromolecules such as low density lipoprotein (LDL), increased adhesion of platelets and 
leukocytes, and upregulation of inflammatory molecules expression. As a result of these changes, 
LDL passes through the damaged endothelium and accumulates in the subendothelial space. White 
blood cells (particularly leukocytes and monocytes) transmigrate across the endothelium, after 
which they release enzymes, oxidize LDL, and initiate inflammatory signal cascades. With time, 
the accumulating inflammatory cells, cholesterol, and oxidized lipids form plaques that narrow the 
artery lumen and may eventually completely block the artery. Narrowing of the arteries alters both 
blood velocity and blood flow induced shear stress, factors that have been found to influence 
normal vascular cell activities and functions. 
3.1.1 Blood vascular system 
 Blood vessels are blood carrying conduits that are flexible enough to move freely with the 
underlying tissues, but strong enough to accommodate changes in blood pressure. In the 
cardiovascular system, blood vessels are classified into five main categories: arteries, arterioles, 
capillaries, venules, and veins. Blood vessels that carry blood away from the heart are known as 
arteries and are the primary focus of these studies. The wall of arteries is composed of three distinct 
layers: the tunica interna, tunica media, and tunica externa. The tunica interna, the innermost layer 
of an artery, consists of a monolayer of endothelial cells (EC) surrounded by extracellular 
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membrane (ECM) proteins and a thick underlying elastic fiber layer. The tunica media, the middle 
layer of an artery, is composed of a concentric layer of smooth muscle cells (SMC) surrounded by 
extracellular basement membrane, and is separated from the tunica intima and tunica externa by 
the internal and external elastic laminae. In large arteries, the tunica media contains many layers of 
SMC. Contraction and relaxation of these SMC modulates the radius of the blood vessel and 
accommodates changes in blood pressure and/or volume. The tunica externa, the outermost layer 
of an artery, is composed mainly of collagen fibers and fibroblasts. The connective tissue of this 
layer blends into the surrounding tissue and provides anchorage and stability of the blood vessel.  
3.1.2 Hemodynamics of coronary artery blood flow  
Coronary arteries, which originate from the aortic root, supply oxygen- and nutrient- rich 
blood to the cardiac muscle to support the proper function of the heart. The left main coronary 
artery (LMA), supplies blood to the left side of the heart and has two major branches: the left 
anterior descending artery (LAD) and the left circumflex artery (LCA) (shown in Figure 3.1A).  
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Figure 3.1: (A) Exterior anatomy of the heart. Atherosclerotic plaque formation has caused 
narrowing of the LAD, resulting in insufficient blood flow eventually leading to heart attack and 
muscle death in the region downstream of the occlusion. (B) Enlarged schematic representation of 
the atherosclerotic plaque inside the LAD branch. A blood clot has blocked blood flow completely, 
causing a heart attack (NIH NHLBI, 2015)22. 
The LMA is characterized by complex vascular geometry (such as bifurcations, twists, and 
curvature) and varying shear stress regions (due to flow skewing and flow separation). Therefore, 
the LMA has a high potential to develop atherosclerotic lesions23. Likewise, the presence of 
complex secondary flow (due to the curvature) and a bifurcation in the upstream region makes the 
LAD vulnerable to atherosclerosis (Figure 3.1B). The formation of atherosclerotic plaque inside 
the artery narrows the vessel diameter, altering local blood flow conditions and resulting in 
elevated, low, and/or oscillatory shear stress. It is well established that shear stress levels from 1.5-
7 Pa are atheroprotective, whereas low shear stress (below 0.4 Pa) is atherogenic, and elevated 
shear stress (above 7 Pa) is pro-thrombotic on vascular EC24-26.  
As platelets travel along the blood vessel wall, they are exposed to shear stress at a 
magnitude similar to that experienced by EC. The large shear stress gradient within the stenotic 
(narrowed) region of an artery can rapidly activate platelets. Similarly, recirculation shear stress 
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conditions downstream of the stenosis can promote EC activation, possibly leading to platelet 
activation. Several studies have reported that platelet and EC activation is dependent on both shear 
stress magnitude and shear exposure duration27;28. Therefore, it is necessary to characterize platelet 
and EC responses under physiologically relevant dynamic shear stress conditions that replicate both 
normal and diseased states. 
3.1.3 Endothelial cells  
The endothelium is the innermost layer of the blood vessels and acts as a barrier between 
blood and tissues. Endothelium is comprised of endothelial cells (EC) which have a critical role in 
maintaining normal vascular function. ECs are ~10-20 µm in diameter, flat, cobblestone-like in 
shape, and have central nuclei. Under physiological conditions, the major function of EC is to 
maintain hemostasis. The other functions of EC include regulation of vascular permeability, 
transportation of molecules (nutrients, oxygen, waste) between blood and surrounding tissues, 
maintenance of an atheroprotective environment through production of nitric oxide (NO) and other 
mediators, and regulation of angiogenesis/arteriogenesis. EC release various vasoactive 
compounds (NO, prostaglandin, endothelin) that regulate vascular diameter and blood flow through 
acute responses such as vasodilation and vasoconstriction. These vasoactive compounds can inhibit 
platelet adhesion and aggregation as well29. However, under pathological conditions, in the 
presence of biochemical agonists (inflammatory cytokines including tumor necrosis factor-α, 
interleukin-6, thrombin, and ADP) and biomechanical agonists (shear stress), EC become activated 
and these normal activities are impaired. Activated EC release various mediators that are pro-
coagulant and inflammatory in nature, and express adhesion molecules on their surface to facilitate 
adherence of platelets and leukocytes which may lead to thrombosis, atherosclerosis, and other 
inflammatory responses.  
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3.1.4 Endothelial cells and shear stress 
Due to the pulsatile nature of blood flow, vascular EC and SMC are continuously exposed 
to blood flow induced shear stress and stretch. However, shear stress primarily affects EC, whereas 
cyclic stretch impacts SMC. Therefore, EC are sensitive to shear stress variation. Alterations in 
shear stress can be sensed by EC and converted to intracellular signals that can affect gene 
expression and cause structural and functional changes (such as remodeling, proliferation, 
migration) in EC.  
In the vasculature, shear stress is defined as the tangential frictional force applied by 
flowing blood on the vessel wall. Assuming blood as a Newtonian fluid (fluid with a constant 
viscosity and laminar flow pattern), shear stress can be calculated using the following equation:  
𝜏 =  𝜇(
𝑑𝑢
𝑑𝑦
) (Equation 1) 
where τ is shear stress, μ is blood viscosity, u is blood velocity, y is distance from the vasculature 
surface, and (
𝑑𝑢
𝑑𝑦
) is the velocity gradient or shear rate. 
Another way of quantifying shear stress in the vessel wall is using Hagen-Poiseuille’s equation:  
𝜏 =  
4𝜇𝑄
𝜋𝑟3
 (Equation 2) 
where τ is shear stress, μ is blood viscosity, Q is blood flow rate, and r is the internal radius of the 
vessel. 
This equation is only applicable when the blood vessel is assumed to be a straight, inelastic 
cylinder where blood flow is laminar, steady, and behaves as a Newtonian fluid. This formula does 
not strictly replicate the blood flow exerted shear stress environment. However, because of the high 
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expense of imaging techniques like magnetic resonance imaging (MRI) and the unfeasibility of 
direct in vivo quantification of shear stress, the equation is useful for general approximation.  
Detection of shear stress and transformation of mechanical force into intracellular signals 
has been a fascinating field of study for the last few decades. After years of study, researchers have 
found that EC can detect and respond to any changes in shear stress using integrins (GPIa/IIa, α5β1), 
ion channels, receptors (VEGFR1/2/3), and adhesion molecules (PECAM-1) on their surface30-33. 
Blocking these proteins demonstrates that they act as mechanosensors, since a significant reduction 
in shear stress mediated signaling and corresponding changes in EC responses occurs following 
their inhibition34-36. After detecting a change in mechanical stimuli through these multiple 
mechanosensors, the EC transmits the signal from its surface to the nucleus via a network of 
signaling pathways, including the protein kinase C (PKC) pathway, the PI3K pathway, and the 
mitogen activated protein kinase (MAPK) pathway. Numerous studies confirmed the role of shear 
stress in activation of these pathways37;38. Shear mediated activation of different MAPK family 
members, such as ERK1/2 and JNK, has been found to regulate various transcription factors 
including NF-κB, which in turn controls gene expression of various proteins involved in cell 
activation (TNF-α), adhesion (ICAM-1), and inflammation (interleukins)39-42.  
The effect of shear stress on adhesion molecule expression/activation is of interest, since 
EC can interact with platelets and leukocytes using different adhesion glycoproteins present on 
their surface. Increased interaction may facilitate platelet and leukocyte adhesion, activation, and 
subsequent initiation and formation of atherosclerotic plaques. Some of the major adhesion 
molecules expressed/released by EC are intracellular adhesion molecule (ICAM-1), vascular cell 
adhesion molecule (VCAM-1), P-selectin, and von Willebrand Factor (vWF). In addition, the pro-
thrombotic protein tissue factor (TF) plays a major role in thrombus formation, which can acutely 
occlude arteries already narrowed by atherosclerotic plaque and is the immediate cause of many 
heart attacks and strokes. The expression of all of these proteins can be affected by shear stress. 
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Nagel et al. reported up-regulation of ICAM-1 expression on human umbilical vein endothelial 
cells (HUVEC) when the cells were exposed to steady shear stress of 0.25-4.6 Pa13. Sampath et al. 
observed increased ICAM-1 mRNA expression when HUVEC were exposed to constant shear 
stress of 2.5 Pa for 12 hr14. However, ICAM-1 mRNA expression returned to basal levels with 
longer shear exposure duration (24 hr). Lin et al. reported that 1.2 Pa shear stress could induce a 
rapid but transient induction of tissue factor (TF) mRNA expression in HUVEC20. Beside ICAM-
1 and TF, altered shear stress can also affect the expression of vWF by/on EC, as well as generation 
of endothelial cell microparticles. Results from these studies indicate that EC activated by altered 
shear stress can play a major role in CAD development. 
3.1.4.1 Intracellular adhesion molecule-1 (ICAM-1) 
ICAM-1 is a transmembrane glycoprotein of 95 kDa molecular weight, present on the EC 
and leukocyte cell surface. A low level of ICAM-1 is always present on the resting EC membrane 
and increases during cell activation. Therefore, ICAM-1 is often used as an activation marker for 
EC. Many studies have investigated the effects of shear stress on ICAM-1 expression. A study by 
Tsuboi et al. found a 2.7-fold increase in ICAM-1 expression after HUVEC were exposed to shear 
stress at 1.5 Pa in a parallel plate flow chamber for 4 hr, compared to non-sheared HUVEC43. A 
study by Nagel et al. reported a time-dependent and shear stress magnitude-independent 
upregulation of ICAM-1 expression in HUVEC in response to shear stresses varying between 0.25 
to 4.6 Pa for 24 hr13. Morigi et al. also observed an increase in ICAM-1 expression after exposing 
HUVEC to 0.8 Pa shear stress44. Tsou et al.’s study indicated that ICAM-1 expression was 
enhanced as shear stress magnitude increased when human aortic endothelial cells (HAEC) were 
simultaneously exposed to TNF-α and shear stress (0 to 1.6 Pa for 4 hr)45. In a recent study 
conducted by Yin et al., dynamic shear stress (normal, low, and high) was used to stimulate bone 
marrow vascular EC46. Their results demonstrated a significant increase in ICAM-1 expression 
under the pathological low shear stress (0-0.4 Pa) condition, compared to the normal (0.05 to 1 Pa) 
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shear stress condition. A study by Davies et al. revealed that ICAM-1 expression was elevated in 
atherosclerotic regions, which further enhanced disease progression47. It is thus clear that EC 
surface ICAM-1 expression can be regulated by shear stress and can contribute to CVD.  
3.1.4.2 Tissue factor (TF) 
 Tissue factor is a 47 kDa membrane bound glycoprotein that plays crucial role in blood 
coagulation during blood vessel injury. Activated/injured EC and leukocytes express TF on their 
surface and release soluble TF that binds to factor VII (coagulation factor, present in plasma) nearly 
irreversibly to form a TF:VII complex. This enzymatically inactive complex anchors to the TF 
expressing cells and is quickly (within 20 sec of vessel injury) cleaved to produce an active TF:VIIa 
complex. The TF:VIIa complex eventually activates factor Xa, leading to insoluble fibrin (a fibrous 
protein that facilitates blood clotting) formation.  
An elevated level of TF is observed in EC under conditions of vascular injury, 
inflammation, and in the presence of various agonists (including serotonin, histamine, smoke, and 
shear stress). TF enhances expression of various coagulation factors including FIIa, FVIIa, and 
FXa. FIIa induces platelet activation through interaction with glycoproteins GPIbα and GPIIb/IIIa, 
whereas FVIIa and FXa induce MAPK pathway activation and NF-κB activation in EC48.  
Several studies have investigated the effects of shear stress on EC TF expression. Houston 
et al. exposed EC to shear stress of 1.5 Pa for up to 3 hr in a parallel plate flow chamber and found 
increased TF gene expression with increased shear exposure duration49. They also conducted an in 
vivo study where increased TF expression in the stenosed region of the artery wall was observed. 
Lin et al. reported a transient increase (within 4 to 6 hr) in TF activity after exposing HUVEC to 
shear stress at 1.2 Pa in a flow channel for 12 hr20. These studies suggest that TF expression level 
of EC is regulated by variations in shear stress. 
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3.1.4.3 von Willebrand factor (vWF) 
 vWF is a multimeric adhesion glycoprotein that has a major role in thrombus formation 
initiation. It acts as a bridging molecule between two platelets or between a platelet and exposed 
sub-endothelium, facilitating platelet-platelet and platelet-EC interaction. vWF multimers are of 
high molecular weight (>10,000 kDa) as they are composed of  many identical subunits (each 
subunit is 250 kDa)50. vWF is exclusively synthesized in EC and megakaryocytes, and therefore is 
commonly used as an immunohistochemical marker for identifying EC. Depending on the size and 
location of the blood vessels, the level of vWF expression can vary. It has been observed that EC 
of larger blood vessels tend to have elevated vWF expression, compared to EC of microvessels51;52. 
 vWF is stored in Weibel-Palade bodies of EC and α-granules of platelets. There is also 
some (~15%) vWF circulating in plasma. Upon cell activation, stored vWF is expressed on the cell 
surface and secreted into the plasma, increasing the local concentration of vWF53. Secreted vWF 
molecules have high thrombotic potential, as they can efficiently capture circulating platelets 
through multiple interaction sites. ADAMTS13 (a proteolytic enzyme) limits unnecessary 
thrombus formation by cleaving vWF, regulating the multimer size54. 
During vascular damage and exposure of the sub-endothelium, vWF is required for platelet 
adhesion, especially under high shear stress. Through GPIbα, platelets can adhere to the injured 
vessel wall by binding to vWF55. This vWF-GPIbα interaction causes intercellular signaling, 
platelet activation, and further engagement of other collagen receptors (such as α2β1). In this 
process, glycoprotein GPIIb/IIIa also becomes activated and binds to fibrinogen or vWF to form 
platelet aggregates. Under pathological conditions, aggregation may continue, unless regulatory 
mechanisms are triggered or the blood vessel becomes occluded.  
Since shear stress can modulate EC and platelet responses, several studies have 
investigated the effects of shear stress on expression and function of vWF. A study by Ruggeri et 
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al. reported that platelet adhesion was modulated only by GPIbα-vWF interaction at a shear rate of 
>500s-1 to 1000s-1 56. At that shear rate, the adhesive function of vWF is essential for the initial 
attachment of platelets to the thrombogenic blood vessel wall. Galbusera et al. found a shear stress 
magnitude dependent increase in levels of vWF in HUVEC cell supernatants after exposing 
HUVEC to 0.2, 0.8, and 1.2 Pa shear stress for 6-15 hr57. Though these researchers found a shear 
stress magnitude dependent increase in surface/released vWF expression, altered shear stress did 
not induce any change in vWF mRNA expression, indicating enhanced expression/secretion of 
stored vWF without an increase in new protein synthesis.  
3.1.4.4 Endothelial microparticle generation 
 Endothelial microparticles (EMP) are small vesicles (<1.5 µm) shed from the EC 
membrane upon EC activation, injury, or during apoptosis. Activation/injury induces an increase 
in the intracellular calcium concentration, which subsequently causes translocation of 
phosphatidylserine (PS), activation of cytosolic enzymes, and cleavage of the cell membrane 
leading to membrane budding, i.e., EMP generation. Both biochemical (TNF-α, reactive oxygen 
species, inflammatory cytokines) and biomechanical (shear stress) stimulation can induce EC 
activation leading to EMP generation. 
EMP contain phospholipids, coagulation proteins (tissue factor, thrombomodulin), and 
various adhesion molecules (vWF, ICAM-1, PECAM-1), since they are generated from activated 
EC58-60. EMP bind to different coagulation factors using surface phospholipids, and transfer TF to 
other cells (such as monocytes and platelets) through surface adhesion molecules resulting in pro-
coagulant and pro-inflammatory responses61-63. EMP can also increase stiffness of arteries, decrease 
vasodilation by modulating nitric oxide production, and promote thrombus formation64. Recent 
studies demonstrated that EMP contain transcription factors, mRNA, and microRNA, indicating 
their many possible regulatory roles65;66. A gene profiling study reported that EMP generation 
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induced by thrombin eventually leads to activation of the transcription factor NF-κB67;68. Several 
groups have also studied MP generation upon shear stress exposure69;70. A study conducted by Vion 
et al. has reported that alterations in shear stress induce activation of Rho kinase and the ERK1/2 
pathway, eventually leading to enhanced EMP release. In this study, HUVEC exposed to 0.2 Pa 
shear stress for 24 hr demonstrated increased EMP generation in a time dependent manner70.  
 Though the presence of EMP in blood is a normal phenomenon, elevated EMP generation 
can be an indication of endothelial activation and dysfunction. Therefore, EMP generation has been 
quantified in many clinical studies as a marker of EC activation. Elevated levels of EMP have been 
correlated with alterations in shear stress under various pathological conditions including end-stage 
renal disease, acute coronary syndrome, hypertension, and atherosclerosis71-74. 
3.1.5 Signaling pathway  
 Signaling pathways are complex networks of protein components that transmit biochemical 
signals from the cell surface to the nucleus, contributing to various cellular functions including cell 
proliferation, differentiation, and gene expression. Mechanosensors on the EC surface, sense and 
convert extracellular mechanical (stretch or shear stress) or biochemical (cytokines, growth factors) 
signals into intracellular signals. The intracellular responses then trigger a chain of biochemical 
events which are transmitted through the cytoplasm to the nucleus by signaling pathways. 
Activation of multiple signaling cascades including the protein kinase C (PKC), Akt, and mitogen 
activated protein kinase (MAPK) pathways have been reported previously75-77. Since cellular 
functions depend greatly on the cell’s ability to properly transduce a signal, it is necessary to study 
how the presence of pathological shear stress can modulate signaling pathway activation. 
3.1.5.1 Mitogen activated protein kinase pathway 
Mitogen activated protein kinases (MAPK) are serine/threonine specific protein kinases 
that regulate diverse biological functions including mitosis, cell differentiation, cell proliferation, 
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and gene expression. MAPK can be activated by extracellular stimulation (biochemical or 
biomechanical) that induces dual phosphorylation at serine/threonine and tyrosine residues. The 
MAPK family is composed of three sequentially acting kinase members: MAPK kinase kinase 
(MAPKKK), MAPK kinase (MAPKK), and MAPK. MAPKKK can phosphorylate and activate 
MAPKK which subsequently stimulates MAPK through dual phosphorylation. Activated MAPK 
then phosphorylates target substrates and induces activation of various protein kinases. A variety 
of stimuli such as growth factors, G-protein coupled receptor activation, and shear stress can 
activate MAPK. The most important MAPK members identified in mammals include extracellular 
signal regulated kinases 1 and 2 (ERK1/2), p38 (isoforms , , , ), and c-Jun amino terminal 
kinases (JNKs) 1, 2, and 3. These kinases link extracellular stimuli to diverse cellular responses. 
Figure 3.2 represents activation of different MAPK family members and their roles in various 
biological responses.   
 
Figure 3.2: Mitogen activated protein kinase (MAPK) pathways. 
 ERK1/2 (molecular weight 42/44 kDa) is the first identified member of the MAPK cascade. 
ERK1/2 activation is initiated by the phosphorylation of Raf (a MAPKKK), which can  
phosphorylate MEK1/2 (MAPKK), leading to ERK1/2 (MAPK) activation78. Activated ERK1/2 
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can modulate cell proliferation, differentiation, and gene expression through phosphorylation of 
transcription factors, nuclear factors, and other kinases.  
 p38 is a 38 kDa protein kinase that is activated by stimuli such as cytokines, ultraviolet 
radiation, and physiological stress. Due to the variation of isoforms’ expression, the activation level 
of p38 differs among tissues. Activated p38 is involved in various cellular functions including cell 
differentiation, apoptosis, and inflammation.  
 JNK, with isoforms of 46 and 54 kDa molecular weight, is activated by stimuli similar to 
those that activate p38. MKK4 and MKK7 are the two major upstream MAPKK that initiate JNK 
activation. Phosphorylated JNK can regulate inflammatory events by activating pro-inflammatory 
transcription factors (activator protein 1) and modulating gene expression of cytokine signaling 
molecules (interleukin 2 and 8). 
 Stimuli such as shear stress can activate MAPK family members. Many studies have 
investigated the effects of shear stress on ERK1/2, JNK, and p38 activation. In a study conducted 
by Li et al., ERK1/2 and JNK activation was observed when bovine aortic EC (BAEC) were 
exposed to shear stress at 1.2 Pa in a rectangular flow channel for up to 60 minutes40. Cheng et al. 
observed ERK1/2, p38, and JNK activation after exposing HUVEC to shear stress at 0.42 Pa for 2 
hr in a parallel plate flow channel79. Shepherd et al. investigated the long term (up to 20 hr 
exposure) effect of pulsatile shear stress (2±1 and 1±0.3 Pa) on MAPK activation in human aortic 
EC77. Their results indicated time- and magnitude-dependent activation of ERK1/2, p38, and JNK 
by shear stress. Activated members of the MAPK pathway can engage in cross-talk, as they share 
different upstream and downstream kinase members. Each member can also negatively affect 
functions of other members80. A study by Zhang et al. demonstrated that activated p38 can inhibit 
phosphorylation of ERK1/281. It has been also observed that ERK1/2 can regulate JNK function 
via MAPK phosphatase 2, indicating cross-talk among the members82.  
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Activation of MAPK pathway members leads to phosphorylation of the transcription factor 
NF-κB, which can eventually lead to modulation of gene expression and protein synthesis of 
various adhesion molecules, cytokines, and growth factor receptors such as TF, ICAM-1, and 
VEGFR. Vega-Ostertag et al. found a significant increase in TF expression in antiphospholipid 
antibody-treated HUVEC due to phosphorylation of MAPK (p38) and NF-κB pathway83. 
Involvement of MAPK family members in modulation of EC surface expression of ICAM-1 has 
also been reported by several groups84;85. Tamura et al. found that inhibiting MAPK activation 
caused a decrease in ICAM-1 expression in pulmonary microvascular EC86. Curtis et al., using 
TNF-α treated human aortic endothelial cells, reported that MAPK pathway activation can 
selectively regulate generation and maturation of EMP87. Grugel et al. reported that oncogenes, 
associated with the MAPK pathway, can potentiate expression of VEGF which eventually 
modulates VEGFR expression88. 
3.1.5.2 Nuclear factor-κB (NF-κB)  
NF-κB, a transcription factor, plays important roles in expression of various EC growth 
factors, cytokines (tumor necrosis factor-α), and inflammatory (ICAM-1, VCAM-1, E-selectin) 
genes89. NF-κB is generally sequestered in the cytoplasm by an inhibitory protein, IκB. This 
regulatory protein non-covalently interacts with NF-κB and prevents its translocation into the 
nucleus90. However, in the presence of certain stimuli (such as cytokines, growth factors, and shear 
stress), IκB specific kinases (IKK) phosphorylate IκB at its N-terminal residue and degrade the 
protein. As a result, NF-κB translocates into the nucleus and modulates gene transcription.  
Phosphorylation of MAPK proteins plays a major role in activation and nuclear 
translocation of NF-κB91. Yang et al., by blocking p38 MAPK with an inhibitor, reported a 
significant decrease in NF-κB phosphorylation and translocation92. Their study also indicated that 
MAPK and NF-κB pathway activation can induce a pro-inflammatory phenotype in cardiac muscle 
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cells. Several other studies also reported modulation of transcriptional activity of NF-κB by MAPK 
members93;94.  
Since various cellular functions are dependent on NF-κB activation, it has been of interest 
to several researchers to study phosphorylation level of NF-κB with shear stress variation. Lan et 
al. observed NF-κB activation in bovine aortic EC after exposing cells to shear stress of 1.2 Pa for 
1 hr95. NF-κB activation was reported to occur after 90 minutes by Liang et al., when HUVEC were 
exposed to 0.42 Pa shear stress for up to 120 min96. Mohan et al. studied the effect of steady low 
shear (2 Pa), pulsatile low oscillatory shear (0.2±0.2 Pa), and physiological laminar shear (1.6 Pa) 
stress on human coronary artery endothelial cell (HCAEC) for up to 24 hr. Their results indicated 
that physiological laminar shear of 1.6 Pa can cause a rapid and transient increase in NF-κB 
activation that returns to baseline with longer shear exposure duration97.  
NF-κB activation can induce gene transcription of various immune and inflammatory 
proteins (including receptors, cytokines, and adhesion molecules) that are involved in EC 
activation. Read et al. indicated that TF expression can be modulated by NF-κB, as the TF gene 
carries recognition elements for NF-κB98. Several studies reported up-regulation of ICAM-1 
expression by activated NF-κB99;100. Activation of NF-κB can regulate EMP generation as well 
through the synthesis of several cytokines including TNF-α, interleukin-1β, and interleukin-6101.  
The literature review above demonstrates that shear stress has a profound effect on EC 
activation as assessed by EC vWF, TF, ICAM-1, and VEGFR expression, EMP generation, as well 
as activation of MAPK and NF-κB signaling pathways. Since most of these previous studies 
utilized steady shear stress to activate EC, our goal was to characterize the physiological relevance 
of these EC responses under simulated blood flow induced dynamic shear stress conditions. 
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3.1.6 Platelets   
Platelets are small non-nucleated cells, shed from megakaryocytes in bone marrow, that 
circulate through the blood. They are ellipsoidal in shape with a diameter of ~4 µm. Due to this 
ellipsoidal shape and small size, platelets are forced to travel along the apical surface of the 
endothelium by the blood flow, allowing platelets to respond rapidly to any vascular damage. The 
average lifespan of platelets is 10 to 12 days. Though the concentration of platelets in plasma varies 
among people, the normal physiological concentration is between 150,000-500,000/µL102.  
 Resting platelets have a tri-laminate cytoskeletal membrane that gives them the discoid 
shape described above and allows them to encounter blood flow induced shear stress efficiently. 
The membrane is composed of a phospholipid bilayer with embedded cholesterol, glycolipids and 
many glycoproteins103. GPIbα and GPIIb/IIIa are the two most important platelet surface 
glycoproteins that play major role in platelet adhesion (GPIbα – receptor for vWF) and aggregation 
(GPIIb/IIIa – receptor for vWF or fibrinogen). In quiescent platelets, negatively charged 
phospholipids are present on the inside of the cell membrane; upon activation, these translocate to 
the outer surface of the cell membrane, participating in coagulation. Platelets also contain different 
organelles (peroxisomes, mitochondria) and granules in their cytoplasm that play important roles 
in platelet activities. There are two types of granules in platelets: α-granules and dense granules. 
Alpha granules are the most abundant type (50 to 80 per platelet) and the larger of the two types; 
they contain matrix adhesion molecules (vWF, fibronectin, and fibrinogen), growth factors [VEGF, 
basic fibroblast growth factor (bFGF)], and coagulation proteins (factor V and XIII). Alpha 
granules also contain P-selectin (a surface glycoprotein not expressed on quiescent platelets), 
GPIbα, and GPIIb/IIIa in their membranes that are translocated to the platelet surface upon 
activation. Dense bodies, another type of granule, contain biochemical mediators such as ADP, 
serotonin, thrombin, and calcium (Ca2+). Upon stimulation, Ca2+ ions are released from dense 
bodies, raising the intracellular Ca2+ concentration from ~100nM to ~2-5 μM104. This Ca2+ ion 
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release is central to key platelet functions such as activation and adhesion. Activated platelets 
release substances from α- and dense granules, which then act as a positive feedback mechanism 
to induce further activation of nearby quiescent platelets105.  
The major function of platelets is to maintain hemostasis through detection of, and response 
to, any damage in the blood vessel wall. Platelets accomplish this feat through initial interaction of 
their specific surface membrane receptors with exposed connective tissue (collagen and laminin) 
or soluble factors such as plasma vWF released by the damaged endothelium. Interaction induces 
formation of pseudopods, translocation of negatively charged phospholipids to the outer 
membrane, secretion of α- and dense granule components, activation of signaling pathways that 
initiate production and release of platelet agonists (thromboxane, ADP, thrombin, collagen), and 
activation of surface integrins (GPIbα and GPIIb/IIIa). Under conditions of high shear stress, bound 
or soluble vWF interacts with the GPIbα complex on activated platelets, facilitating platelet 
adhesion to the damaged vessel wall106. This interaction results in activation of GPIIb/IIIa and 
GPIa/IIa on the platelet surface. Through GPIIb/IIIa, activated platelets can firmly adhere to the 
sub-endothelium and initiate platelet aggregation. Along with vWF, fibrinogen (a dimer) can also 
act as a bridging molecule between the GPIIb/IIIa receptors of two activated platelets107. However, 
in low shear stress regions, activated platelets use their GPIa/IIa receptors to adhere to collagen. 
Translocation of negatively charged phospholipids promotes the coagulation process by: 1) acting 
as a catalytic surface, 2) binding circulating coagulation factors, and 3) eventually forming a 
platelet plug (Figure 3.3) by trapping the platelets in the insoluble fibrin mesh formed at the end of 
the coagulation cascade.  
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Figure 3.3: Dynamics of platelet dependent thrombus formation108. 
Under physiological conditions, this plug formation remains controlled, and the plug is 
later dissolved (hemostasis). However, during pathological conditions, unregulated clotting activity 
can happen, resulting in thrombosis (formation of a clot within a blood vessel). Thrombus 
formation may narrow the blood vessel lumen and change the local blood flow rate, inducing altered 
shear stress which can promote disease pathogenesis by further activating platelets and 
endothelium.  
3.1.7 Platelets and shear stress 
Blood flow induced shear stress, especially altered shear stress, can induce platelet 
activation, adhesion, and aggregation. Many investigators have studied the effects of shear stress 
on platelet responses109. Brown et al. reported both platelet activation and aggregation when 
platelets were exposed to shear stress at 5 Pa in a cone-plate shearing system110. Their findings also 
showed platelet lysis at 10 Pa and platelet fragmentation at 25 Pa. A study conducted by Anderson 
et al. demonstrated that platelet lysis occurred when platelets were exposed to shear stress of 16 Pa 
for 5 min, or 60 Pa for less than 30 sec, indicating the importance of considering shear exposure 
time as a parameter during platelet functional studies12. Yin et al. also demonstrated that low shear 
stress (0.24 Pa) can activate platelets if the shear exposure time is long enough111. Apparently, 
28 
 
either a short exposure to high shear stress or a long exposure to low shear stress can both lead to 
platelet activation12. Exposing platelets to various shear stress levels (30, 75, or 100 Pa) for 25-
1650 ms, Ramstack et al. also reached to this conclusion21. A study by Bluestein et al. indicated 
that platelets exposed to high shear (5, 6, or 7 Pa for 5-40 sec) and subsequent low shear stress (0.1 
Pa for 14-60 min) activate 20 times faster than platelets not exposed to the initial high shear 
condition112. 
Platelet activation can lead to expression and activation of various surface glycoproteins 
(including PECAM-1, GPIbα, and GPIIb/IIIa) which can participate in platelet adhesion and 
aggregation. Dysregulated expression of these proteins can contribute to atherosclerosis or 
thrombosis.  
3.1.7.1 Platelet endothelial cell adhesion molecule (PECAM-1) 
PECAM-1 is a 130 kDa glycoprotein expressed on the membrane of platelets and in the 
intracellular junctions of EC113;114. Upon activation, a significant increase in PECAM-1 expression 
is observed on the platelet membrane. When platelets were activated by thrombin, Wu et al. and 
Metzelaar et al. found a three-fold increase in surface PECAM-1 expression compared to that of 
resting platelets115;116. Whether the increase in PECAM-1 expression was due to the increased 
exposed surface area of activated platelets or to fusion of α-granules containing PECAM-1 is yet 
to be elucidated. The presence of PECAM-1 in α-granules is also still controversial as one study 
reported no PECAM-1, whereas another found a significant amount of PECAM-1 localized in α-
granules115;117. 
The major role of PECAM-1 is to mediate cell-cell interaction by acting as an adhesion 
molecule. PECAM-1 receptors expressed in one cell can interact with both homophilic (PECAM-
1) and heterophilic (integrin αVβ3) ligands of adjacent cells. Other functions of PECAM-1 include 
up-regulation of integrin functions and participation as a mechanosensing molecule. As PECAM-
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1 is expressed on the cell surface or in cell junctions, it can be directly activated by blood flow 
induced shear stress118. The cytoplasmic tail of PECAM-1 has several serine, threonine, and 
tyrosine residues that are phosphorylated during cell activation. Phosphorylation of PECAM-1 
tyrosine residues has been detected in both fluid shear stress stimulated EC and in aggregating 
platelets119;120. Phosphorylated PECAM-1 can activate the MAPK pathway and NF-κB. Thus, 
PECAM-1 is a major player in signal transduction. Several studies, using PECAM-1 knockout 
mouse models, have reported the contribution of PECAM-1 to the initiation and progression of 
atherosclerosis121;122. These studies indicated that atherosclerosis developed mainly in the flow 
reversal regions due to continuous expression and activation of PECAM-1. Interestingly, in the 
unidirectional flow region, atherosclerotic development was not observed, which the researchers 
have attributed to the adaptation or desensitization of PECAM-1 with time. Blocking PECAM-1 
with an antibody in a rat model, Gumina et al. demonstrated a significant reduction in myocardial 
infarct size as cell adhesion to the myocardium decreased, confirming the role of PECAM-1 in 
atherosclerotic plaque development123.  
Though PECAM-1 potentially acts as an initiator of EC activation, several studies reported 
that PECAM-1 also acts as a potent inhibitor of platelet activation124. Cicmil et al. reported that 
cross-linking of PECAM-1, in presence of collagen and thrombin, can inhibit platelet activation 
and aggregation in vivo125. In another in vivo study, conducted by Falati et al., large and stable 
thrombus formation was observed in PECAM-1 deficient mice compared to control mice126. 
Rathore et al. indicated that, along with an activation signal, GPIbα-vWF interaction triggers a 
negative feedback loop involving PECAM-1 that can modulate the rate and extent of platelet 
function127. Since PECAM-1 potentially plays a controversial role in activation of platelets and EC, 
it is of interest to investigate the effects of dynamic shear stress on PECAM-1 expression and 
function. 
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3.1.7.2 GPIIb/IIIa complex 
 GPIIb/IIIa is the most abundant platelet membrane glycoprotein and plays an important 
role in platelet aggregation. It is a heterodimer consisting of an α subunit (GPIIb) and a β subunit 
(GPIIIa)128. Resting platelets have ~80,000 inactive GPIIb/IIIa molecules randomly distributed on 
their surface, which accounts for about 1.5% of the total protein in platelets129;130. Along with the 
randomly distributed GPIIb/IIIa on the platelet membrane, α-granules also contain a pool of 
GPIIb/IIIa131.  
Activation of platelets initiates signaling events that cause a conformational change in 
platelet surface GPIIb/IIIa. This change transforms the protein from the inactive to the active state, 
resulting in increased affinity for receptors such as vWF, fibrinogen, and fibronectin. Fibrinogen 
and vWF can act as bridging molecules between two GPIIb/IIIa receptors on different platelets and 
accelerate platelet aggregation. Activation of GPIIb/IIIa can also enhance platelet spreading, 
procoagulant granules secretion, and clot retraction132.  
Several studies have investigated the effects of various agonists, including shear stress, on 
GPIIb/IIIa activation. Ikeda et al. observed that, under low shear stress, platelet aggregation was 
induced by the interaction between GPIIb/IIIa and fibrinogen133. However, the formed aggregate 
was unstable and disintegrated under higher shear stress conditions. Their study also demonstrated 
that interaction of vWF with both GPIb and GPIIb/IIIa was necessary for stable aggregates to 
form under high shear stress. Initial interaction between immobilized vWF and platelet GPIb, 
under high shear stress, triggers an increase in intracellular calcium concentration, in turn inducing 
release of various activating factors by platelets, and activation of the GPIIb/IIIa receptor134-136. 
Activated GPIIb/IIIa then interacts primarily with vWF (under high shear stress) and fibrinogen 
(under low shear stress) to form stable aggregates. However, a recent study reported that GPIIb/IIIa 
31 
 
mediated signaling can regulate both platelet activation and aggregation independent of the vWF-
GPIb interaction132.  
 The major function of GPIIb/IIIa is to induce platelet aggregation during hemostasis. 
Dysfunction of this glycoprotein can lead to disease conditions including mild bleeding disorder, 
myocardial infarction, and stroke137;138. Though GPIIb/IIIa makes a crucial contribution to 
aggregation and thrombus formation, no study has yet investigated the effects of physiologically 
relevant dynamic shear stress on platelet GPIIb/IIIa expression.  
3.1.7.3 Platelet microparticle generation 
Platelet microparticles (PMP) are small plasma membrane vesicles shed by platelets during 
activation and apoptosis139. Due to their small size (0.1 to 1 µm), PMP were first described as 
“platelet dust”140. As PMP are generated by membrane shedding, they contain most of the 
glycoproteins found in intact platelets, including P-selectin, PECAM-1, GPIbα, and GPIIb/IIIa141. 
PMP also express negatively charged phospholipids on their membrane and have multiple binding 
sites for coagulation factors including factor Va and Xa. Due to these binding sites, PMP are more 
procoagulant (~100 times) than activated platelets142. The presence of different glycoprotein 
receptors on the surface of PMP enables them to interact with different cell types (platelets and EC) 
inducing cell activation and facilitating platelet adhesion to the vascular wall143;144.  
Fracture of pseudopods of activated platelets under high shear stress conditions is one of 
the mechanisms for PMP generation145. Interaction of platelet surface receptor GPIbα with vWF 
can also lead to PMP generation via an increase in cytosolic calcium concentration which 
subsequently inhibits phosphatases, activates kinases and calpain (a calcium dependent protease), 
leading to disruption of the membrane cytoskeleton and formation of PMP146;147;148. However, in 
apoptotic cells, instead of cytosolic calcium, activation of caspases induces PMP generation. 
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Several studies have investigated the effects of shear stress on PMP generation149. 
Exposing platelets to shear stress of 10.8 Pa, Nomura et al. observed an increase in PMP 
generation109. The generated PMP further activated platelets, acting as a positive feedback 
mechanism, and induced the release of inflammatory cytokines. Holme et al. sheared whole blood 
at 1.3, 8, and 31.5 Pa for 0.075 sec to 3.045 sec using a parallel plate perfusion chamber and found 
an increase in PMP generation in a shear stress magnitude dependent manner150.  
PMP have been observed to increase in various disease conditions like hypertension, 
transient ischemic attack, and myocardial infarction, but to decrease in mild bleeding disorder151;152. 
As PMP generation varies with different disease conditions, it can be used as an early predictor of 
disease development.  
3.1.8 Cell-cell interaction 
Cell-cell interaction can greatly affect cellular functions, contributing to many 
physiological and pathological conditions153. Both platelet-EC and EC-SMC communication play 
a vital role in modulation of their individual behavior. Under physiological conditions, healthy EC 
inhibit platelet activation and adhesion by providing an atheroprotective surface and releasing 
platelet activation inhibiting substances such as NO and prostacyclin (PGI2). Although NO can 
directly activate platelet guanylyl cyclase to synthesize cyclic guanosine monophosphate GMP 
(cGMP), PGI2 first binds with platelet surface G-protein coupled receptors to activate platelet 
adenyl cyclase to produce cyclic adenosine monophosphate (cAMP). cGMP and cAMP inhibit 
increase in the intracellular Ca2+ ion level and, thus prevent any undue activation of platelets. 
Hence, though platelets travel along the close proximity of the EC of the vasculature, they do not 
interact with EC under normal conditions, providing natural resistance to thrombus formation. In 
response to vascular damage, platelets and EC work together to support coagulation, form and 
dissolve thrombi, and repair damaged tissues. Beside working as platelet activation inhibitors, NO 
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and PGI2 can act as potent vasodilators by modulating SMC contractile properties. On the other 
hand, SMC can modulate EC function through release of different pro-inflammatory molecules 
such as cyclophilin A.  
Generally, platelets, EC, and SMC all stay in a non-activated and non-proliferative state. 
However, under pathological conditions, the normal function of EC and SMC is disrupted resulting 
in overexpression of adhesion ligands, upregulation of cytokines and inflammatory molecules, 
release of platelet activating agents, and a switch of the SMC phenotype from contractile to 
secretory/proliferative state. These events lead to platelet activation and adhesion to the vascular 
wall, perpetuating disease progression. It has been established that interaction between platelets 
and EC is involved at every stage of atherosclerosis, and the interaction is greatly modulated by 
blood flow induced shear stress154. Events associated with platelet and EC activation, platelet-EC 
interaction, and platelet aggregation are summarized in Figure 3.4. Endothelial cells and activated 
platelets interact with each other through the expression of many inflammatory and adhesion 
proteins, including TF, GPIbα, vWF, ICAM-1 and GPIIb/IIIa. Adhesion takes place when activated 
platelets bind to activated EC or damaged sub-endothelium through GPIbα-vWF interaction. 
Platelets may also bind to activated EC through P-selectin or PECAM-1 expressed on the surface 
of both cell types9;119. After initial adhesion, platelets start to form aggregates with surrounding 
activated platelets through GPIIb/IIIa interaction. Fibrinogen and vWF serve as links between two 
GPIIb/IIIa or GPIIb/IIIa and ICAM-1 receptors, thus facilitating adhesion and aggregation which 
can contribute to thrombosis or atherosclerotic plaque formation. 
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Figure 3.4: Schematic representation of platelet and EC activation, their interaction, and platelet 
aggregation. 
Different studies have investigated the effects of shear stress on platelet and EC responses. 
However, very few of them focused on how platelet/EC interactions affect platelet and EC behavior 
in response to shear exposure. Moreover, most of these studies utilized constant shear stress for 
platelet and EC activation. A study by Martin et al. indicated that activated EC express P-selectin 
glycoprotein ligand-1 (PSGL-1) on their surface, which can mediate platelet tethering and rolling 
via P-selectin–PSGL-1 binding155. Frenette et al. showed that this P-selectin–PSGL-1 binding 
happens in a low shear stress environment. Activated platelets and EC also generate microparticles 
under high shear stress exposure, which increase cytokine production and induce adhesion 
molecule expression on both platelets and EC109,156.  
The above literature review indicates that interactions between platelets and EC can affect 
their functions and activities. Also, different shear stress magnitudes and exposure durations have 
different effects on platelet and EC behavior. Therefore, the goal of study 1 was to apply 
physiologically relevant dynamic shear stress mimicking conditions in both healthy and diseased 
coronary arteries to platelets and EC, in order to better understand how dynamic shear stress and 
platelet-EC interactions can modulate activation in both cell types. Furthermore, we wished to 
determine how the corresponding signaling pathways are affected, especially under disease 
conditions. Our findings demonstrated that dynamic shear stress and platelet-EC communication 
can affect their activation through modulation of expression/release of different surface adhesion 
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ligands (platelet PECAM-1, GPIb, and GPIIb; EC vWF), EMP generation, as well as EC signal 
transduction pathways (MAPK and NF-κB). Findings from this study may lead to potential 
therapeutic approaches to treat CAD progression. 
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3.2 Study 2 
In addition to the large arteries, some tissues also contain much smaller (~30 -100 μm 
diameter) interconnecting blood vessels known as “collateral arteries.”. Collateral arteries are 
natural bypasses which connect two major arteries that supply neighboring perfusion zones. Due 
to their narrow diameter and high resistance, collateral arteries carry little blood under 
physiological conditions. Only during vascular occlusion, when there is a drop in the pressure 
gradient across the collateral due to a blockage in one of the two major blood vessels, does blood 
starts re-routing through the collaterals. Under these circumstances, collaterals may increase their 
local flow capacity up to 200 fold. This increase in blood flow activates signaling pathways that 
leads to vascular remodeling. This process of collateral growth (or arteriogenesis) enables collateral 
arteries to accommodate a significantly increased amount of blood flow. 
3.2.1 Hemodynamics of coronary collateral artery blood flow 
Coronary collateral arteries can carry blood to myocardial areas that are at risk of ischemia 
when the primary blood supply route is affected by complete or partial occlusion of major coronary 
arteries. Collateral arteries are a network of small, thin-walled blood vessels, arising from arterioles 
that radially enlarge and interconnect to maintain an alternate pathway for blood supply. Collateral 
connections are found even in the absence of CAD, although they carry little blood under 
physiological conditions. However, during CAD, these pre-existing collaterals become fully 
functional through an outward remodeling process known as arteriogenesis (Figure 3.5). 
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Figure 3.5: Coronary collateral artery remodeling or arteriogenesis157.  
In the presence of a stenosis in the coronary artery, pressure in the post-stenotic region 
drops, generating a pressure gradient which drives blood flow through the pre-existing collateral 
arterioles. Over time, this chronic increase in blood flow increases the mean diameter of the 
collaterals, resulting in a greater capacity for blood flow. However, a key point to keep in mind is 
that this blood flow increase is not due to vasodilation, but rather to actual structural remodeling of 
the blood vessel wall.  
When collateral blood flow increases, ECs on the collateral vessel wall and circulating 
blood cells (like platelets) passing through the collaterals are exposed to enhanced shear stress. In 
a healthy normal coronary collateral artery, the endothelium is exposed to a mean shear stress of 
~0.07 Pa. This shear stress level increases to ~1 – 2 Pa, based on the degree of stenosis in the 
upstream region of the coronary artery158. Increased shear stress is considered to be a key stimulus 
for arteriogenesis, and may act in part by activating pathways leading to the release of growth 
factors by EC and platelets. Therefore, it is necessary to study how EC and platelet growth factor, 
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growth factor receptor, and inflammatory molecule levels change in response to physiologically 
relevant collateral shear stress.  
3.2.2 Arteriogenesis 
 Arteriogenesis is the process by which pre-existing collateral arterioles undergo radial 
growth to remodel into fully functional collateral arteries. It is an adaptive physiological 
compensatory mechanism, through which collateral vessels can enlarge their diameter up to 20 
times more than their original diameter (usually 30 – 50 µm) to meet increased blood flow demand 
when supply arteries are stenosed or occluded159. In the absence of stenosis or occlusion, there is 
minimal blood flow through collateral arterioles due to lack of a significant pressure gradient and 
the presence of high resistance. In presence of an atherosclerotic plaque in an upstream supply 
artery, blood flow in the downstream regions of the occlusion is limited. Therefore, to maintain 
normal tissue function and protect tissue from ischemic damage, the body attempts to preserve 
blood flow downstream of the occlusion by redirecting oxygenated blood through the collaterals.  
Due to the sudden increase in blood flow through collaterals, shear stress on the collateral 
vessel wall increases. Cell surface mechanotransduction receptors on EC of the vessel wall sense 
this change in shear stress, and transduce the signals inside the cell through various signaling 
pathways. These events then converge to activate downstream transcription factors modulating the 
expression of growth factors such as vascular endothelial growth factor (VEGF-A) and placental 
growth factor (PLGF); cytokines such as monocyte chemoattractant protein (MCP-1) and tumor 
necrosis factor-α (TNF-α); cell adhesion molecules such as platelet endothelial cell adhesion 
molecule (PECAM-1) and intracellular adhesion molecule-1 (ICAM-1); and signaling proteins 
such as endothelial nitric oxide synthase (e-NOS) and NADPH oxidase (NOX). Cytokine and 
growth factor expression attracts circulating monocytes and platelets to the site of vascular 
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remodeling, and induces adhesion and transmigration of the cells into the vessel wall through 
growth factor/growth factor receptor and adhesion molecule interaction.  
After invading the vessel wall, monocytes produce a range of proteoglycans and proteases 
(such as matrix metalloproteinases and plasmin) that remodel the extracellular matrix (ECM). 
Monocytes also release abundant amounts of growth factors, especially growth factors from the 
vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) families. These 
growth factors bind to their corresponding receptors on EC and SMC, followed by EC and SMC 
proliferation. At this point, SMC switch to a secretory phenotype (as opposed to their normal 
contractile phenotype), which is typical of SMC during an active growth phase. Meanwhile, the 
internal and external elastic lamina of the tunica media is disrupted by proteases, allowing SMC to 
migrate through the disrupted internal elastic lamina to form a neointima. The external elastic 
lamina of the tunica externa is then degraded by proteolytic enzymes, providing space for radial 
growth of the blood vessels. Additional SMC layers and extracellular matrix start to surround the 
outer periphery of the vessel wall, increasing luminal diameter and vascular wall thickness. These 
steps of arteriogenesis are summarized in Figure 3.6. Clearly, collaterals enlarge through an active 
remodeling process, rather than vasodilation.  
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Figure 3.6: Steps associated with arteriogenesis159. 
 Circulation through collaterals plays a major role in maintaining viable functioning of the 
tissue during abrupt or chronic occlusion of supply arteries. Due to its tremendous adaptive power, 
the collateral circulation can significantly change the outcome of coronary or peripheral artery 
disease. For example, the presence of collateral arteries can significantly improve the survival rate 
in patients who are undergoing surgical intervention after suffering from myocardial infarction160. 
This observation demonstrates the importance of collateral arteries in reducing ischemic tissue 
death and improving blood flow recovery following revascularization therapy.  
3.2.3 Diabetes 
Diabetes (also referred as diabetes mellitus) is a group of chronic metabolic disorders 
primarily characterized by hyperglycemia (persistent high blood glucose) for prolonged period of 
time. When the cells in the body that utilize blood glucose for energy cannot take up glucose 
properly, glucose accumulates in the blood. Over time, this excessive glucose can be converted into 
other reactive byproducts such as advanced glycation end products (AGE). Hyperglycemia and 
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AGE formation have damaging effect on multiple organs including the heart, vasculature, kidney, 
brain, nerves, and eyes. Around 50% of diabetics die due to cardiovascular complications 
(including CAD, PAD, and cerebrovascular disease). One reason for this is that diabetes-associated 
metabolic dysfunction can promote endothelial dysfunction, leading to atherosclerosis in the 
vasculature.  
Diabetes can occur due to either insufficient insulin production (type 1) and/or improper 
insulin action (type 2). In type 2 diabetes, glucose uptake is impaired due to tissue resistance to 
insulin activity. Insulin is a hormone that is produced by the beta cells found in the islets of 
Langerhans of the pancreas. After consumption of food, proteins, fats, and carbohydrates are 
broken down into amino acids, fatty acids, and glucose by digestive enzymes. Insulin regulates the 
blood glucose level, preventing unnecessary glucose buildup in the blood. Insulin works like a key 
to unlock cells by interacting with insulin receptors throughout the body, to allow blood glucose 
entrance into cells for energy production. Insulin/insulin receptor interaction activates intracellular 
signaling pathways that stimulate glucose transporters to translocate to the plasma membrane, 
where they facilitate glucose uptake into the cell. In healthy people, the pancreas releases the right 
amount of insulin in response to a rise in blood glucose after food consumption. However, in 
diabetic people, insulin production may be reduced, or insulin may not function effectively (known 
as insulin resistance).  
Diabetes can be diagnosed in several ways. The most common tests are fasting plasma 
glucose (FPG) and random plasma glucose (RPG). To check FPG, blood is collected in the morning 
after at least 8 hr of fasting, and the plasma glucose level is quantified. The person is considered 
nondiabetic if the glucose level is less than 100 mg/dL, prediabetic (showing abnormal glucose 
levels but not yet diabetic) if the glucose level is between 100 - 125 mg/dL, and diabetic if the 
glucose level is equal or greater than 126 mg/dL. The RPG test can be conducted by testing the 
blood glucose level at any time of the day. If the level is greater than 200 mg/dL, the person is 
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considered diabetic. Other diabetes diagnostic tests include the hemoglobin A1C (HBA1C) test and 
the oral glucose tolerance test (OGTT). For the HBA1C test, a person’s average blood glucose level 
over a period of 2 to 3 mo is estimated by assessing the amount of glucose linked to red blood cell 
hemoglobin. The OGTT assesses how well the body can tolerate and process a glucose load. In the 
OGTT, the blood glucose level is checked before and 2 hr after consuming a drink containing 75 g 
glucose. The person is considered to be nondiabetic if his/her glucose level is less than 140 mg/dL, 
and diabetic if the glucose level is equal or greater than 200 mg/dL. 
Diabetic people are predisposed to have complications including cardiovascular disease, 
cerebrovascular disease, kidney disease, retinal damage, and nerve damage. If not treated, patients 
are at high risk for heart attacks, limb amputations, stroke, blindness, and premature death. 
According to the Centers for Disease Control and Prevention (CDC), around 29.1 million people 
in the US (~9.3% of the total population) had diabetes in 2012. Alarmingly, among these 29.1 
million people, 8.1 million were unaware that they were diabetic, further increasing the risk of their 
health161. This discrepancy exists because many people suffer silently from diabetes, as there are 
no particular symptoms initially. The medical expense for treating diabetes is extremely high. In 
2012, $244 billion and $78 billion were expended for direct and indirect (associated with disability, 
early death, work loss) medical care costs of diabetes respectively in the USA alone162. Diabetic 
people have ~2.3 times the medical expenditures of nondiabetic people, creating an economic 
burden of >$1,000 for each US citizen. 
Diabetes is classified into three types: type 1, type 2, and gestational diabetes. Type 1 
diabetes, also known as insulin-dependent diabetes or juvenile diabetes, develops when the immune 
system attacks the insulin-producing pancreatic beta cells and makes them non-functional. 
Unfortunately, type 1 diabetes is not curable and preventable, and treatment requires taking insulin 
shots every day to keep the glucose level under control. Type 2 diabetes is called non-insulin 
dependent diabetes, as the body is capable of producing enough insulin but is unable to use it 
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properly. This phenomenon arises when cells become insulin resistant or cannot efficiently respond 
to circulating insulin. Therefore, despite an adequate level of insulin, blood glucose levels increase, 
sending a signal to the pancreas to release even more insulin. With time, the pancreas becomes 
incapable of maintaining this increased insulin demand, leading to reduced insulin production.  
Type 2 diabetes is the most common form of diabetes and has few symptoms, leading to it often 
going unnoticed until the condition becomes severe. Obesity, high blood pressure, unhealthy food 
habits, and sedentary behavior can increase the risk of type 2 diabetes. Gestational diabetes is the 
least common type of diabetes, affecting ~2-10% of pregnant women. Similar to type 2 diabetes, 
obesity, unhealthy food habits, a family history of diabetes, and high blood pressure increase the 
risk of this complication during pregnancy. Gestational diabetes affects both the mother and the 
baby, as babies can be born prematurely or become obese with a higher chance of developing 
diabetes themselves. Although gestational diabetes may disappear after delivery, these mothers 
remain at increased risk of eventually developing type 2 diabetes. 
3.2.4 Metabolic parameters associated with diabetes 
Diabetes is associated with alterations in several metabolic parameters, including 
hyperglycemia, hyperlipidemia, hyperinsulinemia, and oxidative stress. Type 2 diabetics are 
predisposed to vascular disease development, especially coronary artery disease or peripheral artery 
disease, as they are more prone to having multiple abnormal metabolic parameters than type 1 
diabetics. In general, compared to nondiabetic people, diabetics have a two- to four-fold higher risk 
of cardiovascular events. Diabetic cardiovascular morbidity and mortality can be reduced if overall 
risk factor management is implemented, including weight loss, more physical activity, management 
of blood pressure and blood glucose level, and normalization of other metabolic parameters. 
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3.2.4.1 Hyperglycemia 
Hyperglycemia (excessive level of glucose), if maintained untreated in the blood plasma 
for long period, causes various long term complications in diabetic people. Prolonged 
hyperglycemia results in glycation of plasma lipids and/or proteins via a non-enzymatic process, 
leading to advanced glycation end product (AGE) formation163. In AGE formation, the amino 
groups of proteins and the carbonyl group of sugars react with each other to generate AGE through 
the Maillard reaction. In the Maillard reaction, the carbonyl group of glucose (or other reducing 
sugars) interacts with free amino groups of proteins to form a reversible Schiff base, an unstable 
compound which forms within a few hours. The labile Schiff base can undergo further 
rearrangement to form the more stable and practically irreversible Amadori product. Formation of 
Amadori products usually takes several days. Through further chemical reactions (e.g. dehydration, 
oxidation), the Amadori product can break down into various reactive bicarbonyl compounds. 
However, if not broken, Amadori products can undergo further glycation, chemical modifications, 
and molecular rearrangement to form irreversible AGE. The different steps of AGE formation are 
illustrated in Figure 3.7. In addition to being formed inside the body, exogenous AGE can also be 
consumed through AGE enriched foods (such as butter, sesame oil, broiled beef, grilled chicken 
leg) or tobacco164. 
AGE are complex molecules that can cross-link many different proteins. AGE can modify 
protein half-life, reduce ligand binding capability, and alter enzyme activity165. They can also 
disrupt normal cellular functions by changing molecular conformations and altering corresponding 
receptor (RAGE) function. Interaction between AGE-RAGE can activate downstream intracellular 
signal pathways modulating nuclear factor (NF-κB) activation, gene expression, and cytokines and 
inflammatory molecules release166;167. AGE can accumulate in cells and tissues, where it forms both 
intracellular and extracellular cross links with other proteins, lipids, and nucleic acids. These cross 
links can have serious physiological consequences. For example, intermolecular cross linking with 
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collagen induces systolic hypertension, reduces arterial compliance, and increases vascular 
stiffness (through cross linkage with other proteins that increases extracellular matrix area)168. AGE 
have been found to contribute in different diabetic complications including diabetic atherosclerosis, 
retinopathy, nephropathy, and neuropathy. 
 
Fig 3.7: Steps of protein glycation and subsequent AGE formation169. 
There are several receptors for AGE, among which the receptor of AGE (RAGE) was the 
first to be identified. RAGE, a multi-ligand transmembrane signal transduction receptor of 35 kDa 
molecular weight, can be found on the cell surface of EC, SMC, and macrophages. RAGE has three 
extracellular domains, among which the V-type domain acts as the ligand binding domain170. 
Increased AGE formation during hyperglycemia also upregulates cellular RAGE expression. AGE-
RAGE interaction can cause cellular activation leading to oxidative stress induction, MAPK and 
NF-κB signaling pathway activation, proinflammatory cytokine (TNF-α, interleukin 1 and 6) 
release, and adhesion molecule (ICAM-1, VCAM) expression166;167. 
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Since AGE can exert many detrimental effects, prevention of AGE formation or breaking 
of the cross links formed by AGE are desirable outcomes in diabetic people. The most effective 
way to inhibit diabetic AGE formation in diabetic patients is through limiting or reversing 
hyperglycemia by diet modification or antihyperglycemic agents. When hyperglycemia cannot be 
effectively controlled, some pharmacological compounds can inhibit AGE formation or limit its 
effects. Various compounds have different working principles, including: 1) blocking attachment 
of amino groups of proteins to sugar (using pyridoxical-5-phosphate); 2) preventing attachment of 
carbonyl groups of sugars and Amadori products to protein (using aspirin); 3) reducing 
autooxidative glycation by altering the oxidative environment (using vitamins C and E); 4) 
preventing AGE crosslinks formation by blocking Amadori product interaction with target 
molecules (using metformin, aminoguanidine); 5) trapping reactive carbonyl intermediate 
compounds (using metformin, aminoguanidine); 6) breaking AGE and some existing crosslinkage 
after their formation (using alagebrium chloride and N-phenacyl thiazolium bromide); or 8) 
blocking RAGE interaction and signaling169. Using soluble RAGE (sRAGE, an isoform of RAGE 
protein) or RAGE specific antibody, AGE-RAGE interaction can be blocked. Since, sRAGE lacks 
the transmembrane signaling domain of the full length RAGE protein, it can interact with AGE, 
but, cannot transduce intracellular signal. Thus, sRAGE, acting as a decoy protein, counteracts the 
detrimental effects of RAGE protein.   
As mentioned above, AGE-RAGE interaction can induce oxidative stress. The main 
mechanism for oxidative stress is the overproduction of reactive oxygen species (ROS) that can be 
generated by different enzyme families including NADPH oxidases (Nox), xanthine oxidases 
(XO), and uncoupled endothelial nitric oxide synthase (eNOS), all of which has been found to be 
modulated by AGE171;172. The Nox family consists of several members (Nox 1-5 and dual oxidase 
1-2), each of which is distinctly distributed in different cells and tissues. By transferring electrons 
from NADPH to oxygen molecules (O2) across the cell membrane, most Nox isoforms generates 
47 
 
superoxide anion radicals (O2.-) which are then dismutated to H2O2 by superoxide dismutase 
enzymes. In contrast to most Nox family members, Nox4 directly produces hydrogen peroxide 
(H2O2). The activity of Nox4 is regulated by its expression level, and Nox4 only requires regulatory 
subunit p22phox association to be activated17. On the other hand, for activation, Nox2 requires 
stimulus to induce translocation of its regulatory subunits (such as p47phox, p67phox, and Rac1) to 
the membrane173. When any agonist stimulates the G-protein coupled receptors of the cell surface, 
Nox2 regulatory subunits translocate to the membrane to form heterodimers with Nox2. The 
formed heterodimer is a functionally active complex that initiates O2.- production174. Since H2O2 is 
quite stable and can easily diffuse through the membrane, it is currently considered to be the main 
ROS for physiological signaling. H2O2 can directly or indirectly regulate phosphorylation of 
specific downstream signaling protein molecules (such as PI3K and p38 MAPK), thereby 
regulating cell growth, proliferation, and survival175. H2O2 production by Nox4 has also been found 
to enhance activity of eNOS and bioactivity of NO176. 
Iron metabolism is another potential source of oxidative stress. Heme proteins are highly 
toxic, as they can catalyze ROS production. Heme oxygenase-1 (HO-1), an inducible stress protein, 
protects cells against oxidative stress and programmed cell death by controlling free heme levels 
and promoting the synthesis of ferritin (an iron binding protein). HO-1 degrades toxic free heme 
groups to biliverdin, carbon monoxide (CO), and ferrous ion (Fe2+). Ferritin, eliminates the pro-
oxidant iron by binding it so that it can be transported into the extracellular space. This mechanism 
reduces the intracellular iron level, providing cytoprotection against oxidative stress and inhibiting 
apoptotic compound formation. 
Increased oxidative stress leads to further AGE formation and nuclear factor kappa B (NF-
κB, a transcription factor) activation177. NF-κB activation increases release of proinflammatory 
cytokine (interleukin 6, TNF-α, MCP-1) and RAGE expression, further intensifying inflammatory 
cellular responses. MCP-1, the first chemokine discovered due to its high abundance, plays a crucial 
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role in attracting monocytes/macrophages to sites of inflammation and mediates their migration 
and infiltration across the vascular wall, increasing vascular permeability178. It is produced (either 
constitutively or in response to oxidative stress) by several different cell types including monocytes, 
EC, SMC, fibroblasts, epithelial cells. TNF-α exerts the same inflammatory effects as MCP-1, and 
plays an important role in endothelial cell dysfunction. It enhances the transcription of different 
cytokine genes that contribute to cell proliferation, inflammatory response, and cell adhesion 
through further activation of NF-κB. TNF-α increases oxidative stress generation, by inducing 
NADPH oxidase enzyme expression, which can lead to further TNF-α expression through a 
positive feedback mechanism (for example, as found in diabetic nephropathy)179;180. Thus, chronic 
hyperglycemia and the resulting AGE formation can induce oxidative stress promoting a pro-
inflammatory state through inflammatory cytokine production. This inflammatory state can 
damage pancreatic β-cells, causing endocrine pancreatic malfunction which further affects 
intracellular insulin signaling and diabetic complications. 
3.2.4.2 Hyperinsulinemia 
Hyperinsulinemia happens when insulin receptors become resistant to insulin action, 
resulting in higher insulin production by the pancreas to exert the usual effects. When the insulin 
level in blood remains high for a long period, cells and tissues become less responsive to the 
hormone. For example, a diabetic person may need 10 times more insulin than a healthy person to 
metabolize the same amount of glucose. With time, the pancreas can no longer keep up with the 
increased production and secretion of insulin, causing impaired insulin release in response to 
elevated glucose levels which in turn causes hyperglycemia. Therefore, insulin resistance and 
hyperinsulinemia are considered to be risk factors for the development of diabetes. When this 
hyperinsulinemic state is maintained for a long period, cytokine production is elevated, increasing 
inflammatory responses in the body. Hyperinsulinemia also increases blood pressure and the 
release of low density lipoprotein (LDL). 
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3.2.4.3 Hyperlipidemia 
Hyperlipidemia is a condition characterized by elevated levels of cholesterol, lipids, and 
triglycerides in the blood stream. Obesity, unhealthy food habits, and a sedentary lifestyle increase 
the risk of hyperlipidemia. In addition, diabetics have a higher chance of developing hyperlipidemia 
than nondiabetics, as diabetes tends to reduce high density lipoprotein (HDL) and increase the low 
density lipoprotein (LDL) and triglyceride level. Hyperlipidemia arises due to impaired function of 
the body’s systems for transporting and metabolizing cholesterol, lipids, and triglycerides. High 
cholesterol levels (hypercholesterolemia) are considered to be a major risk factor for cardiovascular 
disease. Cholesterol must be transported within protein particles known as lipoproteins because of 
cholesterol’s water insolubility. Several types of lipoproteins exist. HDL delivers excess 
cholesterol to the liver for processing and elimination and is referred to as “good cholesterol”.  
LDL, in contrast, contributes to buildup of excess cholesterol in the blood and to the transport of 
cholesterol and lipids into the artery wall, and is often called “bad cholesterol.” LDL, if present at 
too high of a level in the blood, can accumulate in the artery wall increasing the risk of early 
atherosclerosis.  
High local concentration of LDL can promote atherogenesis by inducing EC injury and 
attracting more monocytes and lymphocytes to the intima of the vasculature. LDL is cytotoxic and 
especially damaging in diabetics as glucose can become linked to LDL. This glucose-LDL complex 
forms harmful sticky plaques due to increased uptake into the arterial wall and increased 
susceptibility to oxidative modification. Reacting with transition metal ions and free radicals 
produced by EC, SMC, or macrophages, LDL particles converts into oxidized LDL (ox-LDL). 
Meanwhile, attracted monocytes transmigrate into the vascular wall that release cytokines and 
chemoattractant proteins such as TNF-α and MCP-1181. Ox-LDL had been found to induce 
differentiation of monocytes to macrophages in vivo through activation of macrophage stimulating 
factor receptor182. Available LDL and ox-LDL further converts macrophages into lipid-loaded foam 
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cells which forms the fatty streak beneath the endothelium leading to atherosclerotic plaque 
formation. 
3.2.4.4 Oxidative stress 
Oxidative stress is another metabolic disorder that plays a crucial role in the development 
of diabetic complications. It results from the overproduction of reactive oxygen species (ROS, 
charged and uncharged molecular species including superoxide, hydroxyl radicals and hydrogen 
peroxide) and/or reactive nitrogen species (RNS, charged and uncharged species including 
peroxynitrite radicals and nitric oxide). ROS levels in the cytoplasm can become elevated due to 
leakage of ROS from mitochondria or by enzymatic/non-enzymatic generation in the cytoplasm. 
ROS and RNS are generated in all cells in the course of normal metabolism, and are necessary for 
various physiological activities (such as redox signaling and cellular defense mechanisms). 
However, their overproduction leads to modification of cellular structure (such as carbohydrates, 
proteins, lipids) alteration of normal biological functions (such as call activation, proliferation), and 
formation of cell-damaging toxic products (such as free radicals). Under hyperglycemic conditions, 
1) an excess amount of free radicals are generated; 2) gene transcription of proinflammatory 
cytokines (TNF-α) increases that induces NADPH oxidase expression; 3) AGE synthesis and AGE 
receptor expression increase; 4) the antioxidant defense system becomes impaired; and 5) auto-
oxidation of glucose occurs. All of these factors act to increase cellular oxidative stress, which 
induces β-cell dysfunction and cellular insulin resistance, thereby playing a role in the pathogenesis 
of diabetes.  
3.2.5 Effects of diabetes on arteriogenesis 
 Diabetes is a negative modulator of angiogenesis/arteriogenesis, acting through 
mechanisms that are yet to be elucidated. In studies of the coronary circulation of diabetics and 
nondiabetics who underwent coronary angiography, collateral development was found to be 
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impaired in the diabetic group183. Results from studies of experimentally induced hindlimb 
ischemia further demonstrated that blood flow recovery through arteriogenesis was less effective 
in type 2 (db/db) diabetic mice than control (C57BL/6) mice184. Diabetes can affect arteriogenesis 
through multiple mechanisms, including: 1) interfering with shear stress sensing; 2) inducing EC 
activation/dysfunction; 3) reducing monocyte growth factor receptor signal transduction capability 
and migration responses; and 4) increasing vasoconstriction and impairing flow mediated 
vasodilation.  
Shear stress is considered to be the primary stimulus for initiating arteriogenesis. 
Therefore, any reduction in the shear stress sensing capability of EC mechanoreceptors and the 
resulting impairment of associated downstream signaling by diabetes compromises arteriogenesis.  
EC dysfunction can occur when the normal functional homeostasis of different mediators 
gets imbalanced. If the generation of a certain mediator is more or less than its elimination level, 
then the overproduction or underproduction of the mediator alters normal cellular functions. One 
such example is optimal level of reactive oxygen species (ROS). A certain physiological level of 
ROS is required for cell to respond properly to extracellular stimuli that modulates normal cell 
survival, proliferation, and cellular signaling. However, when the homeostasis gets imbalanced, 
oxidative stress occurs which can lead to cellular death and different disease development. Several 
studies have reported that oxidative stress can reduce arteriogenesis during diabetes185;186. Diabetes 
reduces eNOS expression and function that has role in different steps of arteriogenesis187.  
Monocyte migration is one of the key steps in arteriogenesis, and is known to be reduced 
under diabetic conditions. For example, monocytes from rabbits with experimentally induced 
diabetes had reduced migratory response to VEGF-A and MCP-1 during the acute phase of 
arteriogenesis (induced by hindlimb ischemia) compared to monocytes from control rabbits188. 
Waltenberger et al. found that the migratory response of monocytes isolated from peripheral blood 
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could be stimulated ~150% by VEGF-A in non-diabetic individuals, but that VEGF-A could not 
stimulate monocyte migration at all in diabetics189. However, a similar level of monocyte migration 
in response to a peptide-G-protein coupled receptor mediated mechanism was seen in both diabetics 
and non-diabetics. These results suggest that impairment in growth factor release and activation of 
the related downstream chemotactic signaling pathways could be a major cause of impaired 
arteriogenesis during diabetes. These studies examined VEGF-A, which is not specific for 
arteriogenesis. Therefore, it is important that further studies be conducted to investigate the effects 
of diabetes on PLGF, a potent arteriogenesis-specific growth factor, to determine whether PLGF 
expression and/or PLGF dependent monocyte migration in arteriogenic collaterals is also impaired 
by diabetes.  
3.2.6 Role of endothelial cells in arteriogenesis 
In the setting of CVD, EC can also participate in the collateral artery remodeling process 
through production and release of growth factors such as PLGF and VEGF, which act to induce 
arteriogenesis and maintain blood supply to the distal tissues following upstream vascular 
occlusion.   
3.2.7 Endothelial cells and shear stress 
Along with enhanced expression of adhesion and inflammatory molecules, EC exposed to 
altered shear stress also release growth factors (VEGF-A) and express increased levels of growth 
factor receptors (VEGFR1/2) on their surface. These changes facilitate compensatory collateral 
growth and remodeling. Blood flow induced shear stress increases in collaterals during 
atherosclerotic plaque formation in major arteries, and numerous studies have provided evidence 
that this increase in shear stress is a major driving force for arteriogenesis190;191. Several studies 
have investigated the effect of shear stress on EC VEGF expression. Dela-Paz et al. reported a 
significant increase in VEGF and VEGFR2 mRNA and protein expression after exposing HUVEC 
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to orbital shear stress of 0.6 – 4 Pa for 72 hr192. Abumiya et al. found a 3- and 5-fold increase in 
VEGFR2 mRNA expression in HUVEC after 8 hr of 1.5 Pa and 4 Pa laminar shear stress, 
respectively193. Results from these studies indicate that EC activated by altered shear stress can 
play a major role in compensatory vascular remodeling. 
3.2.7.1 Placental growth factor (PLGF) 
Placental growth factor (PLGF), the second member of the vascular endothelial growth 
factor (VEGF) family to be discovered, plays a major role in the modulation of arteriogenesis. 
Though only 42% of the amino acid sequence of human PLGF matches that of VEGF-A (the best 
characterized VEGF family member), both proteins have remarkable topological similarity. Human 
PLGF gene encodes four different isoforms of PLGF, among which the primary difference lies in 
the presence or absence of the heparin binding domain194. All the isoforms are secreted as 
monomers and dimers. Due to the fact that PLGF was first cloned from a human placental cDNA, 
the growth factor was named PLGF. Though PLGF is indeed abundantly produced by the placenta, 
it is also produced in heart, lungs, and skeletal muscle by vascular EC, SMC, and activated 
inflammatory cells. Quiescent EC generally release less PLGF, whereas upon activation they can 
produce abundant PLGF195. However, PLGF does not directly promote angiogenesis (capillary 
proliferation), due to its lack of effect on EC proliferation196. Rather, PLGF stimulates 
arteriogenesis (enlargement of pre-existing collateral arterioles) by binding to its receptor VEGFR1 
on SMC and inflammatory cells like monocytes. VEGFR1 activation stimulates SMC growth, 
attracts monocyte migration into the vessel wall, induces cytokine (such as TNF-α and MCP-1) and 
SMC/EC mitogen production, and enhances the angiogenic activity of VEGF-A. The mitogenic 
response of capillary ECs to VEGF was found to be enhanced ~50% when cells were treated with 
VEGF and PLGF together, as compared to VEGF treatment alone197. PLGF deficiency has also 
been shown to impair responses to VEGF, but not basic fibroblast growth factor (bFGF), indicating 
that PLGF is a controlling switch for VEGF activity198.  
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PLGF expression also determines how SMC respond to VEGF, as PLGF deficient SMC 
were reported to proliferate normally only in the presence of both PLGF and VEGF199. Modulation 
of SMC behavior is important, as it is crucial for development of mature, durable, and functional 
collateral arteries. Indeed, when the angiogenic/arteriogenic stimulus such as increased shear stress 
reduces, collaterals can undergo rarefaction (diameter reduction and disappearance of some 
collaterals) and the remodeling process stops. PLGF may induce blood vessel growth in a more 
balanced way than other growth factors [VEGF or platelet derived growth factor (PDGF)] as it 
stimulates both EC and SMC behavior simultaneously; whereas, VEGF and PDGF preferentially 
modulate EC or SMC behavior, respectively200.  
PLGF can stimulate post-ischemic myocardial revascularization as effectively as VEGF, 
without the negative side effects of VEGF such as edema or hemangioma199. The PLGF-VEGF 
heterodimer has been reported to have more of a mitogenic effect on EC than the PLGF homodimer, 
but less effect than the VEGF homodimer201. The heterodimer has a higher binding affinity toward 
VEGFR1 that enables VEGFR1 to dimerize with either VEGFR1 or VEGFR2, if both receptors 
are simultaneously expressed on the cell surface. Depending on the receptor dimerization pattern, 
the receptor’s tyrosine residue phosphorylation level and resulting downstream signal pathway 
activation may vary202. Thus, PLGF directly activates VEGFR1 due to its binding specificity for 
the receptor and indirectly activates VEGFR2 1) by displacing VEGF-A from VEGFR1 and making 
more VEGF-A available for binding to VEGFR2, 2) forming heterodimers with VEGF-A that can 
bind to VEGFR2, and 3) through the VEGFR1/VEGFR2 transphosphorylation mechanism203. 
Mouse models lacking the PLGF gene have been developed for increasing our 
understanding of the role of PLGF. PLGF knock out (PLGF-/-) mice have no apparent defects in 
blood vessel development, but show reduced angiogenic or arteriogenic capability in response to 
ischemic insults such as myocardial infarction or hindlimb artery ligation198. For example, hindlimb 
collateral arteries are initially small in both PLGF-/- and wild type mice, but enlarge and become 
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tortuous post-ligation of the femoral artery only in wild type mice, not in PLGF-/- mice. In wild type 
mice, the PLGF level increases by ~45% in ligated femoral arteries, compared to non-ligated 
controls, resulting in attraction and infiltration of more monocytes and macrophages in collateral 
arteries of wild type mice than PLGF-/- mice. Moreover, fibronectin (which provides extracellular 
scaffolding for migrating SMC), extravasated or leaked in 70% of wild type mice but only 25% of 
PLGF-/- mice. These results further demonstrate PLGF’s role in increasing vascular permeability 
and plasma extravasation, which is important for arteriogenesis. Results from high resolution 
micro-CT scans indicate enhancement of collateral vessel growth after PLGF administration in 
mouse models of hindlimb ischemia. This increase in number and size of collateral vessels enlarges 
the total collateral perfusion area, thus restoring blood volume and flow following ischemia204. 
Similarly, Takaoka et al. found that administration of recombinant human PLGF for 3 days in a 
mouse model of acute myocardial infarction (MI) improved survival rate and cardiac function, 
suggesting an important role for PLGF in the healing process through stimulation of 
arteriogenesis205. Scholz et al. found a significant delay at the early stages of collateral enlargement 
in PLGF-/- mice, implying that PLGF is an important early mediator of arteriogenesis206. Luttun et 
al. reported that PLGF release can stimulate stable and mature vessel formation as effectively as 
VEGF in mouse ischemic heart. Likewise, in mouse ischemic hindlimb, PLGF administration 
increases perfusion area and improves functionality199.  
Although PLGF is one of the first factors to increase at the onset of arteriogenesis, it has 
not been studied as extensively as VEGF-A. Therefore, our group set out to investigate how PLGF 
expression is regulated and to identify molecular mechanisms modulating PLGF under 
physiological and pathological conditions, especially in the heart and skeletal muscle where 
arteriogenesis is very important as a compensatory mechanism during diabetic CAD or PAD. 
Though shear stress is considered as a major modulator of arteriogenesis and PLGF is a key 
arteriogenic growth factor, the effect of shear stress on PLGF expression has not been directly 
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investigated. Recently, our lab was the first to report that PLGF protein and mRNA expression in 
EC is significantly increased after exposure of coronary EC-SMC co-cultures to high dynamic shear 
exposure (mean time average of 1.24 Pa) mimicking conditions in remodeling collateral arteries. 
Our group also demonstrated that there is a significant increase in PLGF mRNA expression in 
mesenteric arterioles following exposure to a pressure gradient of 50 mmHg, compared to 20 
mmHg17.  
3.2.7.2 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a signaling protein that has a potent role in 
stimulation of vasculogenesis and capillary proliferation. The VEGF family consists of six 
members: VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and PLGF. All the six VEGF proteins are 
found as homodimers or heterodimers, covalently linked by disulfide bonds. Dimeric VEGF 
molecules act through binding to their tyrosine kinase receptors (VEGFRs).  
Before the discovery of the latter family members, VEGF-A was known as VEGF.  VEGF-
A, a heparin-binding dimeric glycoprotein of 34-42 kDa, acts mainly on EC, although it has effects 
on SMC and monocytes. VEGF-A contributes to angiogenesis (primarily) and arteriogenesis by 
increasing cell permeability, survival, proliferation, migration, and signal transduction through 
stimulating nitric oxide (NO) production and modulating signaling pathways. Gerber et al. reported 
that VEGF-A enhances cell survival in HUVEC via anti-apoptotic signaling through the Akt and 
PI3 kinase pathways207. VEGF-A was reported to enhance EC proliferation via VEGFR2 pathway 
stimulation and activation of ERK1/2 and JNK members of the MAPK family208. VEGF-A was 
also found to activate several transcription factors and modulate TF, PLGF, and NOS gene 
expression209;210. Vascular permeability is affected by VEGF-A, as the protein stimulates NO and 
prostacyclin (PGI2) production by endothelial cells210;211. Results from several studies indicated that 
VEGF-A is required for coronary collateral growth, and that blood flow induced shear stress has a 
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profound effect on VEGF-A protein and mRNA expression. Toyota et al. found that VEGF-A 
modulate coronary collateral growth in a rat model of repetitive coronary occlusion, as anti-VEGF-
A administration diminished collateral growth. dela-Paz et al. reported that arterial shear stress can 
increase VEGF-A expression in HUVEC both in vitro and in vivo192. Likewise, Conklin et al. found 
a significant increase in endothelial cell VEGF-A mRNA and protein expression after exposing 
porcine carotid arteries to low shear stress for 24 hr16.  
3.2.7.3 Vascular endothelial growth factor receptor (VEGFR) 
Vascular endothelial growth factor receptors (VEGFRs) are tyrosine kinase receptors that 
participate in angiogenesis and arteriogenesis by modulating various cellular functions. Three main 
isoforms (VEGFR1, VEGFR2, and VEGFR3) have been discovered that are present either as 
membrane bound proteins or in soluble forms generated by alternative splicing. VEGFR1 was the 
first VEGF receptor to be discovered on the EC surface of the vasculature. Though both VEGFR1 
and VEGFR2 are predominantly expressed by EC, they can also be found in SMC, monocytes, and 
trophoblasts. Whereas VEGFR1 is the receptor for both PLGF and VEGF-A ligands, VEGFR2 
exclusively interacts with VEGF-A. By competing with VEGF-A to bind with VEGFR1, PLGF 
potentially makes more VEGF-A available to bind with VEGFR2195.  
VEGFR1 and VEGFR2 generally form homodimers upon ligand binding, but can also form 
heterodimers with each other depending on the ligand’s dimer form (homodimeric or 
heterodimeric). Upon binding with PLGF or VEGF-A homodimers or heterodimers, VEGFRs 
dimerize resulting in tyrosine kinase activation and autophosphorylation of the tyrosine residues212. 
These events cause attraction of adaptor proteins or kinases to the phosphorylation region, inducing 
activation of downstream signaling pathways. After blocking VEGFR1 activity using an antibody, 
EC growth inhibition was observed, suggesting the necessity for PLGF or VEGF-A binding to 
VEGFR1 for EC proliferation. PLGF binding to VEGFR1 can initiate crosstalk with VEGFR2, 
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influencing the VEGFR2 activation level and eventually enhancing VEGF-VEGFR2 signaling. 
Also, soluble VEGFR1 can form complexes with VEGF-A and VEGFR2 which are inactive in 
nature. In human microvascular EC, this type of complex formation was found to inhibit VEGF-A 
induced cell migration and proliferation213. Thus, VEGFR1 can modulate VEGFR2 signaling either 
through crosstalk or by acting as a decoy receptor. Activation of VEGFR1 induces monocyte 
migration, and increases EC production of inflammatory and adhesion molecules; whereas 
VEGFR2 activation leads to enhanced cell proliferation, migration, and NO release214;215.  
Several studies have investigated the effect of shear stress on EC VEGFR expression. After 
applying orbital shear stress on HUVEC for 72 hr, dela-Paz et al. found a four-fold increase in 
VEGFR2 protein expression in shear stress stimulated cells compared to static HUVEC192. Urbich 
et al. reported a time- and dose-dependent increase in VEGFR2 expression after exposing HUVEC 
to shear stress of 1.5 Pa for 6-24 hr, and to 0.5-4.5 Pa for 16 hr216. These studies suggest that VEGFR 
expression of EC is modulated by shear stress. 
3.2.8 Role of platelets in arteriogenesis 
Another important function of platelets is to transport proteins. Platelets can take up proteins 
from one region of the circulation and release them upon activation in a different/targeted region, 
helping to localize inflammation and collateral outward remodeling. Platelets take up proteins by 
diffusion, endocytosis, or through the export transporters present on their surface membrane. They 
also have the “open canalicular system” of channels, arising on the plasma membrane and leading 
into the platelet interior, which may facilitate uptake or secretion of protein molecules. Platelets are 
effective transporters of proteins as they are present in large numbers in blood, have compartments 
to store proteins, and circulate freely through the body. Thus, by transporting growth factors to 
collateral blood vessels, platelets can contribute to arteriogenesis. However, during hyperglycemia 
(fasting plasma glucose level >126 mg/dL or >200 mg/dL after two hours of 75 g oral glucose 
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intake) or hyperlipidemia (total plasma cholesterol level >200 mg/dL and LDL level >130 mg/dL), 
associated with coronary artery disease (CAD) in diabetic patients, altered platelet calcium 
homeostasis can occur, resulting in platelet hyperactivity217;218. Evidence has shown that an elevated 
blood glucose level can increase production and secretion of platelet activation agonists (such as 
thrombin), platelet activation, and adhesion, suggesting that hyperglycemia may affect 
uptake/release of growth factors by platelets as well. 
To compensate for the reduced arterial blood flow arising from these disease conditions such 
as CAD, activated platelets can take up or release growth factors like PLGF and VEGF to induce 
arteriogenesis. Even though several studies have quantified the release/uptake of these proteins by 
activated platelets in response to shear stress, few have utilized physiologically relevant dynamic 
shear stress conditions. Therefore, those in vitro studies may not accurately replicate in vivo 
conditions. 
3.2.9 Cell-cell interaction 
The presence of pathological atherosclerotic plaque in major blood carrying arteries 
reduces blood flow through the arteries, resulting in increased flow through collaterals. Increased 
blood flow increases shear stress level on the EC of the collateral artery wall. Hence, EC of 
collateral arteries become activated and release growth factors like PDGF, PLGF and VEGF. EC-
released growth factors can be sensed by SMC through tyrosine kinase receptors that modulate 
SMC’s migration, proliferation, and growth factor expression. Thus, paracrine signaling between 
EC and SMC through released or diffusible mediators plays a major role in blood vessel 
formation/radial growth and function under both physiological and pathological conditions. 
Compared to SMC, EC produce and release less VEGF and more PLGF. However, PLGF produced 
by EC and VEGF released by SMC influence each other in a paracrine manner to enhance each 
other’s mitogenic potential. Activated platelets or platelets adhering to EC can take up these growth 
factors through endocytosis and via uptake transporters present on platelet plasma membrane. 
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Circulating activated platelets can then act as a transporter, releasing the growth factors at another 
site through fusion and exocytosis. Released PLGF and VEGF interact with their corresponding 
receptors, VEGFR1 and VEGFR2, present either in soluble form or on the platelet and EC surface, 
initiating signaling cascades for arteriogenesis.  
The goal of study 2 was to investigate how levels of the arteriogenic growth factor PLGF 
are modulated in heart and skeletal muscle cells. Building on previous results from our lab, we 
characterized molecular mechanisms by which diabetes-associated metabolic dysfunction alters 
PLGF expression. In further experiments, we tested how high dynamic shear stress mimicking 
conditions in coronary/peripheral collateral arteries can modulate PLGF production, and how 
hyperglycemia can alter these effects of shear stress. Our findings suggested a novel mechanism 
for the impairment of coronary and peripheral collateral artery growth that is observed to occur in 
diabetes. Further exploration of this mechanism may lead to the development of novel therapeutic 
treatments that will benefit people suffering from CAD/PAD and diabetes. 
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CHAPTER IV 
 
 
RESEARCH DESIGN AND METHODS 
 
4.1 Detailed methods section 
Washed platelets 
Fresh platelet rich plasma (PRP) was purchased from Oklahoma Blood Institute (Oklahoma 
City, OK) and centrifuged at 3,000 rpm (1,100xg) for 9 min to separate platelets from plasma. The 
supernatant (or platelet poor plasma, PPP) was collected separately and stored at -80ºC for future 
use. Platelet pellets were resuspended in HEPES buffered modified Tyrode’s solution (HBMT; 137 
mM sodium chloride, 2.7 mM potassium chloride, 0.36 mM monobasic sodium phosphate, 12 mM 
sodium bicarbonate, 2 mM magnesium chloride, 0.2% BSA, 5.5 mM 2% dextrose, and 0.01M 
HEPES; pH = 7.4) to prepare washed platelets. The platelet number was counted using an optical 
particle counter (Z1 Coulter particle counter, Beckman Coulter, Brea, CA) and the volume of 
washed platelets was adjusted to achieve a final platelet concentration of 250,000/μL. This 
concentration was maintained for all the experiments. 
Cell culture – Monoculture model 
Human coronary artery endothelial cells (HCAEC) and human skeletal muscle cells 
(HSKMC) were purchased from LONZA (Walkersville, MD), and, human cardiac muscle cells
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(HCM) and mouse cardiac muscle cells (MCM) were purchased from Sciencell Research 
Laboratories (Carlsbad, CA). Mouse skeletal muscle cells (MSKMC; ATCC, Manassas, VA) were 
kindly provided to us, for experimental purpose, by Dr. Clarke of OSU. Initially, cells were thawed 
and cultured in T-75 (75 cm2 rectangular area) flasks. Cells were maintained in Endothelial cell 
basal medium (EBM), Skeletal muscle cell basal medium (SKBM), Cardiac muscle cells medium 
(CMM), and Dulbecco's modified eagle's medium (DMEM) respectively, supplemented with 
corresponding growth factors and bullet kits as mentioned by the manufacturers and were kept in 
5% CO2 containing, 37 ºC temperature humidified incubator. The culture medium was refreshed in 
every alternate day. For cardiac muscle cells, T-75 flasks were coated initially with poly-L-lysine 
solution to enhance cell attachment and growth. Also, HCM and MCM were used directly, without 
sub-culturing into different passages, as they can terminally differentiate in other cell types in long-
term culture. For other cell types, upon confluency, cells were trypsinized and sub-cultured in 6 or 
12 well plates/petri dishes according to the need of the experiments. For a particular cell line, equal 
numbers of viable cells were seeded on each well of the plates or petri-dishes after conducting cell 
count using hemocytometer.  
Cell culture – Co-culture model 
 Human coronary artery smooth muscle cells (HCASMC) and human iliac artery EC 
(HIAEC) were purchased from LONZA. After thawing, cells were grown in T-75 flasks and 
maintained in smooth muscle cell basal medium (SMBM) and endothelial cell basal medium 
(EBM) respectively, supplemented with the bullet kit components, until reached to confluency. To 
enhance physiological relevance further through cell-cell interaction, cells were trypsinized, 
neutralized, and co-cultured on porous Transwell inserts (Corning Costar) of 0.4 µm sized pores. 
Two different types of co-culture models were developed: HCAEC-HCASMC (for studying CAD) 
and HIAEC-HCASMC (for studying PAD). Initially, the bottom surface of the inserts was coated 
with 0.1% gelatin (to enhance cell attachment on the insert surface) and kept in the humidified 
63 
 
incubator (37 ºC and 5% CO2) for 1 hr. HCASMC were then seeded on the bottom side of the 
inserts and incubated overnight in the incubator. Next day, inserts with cells were placed in 
supplemented SMBM containing wells of 6 well plates and returned to the incubator for overnight 
incubation. Coating the top surface of the inserts with 0.1% gelatin for 1 hr in the following day, 
HCAEC or HIAEC were seeded with supplemented EBM medium. The plates with the inserts were 
then put back in the incubator and cells were grown to confluency. Afterwards, confluent co-
cultures were serum starved for 24 hr in the corresponding reduced serum medium prior to any 
shearing experiments.   
Cone-Plate shearing device 
A modified cone and plate shearing device, based on the original design of Blackman, was 
used to investigate the effects of shear stress on platelets and EC219. Based on the experimental 
needs, two different types of devices were used in this study to expose platelets and EC layer (both 
in mono and co-cultures) to different constant and dynamic shear stress waveforms. One device 
used a single cone (cone angle 2) and could accommodate a 6 cm diameter polypropylene petri 
dish (Figure 4.1A). The other had four cones (with two different heights and diameter, 0.5 angle) 
in the outer side and could fit with a 6-well plate (Figure 4.1B) with or without the inserts. The 
middle two wells of the 6 well plate were not sheared and were used as static control. The cones 
were made of ultra-high molecular weight polyethylene (UHMWPE) and were coupled to micro-
stepper motors. The motors were connected to a microcontroller (Allegra, Optimal Engineering 
System, Van Nuys, CA) unit which was guided through BASIC programs to generate specified 
shear stress waveforms. Both devices were capable of generating uniform laminar shear stress in 
the flow field. The maximum shear stress the single cone and plate shearing device could achieve 
was 7.2 Pa, and that for the multi-channel cone and plate shearing device was 12 Pa.  
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Using the following equation, the generated shear stress values of the cone and plate 
shearing devices were calculated: 
𝜏 =
µ𝜔
𝛼
  (Equation 3) 
where τ = shear stress, ω = angular velocity of the cone, α = angle of the cone, and µ = dynamic 
viscosity of the fluid. 
 
Figure 4.1: The cone and plate shearing devices: A) Single cone-plate, and B) Multi-channel cone-
plate. 
Coronary artery blood flow induced shear stress 
Four constant (0.1 Pa, 0.3 Pa, 1 Pa, and 3 Pa) and three dynamic (normal, low, and elevated) 
shear stress waveforms were applied to platelets and EC in vitro using the cone-plate shearing 
devices46.  
Constant shear stress of 1 Pa was chosen as it represents shear stress commonly found in 
healthy left coronary arteries; low shear stress at 0.1 and 0.3 Pa are typical in recirculation zones; 
whereas elevated shear stress at 3 Pa is often found on stenotic regions. In order to simulate 
physiologically relevant shear stress conditions, dynamic shear stress (normal, low and elevated) 
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waveforms were also employed. These dynamic shear stress waveforms were obtained from 
numerical modeling conducted in our lab220. 
Platelet shear stress (coronary artery blood flow) 
The normal shear (NS) waveform (varies between 0.05 to 1 Pa in 0.9 sec) mimics the 
physiological pulsatile shear stress condition experienced by platelets in the healthy left coronary 
artery (when platelets travel close to the wall); low shear (LS, varies between 0.06 to 0.4 Pa in 0.9 
sec) stress simulates pathological shear conditions occurring in the recirculation zones past a 
stenosis; and elevated shear (ES) represents pathological shear stress experienced by a platelet as 
it passes through a 60% stenosis. While passing through the stenosis, the platelet experiences an 
elevated shear stress of 6.5 Pa for only 0.1 sec, followed by normal shear (0.1 to 1 Pa) stress for 
rest of the time. For the purposes of this study, it was assumed that platelets pass through the same 
stenosis once every 90 sec. The three dynamic shear stress waveforms that were applied to platelets 
are illustrated in Figure 4.2A. 
EC shear stress (coronary artery blood flow) 
Dynamic shear stress waveforms applied to EC are shown in Figure 4.2B. In a normal left 
coronary artery, wall shear stress varies between 0.1 and 1 Pa (NS) in 0.9 sec; around a stenosis, 
wall shear stress can be elevated to 6.5 Pa (ES). In recirculation zones past a stenosis, low 
unidirectional shear stress can develop, varying between 0 and 0.4 Pa (LS).  
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Figure 4.2: A) Shear stress history of platelets passing through the left coronary artery under 
physiological (normal) and pathological (low and elevated) conditions. Inset A, B, C (at right side) 
show the corresponding trajectories of platelets passing through healthy left coronary artery, 
platelets trapped in a recirculation zone past the stenosis region, and platelets passing through a 
stenosis throat respectively. B) Wall shear stress distribution of EC46. 
Collateral blood flow induced shear stress 
Platelets and EC (of both monoculture and co-culture) were exposed to two different 
dynamic (normal and elevated) shear stress waveforms of coronary/peripheral collateral arteries in 
vitro using the 6 well cone-plate shearing devices. Since coronary/peripheral collateral arteries are 
small in size (~0.2 mm diameter), it was assumed that both EC and platelets (travelling close to 
EC) are exposed to the same shear stress waveforms in vivo.  
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The coronary collateral shear stress waveforms were obtained from a previously published 
paper by Mack et al., in which the authors conducted numerical simulation in a lumped parameter 
model of a coronary collateral artery158. The normal shear waveform (NS, time average value of 
0.07 Pa) models physiological shear stress conditions experienced by EC in a normal collateral 
vessel downstream of a healthy coronary artery; whereas, elevated shear stress (ES, time average 
value of 1.24 Pa) describes the pathological shear stress conditions experienced by platelets or EC 
in a remodeling collateral vessel downstream of a 60% stenosed coronary artery. Figure 4.3 shows 
the applied coronary collateral dynamic shear stress waveforms.  
 
Figure 4.3: Shear stress waveforms (normal and elevated shear) of coronary collateral arteries 
applied to platelets and EC using a cone and plate shearing device. 
 
The peripheral collateral artery shear stress waveforms were obtained from Watanabe et 
al.’s paper, where the authors developed a distributed-parameter hemodynamic model (a simple 
and effective blood flow simulation model in deformable blood vessels) of the arm, focusing on 
the anatomically detailed arterial structure296. From their paper, the flow rate waveform of the 
superior ulnar collateral artery was obtained from which the shear stress waveform was calculated 
using Hagen-Poiseuille’s equation [τ = (4µQ/πr3), τ = shear stress, μ = blood viscosity, Q = blood 
flow rate, and r = the internal radius of the vasculature (provided in the paper)]. The time average 
68 
 
value of the normal shear stress came as 0.156 Pa that models the physiological shear stress of a 
healthy superior ulnar collateral artery. As it was found from coronary collateral circulation that 
the time average value of elevated shear stress was about 17.7 times higher than the normal shear 
stress time average, the same scaling value was utilized for elevated shear stress (ES) calculation 
in the remodeling superior ulnar collateral artery downstream of diseased (60% stenosed) main 
(brachial) artery. This resulted in the time average value of ES as 2.753 Pa. The obtained shear 
stress waveforms of peripheral collateral artery are shown in Figure 4.4.  
 
Figure 4.4: Normal (NS) and elevated shear (ES) stress, of peripheral collateral arteries, applied to 
HIAEC of the co-culture model to mimic healthy/diseased peripheral arterial condition. 
Perfusion flow chamber 
 To further enhance the physiological relevance of our study, a perfusion flow chamber 
(Figure 4.5) was used to investigate the role of dynamic shear stress (as found in coronary blood 
vessels) on EC ex vivo. The chamber was fabricated using polydimethylsiloxane elastomer (PDMS, 
Sylgard-184, Dow Corning). Two 16G2” I.V. catheters were positioned at opposite ends of the 
chamber. A freshly harvested rat aorta was cannulated to the catheters using suture and kept 
immersed in HEPES buffered physiological salt solution (NaCl: 142 mM, KCl: 4.7 mM, MgSO4: 
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1.17 mM, CaCl2 1.56 mM, glucose: 5.5 mM, HEPES: 10 mM, KH2PO4: 1.18 mM, 1% 
penicillin/streptomycin, pH = 7.4). Aortas were obtained, within 10 min of euthanization of a rat, 
through a tissue sharing plan at OSU.  
 
Figure 4.5: A) Flow chamber connected to a pump through silicone tubing to investigate the effects 
of dynamic shear stress on explanted rat aorta’s EC. B) Flow chamber with the cannulated aorta.  
Through pump tubing (Inner diameter 1.587 mm and 3.175 mm; Tygon tubing, vWR 
International, Batavia, IL), the flow chamber (aorta and the catheters) was connected to a 
programmable peristaltic pump (Manostat Varistallic Compulab 3 Modulus Dispensing System, 
Thermo Scientific, Waltham, MA). Physiological salt solution was perfused through the aorta at 
different flow rates using this pump to generate different shear waveforms. Adjusting the pump 
flow rate, the generated shear stress (obtained using equation 4) could be precisely controlled at the 
aorta wall.  
𝜏 =
4µQ
r3
  (Equation 4) 
where, µ = fluid viscosity (1 cP for the physiological salt solution), Q = fluid flow rate, and r = 
blood vessel diameter. Pulsatile flow at 20 mL/min, 8 mL/min, and 124 mL/min could generate 
normal (0 to 1 Pa), low (0 to 0.4 Pa), and elevated (0 to 6 Pa) pulsatile wall shear stress within the 
cannulated aorta. 
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4.2 Specific aim 1: The goal of this aim was to measure platelet and endothelial cell (EC) 
responses under physiologically relevant dynamic shear stress conditions in vitro, and to 
determine whether the presence of one cell type affects the responses of the other to shear. In 
addition, the effects of dynamic shear stress on endothelial cell responses ex vivo, in a rat 
aorta model, was also investigated. 
4.2.1 in vitro study 
Confluent EC and platelets were exposed to constant or dynamic shear stress of the 
coronary artery, either together or separately, in cone-plate shearing devices for 60 min. Platelet 
responses were measured through cell surface PECAM-1, GPIb, and GPIIb expression, as well 
as PMP generation. EC responses were measured through EC surface and released vWF and TF 
expression, as well as EMP generation.  
4.2.1.1 Platelet surface PECAM-1 expression  
After shear exposure (with or without EC), platelet samples were collected and incubated 
with FITC conjugated murine anti-human PECAM-1 (1:50 dilution, Ancell Corporation, Bayport, 
MN) antibody for 30 min at room temperature (RT). Post incubation, samples were diluted in 
HBMT (1:10) and analyzed using flow cytometry (Accuri Cytometers Inc., Ann Arbor, MI). FITC 
conjugated MOPC (1:100 dilution, Ancell Corporation) antibody (an isotype control) was used to 
detect non-specific antibody binding. Thrombin receptor activator peptide (TRAP6, 20 µM, 5min, 
RT) treated platelets were used as the positive control, representing fully activated platelets; 
whereas resting platelets (alone or with EC) were used as the negative control. 
4.2.1.2 Platelet surface GPIbα expression 
Platelets were exposed to various shear stress conditions for 60 min. Platelet samples were 
taken every 15 min and incubated with FITC conjugated mouse anti-human monoclonal GPIbα 
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(CD42b, 1:10 dilution, Abcam, Cambridge, MA) antibody for 30 min at RT. Samples were then 
diluted 10-fold in HBMT and analyzed using flow cytometry. 
4.2.1.3 Platelet surface GPIIb expression 
Timed platelet samples (collected every 15 min during shear exposure) were also examined 
for cell surface GPIIb expression, using FITC conjugated murine anti-human CD41a (30 min at 
RT, 1:50 dilution, Ancell Corporation, Bayport, MN) antibody, by flow cytometry. 
4.2.1.4 EC surface vWF expression 
EC surface vWF expression in response to shear stress was measured using a solid phase 
ELISA approach. Confluent EC were exposed to various shear stress (constant/dynamic) 
waveforms in the presence or absence of platelets. After shear exposure, supernatant (cell media or 
buffer containing platelets) was removed and EC were washed and fixed with 0.5% glutaraldehyde 
(Sigma Aldrich, St. Louis, MO) for 15 min at 37C. Following neutralization using glycine-0.1% 
BSA (30 min at 37C), EC surface vWF expression was measured using monoclonal mouse anti-
human vWF antibody (1 µg/mL, Abcam, Cambridge, MA, 60 min at 37C). Primary antibody 
binding was detected using an alkaline phosphatase conjugated goat anti-mouse (Sigma-Aldrich, 
1:1000 dilution) secondary antibody (60 min at 37C), followed by p-nitrophenyl phosphate 
substrate (pNPP) incubation (20 min). Color development was measured using a micro-plate reader 
(Beckman Coulter, DTX 880) at 405 nm wavelength. 
4.2.1.5 EC surface TF expression 
Using solid phase ELISA, EC surface TF expression was measured similarly as described 
for vWF, in constant shear stress exposed EC, using polyclonal rabbit anti-human TF (1 µg/mL, 
Abcam for 60 min at 37C) antibody.  
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4.2.1.6 Soluble vWF expression  
Soluble vWF (released by activated platelets and EC) expression was measured by 
sandwich ELISA technique using a commercial vWF ELISA kit (Abcam, Cambridge, MA). After 
shear exposure of 60 min, the fluid phase was collected and centrifuged at 3,000g for 6 min. The 
supernatant was then collected and applied to a microtiter plate pre-coated with murine monoclonal 
anti-human antibody against human vWF (2 hr at RT). Biotinylated anti-human secondary antibody 
(2 hr at RT) was used to bind with the captured vWF for detection. Secondary antibody binding 
was then detected using streptavidin conjugated peroxidase (30 min in RT), followed by a 
chromogen substrate (15 min, RT). Color development was measured using a micro-plate reader at 
450 nm wavelength.     
4.2.1.7 PMP and EMP generation 
After shear exposure, the fluid phase (containing platelets, PMP and EMP) was collected 
and centrifuged at 1,500xg for 15 min at RT. Post-centrifugation, supernatant was collected and 
subjected to a subsequent centrifugation at 17,000xg for 2 min at 4ºC. After removing the 
supernatant, the isolated microparticle pellets were resuspended in 50 µL HBMT. The samples 
were then incubated with two different antibodies, CD31 (red, 1:12.5 dilution; BD Pharmingen, 
San Jose, CA) and CD42b (green, 1:12.5 dilution; BD Pharmingen, San Jose, CA) for 30 min at 
RT. Post-incubation, samples were diluted in HBMT (1:10) and analyzed using flow cytometry. 
FITC (green fluorochrome) and R-PE (red fluorochrome) conjugated MOPC antibodies (Isotype 
controls, 1:100 dilution, Ancell Corporation, Bayport, MN) were used to detect non-specific 
binding. 
Suitable gates for platelets (using resting platelets) and MP (smaller than platelets) were 
established based on the particle size in the density plot (side scatter vs forward scatter). 30,000 
events were counted within the MP gate. EMP were distinguished from PMP using CD31 and 
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CD42b dual staining, as EMP are CD31+/CD42b- and PMP are CD31+/CD42b+. Events occurring 
in quadrant 1 (CD31+/CD42b-) were counted as EMP; events occurring in quadrant 2 
(CD31+/CD42b+) were counted as PMP (Figure 4.6).  
 
Figure 4.6: Pseudo-color scatter plots (CD31 vs CD42b) showing EMP (Q1 gate) and PMP 
population (Q2 gate) in A) control and B) sheared sample. 
4.2.1.8 Platelet adhesion to EC 
Platelet adhesion to EC was observed using optical microscopy. Platelet and EC were co-
sheared for 60 min in the cone-plate shearing device under dynamic shear waveforms. After shear 
exposure, platelet supernatant was aspirated out and EC were fixed with glutaraldehyde (15 min, 
37C). Platelet adhesion to EC was then observed using an optical microscope (Nikon TE 2000U). 
White light images at 40X magnification were captured by the digital camera (Coolsnap Fast 
Cooled ES2), connected to the microscope, in each well at 3 different randomized locations. EC 
treated with TNF-α (to induce activation) were used as a positive control. Using ImageJ software 
(v1.46, NIH), number of platelets adhering to EC surface in the total image area were counted 
manually from each images.  
 
74 
 
4.2.2 ex vivo study 
Activation and functional changes of EC were examined in rat aortas ex vivo using a 
perfusion flow chamber. Freshly harvested rat aortas were cannulated to the inlet and outlet 
catheters of the flow chamber. The chamber was connected to a peristaltic pump through silicone 
tubing and the open ends of the tubing were immersed in a reservoir containing physiological salt 
solution. The whole setup, except the pump, was placed within an incubator at 37C. A schematic 
diagram of the perfusion flow chamber and the setup is shown in Figure 4.7. 
 
Figure 4.7: Schematic representation of the flow loop of perfusion flow chamber with the 
cannulated aorta. 
 Through a tissue sharing plan, abdominal aortas of recently euthanized adult rats (Wistar 
rats; combination of males and females of 5 to 7 months of age) were collected. Harvested aortas 
were ~0.15 cm in diameter and 2-3 cm in length. HEPES buffered physiological saline solution 
was used to preserve the aorta (4ºC) until perfusion. All experiments were conducted within 24 hr 
of dissection to ensure integrity and proper functionality of the cells and the tissue. The aorta was 
cleaned and cannulated to the catheters of the flow chamber using 2-0 silk suture. Physiological 
saline solution was then perfused through the aorta for 2 hr to investigate the effects of shear stress 
on EC responses. Dynamic wall shear stresses mimicking conditions within the left coronary artery 
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(normal - 0 to 1 Pa, low - 0 to 0.4 Pa, and elevated - 0 to 6 Pa) were applied to the aorta by adjusting 
the flow rate of the programmable peristaltic pump (Manostat Varistallic Compulab 3 (RD-1) 
Modulus Dispensing System, Thermo Scientific, Rockford, IL). Calculations from Hagen-
Poiseuille’s equation (𝜏 =
4µQ
r3
)  indicated that flow rates of 20 mL/min, 8 mL/min, and 124 
mL/min could generate normal (1 Pa), low (0.4 Pa), and elevated (6 Pa) shear stress conditions 
respectively, assuming that perfusate viscosity (µ = 1 cP for saline solution) and abdominal aorta 
diameter (r = 1.52 mm) were constant. Post-shearing, the shear exposed section of the abdominal 
aorta was collected and gently washed in phosphate buffer saline (PBS; 9% sodium chloride, 1 M 
sodium dibasic phosphate, 0.5 M sodium monobasic phosphate; pH = 7.4) to remove any perfusate 
remaining, then fixed in 4% paraformaldehyde (4C, overnight). The fixed aorta samples were 
prepared for paraffin embedding and tissue sectioning (5 µm thickness), as well as haematoxylin 
and eosin (H&E) staining, at the Oklahoma Animal Disease Diagnostic Laboratory. In parallel, 
sheared rat aortas were homogenized using a motor pestle, and aorta wall proteins were extracted 
to run Western blot experiments. 
4.2.2.1 Immunostaining of paraffin-embedded tissue sections 
 To remove the fixative from the tissue sections, the slides were washed through 
consecutive changes of xylene (2 changes, 5 min each) and alcohol (100% dehydration alcohol and 
95% dehydration alcohol, 1 change, 5 min each). After washing with PBS+0.05% Tween 20 for 10 
min, tissue sections were blocked with 3% hydrogen peroxide (3 min, RT) and 2% goat serum (25 
min, 37C). After another set of washes, mouse monoclonal anti-rat vWF antibody, mouse 
monoclonal anti-rat ICAM-1 antibody, and rabbit polyclonal anti-rat TF antibody (all at 1:100 
dilution, overnight at 4C) were used to detect vascular wall vWF, ICAM-1, and TF expressions 
respectively. Non-specific antibody binding was also detected using MOPC antibody. To detect 
primary antibody binding, biotinylated secondary antibody (diluted in 2% serum at 1:1000 dilution) 
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was added to the slides and incubated for 30 min at RT. Immunoreactivity was further enhanced 
by amplifying the signal intensity using avidin-biotin complex (ABC reagent, Thermo Scientific, 
Rockford, IL) for 30 min at RT. The tissue sections were then stained with DAB substrate (1:10 
dilution in stable peroxide buffer, 10 min at RT; Thermo Scientific), followed by counter staining 
with haematoxylin (2 min, RT). Using a Nikon TE 2000U microscope, the slides were then 
examined and the images (at random locations) were captured using a CoolSnap fast cooled digital 
camera.  
4.2.2.2 Sub-cellular protein extraction for Western blotting  
 Cytoplasmic and membrane proteins of the abdominal aorta wall were extracted using a 
commercial kit (Thermo Scientific, Rockford, IL). After washing with ice-cold PBS, tissue samples 
were finely chopped on ice to prevent degradation of proteins and placed in ice-cold cytoplasmic 
extract buffer (with protease inhibitors). Tissues were then homogenized for 20-30 sec using a 
motor pestle (vWR international, Batavia, IL). The cytoplasmic extraction buffer released the 
cytoplasmic contents by permeabilizing the cell membranes. Homogenized samples were 
centrifuged at 500g for 5 min to separate the tissue debris from the protein extract. Post 
centrifugation, cytoplasmic protein extract was collected and stored immediately at 4C. Ice cold 
membrane extract buffer with protease inhibitors was then added to the tissue pellets and mixed 
gently for 10 min at 4C. After proper mixing, the samples were centrifuged at 3,000g for 5 min 
and the supernatant containing membrane protein extract was collected. Extracted proteins 
(cytoplasmic and membrane) were stored at -80C until use. The bicinchoninic acid (BCA) protein 
assay (Thermo Scientific, Waltham, MA) was used to determine the total protein concentration of 
the tissue samples. Extracted samples were used to determine the aorta wall vWF, ICAM-1, and 
TF expressions by Western blotting. A Dual Cool Mini-Vertical Electrophoresis/Blotting System 
(DCX-700, CBS Scientific, vWR International, Houston, TX) was used for this purpose. Adding 
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sample buffer (containing Sodium Dodecyl Sulfate (SDS) and beta-mercaptoethanol) to tissue 
protein extracts, samples were reduced and denatured at 95C for 5-7 min. Same amounts of 
denatured samples (cellular and membrane protein extracts) were loaded in each lane of the 4% 
loading gel (0.83 mL of 30% protogel, 1.57 mL of 2M Tris-Cl-, pH 8.7, 3.81 mL deionized water, 
0.05 mL 10% Ammonium persulfate, 0.031 mL 20% SDS, 0.013 mL Tetramethylethylenediamine) 
and electrophoretically separated according to their molecular weight in 10% running gel (4.2 mL 
of 30% protogel, 3.14 mL of 2M Tris-Cl-, pH 8.7, 5.1 mL deionized water, 0.1 mL 10% Ammonium 
persulfate, 0.062 mL 20% Sodium dodecyl sulfate, 0.026 mL Tetramethylethylenediamine) at 150 
V (constant voltage) for 90 min. Constant voltage was used so that proteins could migrate through 
the gel at a constant rate without overheating the gel (according to manufacturers’ instruction). The 
protein bands of the gel were transferred and immobilized from gel to nitrocellulose membrane 
through application of electrical current at 200 mA (constant current) for 3 hr (according to 
manufacturers’ instruction). Care was taken to maintain the electro-blotting buffer temperature 
below 4C. Dual color precision plus protein standard (Biorad, Hercules, CA), tagged with 
recombinant proteins of molecular weight of 10-250 kDa, was used for monitoring electrophoretic 
separation and efficient blot transfer, and easier identification of the targeted proteins. Running gels 
were Coomassie blue stained to assess whether protein transfer from gel to membrane was proper 
or not. Nitrocellulose membranes were then blocked in 5% bovine serum albumin (BSA) for 1 hr 
at RT and incubated with rabbit polyclonal anti-rat vWF, mouse monoclonal anti-rat ICAM-1, and 
rabbit monoclonal anti-rat tissue factor primary antibodies separately (all antibodies at 1:1000 
dilution, overnight, 4C, with gentle agitation; Abcam, Cambridge, MA). Primary antibody binding 
was detected using HRP conjugated goat anti-mouse or goat anti-rabbit secondary antibody (1:1000 
dilution, 1 hr, RT; Abcam, Cambridge, MA). An enhanced chemiluminescence (Novex ECL 
chemiluminescence substrate reagent kit, Invitrogen, Grand Island, NY) substrate was used to bind 
to the secondary antibody which was detected using the FluorChem system (Cell Bioscience, Santa 
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Clara, CA). Using spot densitometry (intensity of light within a certain region), the intensity of the 
developed protein bands was then quantified. In all the experiments, beta actin was used as the 
loading control. Intensity of each protein expression of the sheared aorta was normalized to the 
corresponding total protein concentration (from the BCA assay), and to the non-sheared aorta's 
corresponding protein expression for data analysis purpose. 
4.3 Specific aim 2: The goal of this aim was to study signaling pathways involved in 
endothelial cell responses to dynamic shear stress. 
Confluent EC were exposed to dynamic shear stress waveforms (of coronary artery) to 
investigate if the MAPK pathway and NF-κB activation were involved in EC responses to shear 
stress. Effect of platelets on EC signaling pathway activation was also examined.  
4.3.1 Level of MAPK members’ phosphorylation of EC  
Protein concentration of phosphorylated ERK1/2, JNK, and p38 were measured using 
Western blot after EC were exposed to various dynamic shear stress (normal and low) waveforms 
with or without the presence of platelets for 2, 5, 15, 30, and 60 min.  
Post shearing, EC were washed 2X with PBS and detached from the plate using trypsin-
ethylenediaminetetraacetic acid (EDTA). EC were then lysed (60 min at 4C) using lysis buffer 
(TBS with 1% Triton X-100, supplemented with protease and phosphatase inhibitor cocktail). 
Based on calculation, volumes of lysis buffer were so adjusted that protein concentration remain 
same in different samples. Lysed samples were centrifuged at 14,000g for 5 min, and the 
supernatants (lysate) were collected and stored at -80C until use.  
MAPK pathway activation was assessed through quantification of phosphorylated 
ERK1/2, JNK, and p38 proteins level using Western blot (following similar procedure mentioned 
in “Sub-cellular protein extraction for Western blotting” in the previous specific aim). Same 
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amount of extracted samples was loaded in the gel, separated, and transferred from gel to 
nitrocellulose membrane. The membranes were then blocked in 5% w/v bovine serum albumin 
(BSA) solution (dissolved in 1X Tris Buffer Saline Tween 20; 137 mM Sodium Chloride, 20 mM 
Tris, 0.1% Tween-20, pH = 7.4) for 1 hr at RT. Phosphorylation levels of MAPK proteins were 
detected using rabbit monoclonal anti-human antibodies against phosphorylated ERK1/2, JNK, and 
p38 (Cell Signaling Technology, Danvers, MA) (overnight, 4C, with gentle agitation). Primary 
antibody binding was detected using HRP conjugated goat anti-rabbit secondary antibody (1:1000 
dilution, 1 hr, RT) (Abcam, Cambridge, MA). Enhanced chemiluminescence was used for signal 
detection as described before. The intensity of the bands was quantified using the spot densitometry 
technique to measure the level of protein phosphorylation. In all the experiments, beta actin was 
used as an experimental control and purified ERK1/2, JNK, and p38 proteins (15 µL of each control 
extract) were used as positive control. 
Alternatively, MAPK pathway activation was assessed using immunocytochemical 
staining. Following shear treatment for 60 min, cells were washed with warm PBS and fixed with 
0.5% glutaraldehyde (for 15 min at 37C). After fixing, the cells were blocked with glycine-0.1% 
BSA (for 30 min at 37C) and permeabilized with 0.2% Triton-X for 5 min. Permeabilized cells 
were then incubated with phosphorylated antibody against ERK1/2 (1:200 dilution, Cell Signaling 
Technology, Danvers, MA) for 2 hr at RT. Primary antibody binding was detected using a 
biotinylated secondary antibody (1:4 dilution in blocking serum, 1 hr at RT). Immunoreactivity 
was further enhanced using avidin-biotin complex (ABC reagent, Thermo Scientific). Cells were 
then stained with DAB substrate (1:10 dilution in stable peroxide buffer, 10 min at RT; Thermo 
Scientific), followed by counterstaining with haematoxylin. Level of ERK1/2 phosphorylation at 
various locations was then examined using an optical microscope (Nikon TE 2000U) and images 
were captured by the digital camera connected to the microscope. A Matlab program was used to 
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measure the intensity (in grayscale) of the captured images of sheared and non-sheared EC ERK1/2 
phosphorylation level.  
4.3.2 NF-κB (p65) activation 
The level of phosphorylated NF-κB p65 protein was measured using a commercial 
sandwich ELISA kit (Cell Signaling Technology, Danvers, MA). After shearing EC with or without 
platelets for different durations (2, 5, 15, 30, and 60 min), the supernatant was removed and EC 
were washed with warm PBS. EC were then detached and lysed using lysis buffer as previously 
mentioned. Cell lysates were applied (for 2 hr at 37C) to micro-titer plates pre-coated with mouse 
monoclonal anti-human antibody against phosphorylated NF-κB p65 protein. Post incubation, the 
captured phosphorylated NF-κB p65 protein was detected using a rabbit NF-κB p65 primary 
antibody (1 hr, 37C) followed by an HRP conjugated secondary antibody (30 min, 37C). Level 
of NF-κB p65 phosphorylation was detected using tetramethylbenzidine (a choromogenic 
substrate) for 10 min at 37C. The magnitude of the optical density (proportional to the level of 
NF-κB p65 protein phosphorylation) of the developed color was measured using the micro-plate 
reader at 450 nm.  
4.4 Specific aim 3: The goal of this aim was to characterize the uptake/release of endothelial 
growth factors by platelets, and to test the effect of dynamic shear stress on these processes. 
 Platelets were exposed to dynamic shear stress of coronary collaterals representing normal 
shear stress (as found in a healthy collateral) and elevated shear stress (as found in a collateral 
artery downstream of a 60% stenosed main coronary artery), in a cone-plate shearing device for 1 
hr to observe the effects of dynamic shear stress on uptake/release of growth factors (PLGF and 
VEGF-A) by platelets. The effects of calcium chelator and hyperglycemia on uptake/release were 
also tested.  
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4.4.1 Platelet mRNA expression 
 The reverse transcription polymerase chain reaction (RT-PCR) technique was employed to 
quantify the mRNA expression of PLGF, VEGF, and β-actin in platelets. Total RNA was collected 
using RNeasy mini columns (Qiagen, Valencia, CA) following manufacturer provided protocol. 
The quantity and purity of total RNA was analyzed using Take3 micro volume plate of BioTek 
Synergy HT Multi-mode Plate Reader (BioTek Instruments, Winooski, VT) at A260/280 ratio. 
Samples were either directly used or stored in -80C until use. RNA was reverse transcribed to 
cDNA using the QuantiTect reverse transcription kit (Qiagen, Valencia, CA) according to the 
manufacturer’s instructions. Forward and reverse primer sequences were: human PLGF, 
CCTACGTGGAGCTGACGTTCT and TCCTTTCCGGCTTCATCTTCT; human VEGF, 
ACGAGGGCCTGGAGTGTGT and GATCCGCATAATCTGCATGGT; and human β-actin, 
TGCCGACAGGATGCAGAAG and CTCAGGAGGAGCAATGATCTTGAT, respectively. 
Target genes were amplified from cDNA in an ABI 7500 Fast instrument (Life Technologies, 
Grand Island, NY) using PerfeCTa SYBR Green FastMix, Low ROX (Quanta Biosciences, 
Gaithersburg, MD) with the appropriate forward and reverse primers. Relative PLGF and VEGF 
mRNA expression (RQ value) was quantified using the comparative Ct and Ct method. All the 
gene expressions were normalized to the β-actin gene expression for comparison purpose. 
4.4.2 Uptake of PLGF and VEGF-A by platelets 
 Levels of PLGF or VEGF-A protein uptake by platelets were measured using a commercial 
DuoSet ELISA development kit (R&D Systems, McKinley Place, MN). Equal volumes of washed 
platelet (250,000/µL) aliquots were incubated with varying concentrations (12, 18, 30, 60, and 120 
ng/mL) of recombinant human PLGF and recombinant human VEGF-A (R&D Systems, McKinley 
Place, MN) for 1 hr at RT with gentle rocking motion. The effect of shear stress on uptake was 
observed by shearing platelets under normal and elevated shear stress conditions in the presence of 
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recombinant PLGF or VEGF-A protein. The effect of calcium chelator (EDTA) or beraprost 
sodium (prostacyclin analogue) or hyperglycemia on uptake of these two growth factors was 
assessed by incubating platelets with EDTA (2 mg/mL) or beraprost sodium (120 ng/mL), or 250 
mg/dL glucose (to induce hyperglycemia), along with recombinant PLGF or VEGF-A. EDTA is a 
metal ion chelator that diminishes Ca2+ ion reactivity by sequestering the ion. Beraprost sodium 
inhibits increase in intracellular Ca2+ level through modulation of cAMP production. Since, Ca2+ 
ion plays major role in most of the platelets functions, EDTA and beraprost sodium was used to 
see whether PLGF and VEGF-A uptake/release by platelets is Ca2+ signaling dependent process or 
not. Post incubation, samples were centrifuged at 1,100×g to pellet the platelets. After aspirating 
the supernatant, platelet pellets were gently washed with 0.9% NaCl without disturbing the pellets. 
The samples were then re-centrifuged at 14,000×g for 2 min and the supernatants were discarded. 
Afterwards, the pellets were lysed using lysis buffer (RIPA buffer containing protease and 
phosphatase inhibitors) and incubated for 60 min on ice. The lysed samples were then centrifuged 
at 14,000×g for 5 min and the supernatants were collected in fresh tubes, discarding any pellet at 
the bottom of the tubes. Samples were either stored at -80˚C for future use or added to prepared 
micro-titer plates. Microplates were prepared by applying PLGF or VEGF-A capture antibody 
(provided in the kit) and incubating overnight on a shaker at RT. The next day, the plate was first 
blocked with 1% BSA (1 hr at RT) and then incubated with samples and standards for 2 hr at RT. 
After adding detection antibody (for 2 hr at RT), streptavidin-HRP (for 20 min at RT, in the dark), 
substrate solution (for 20 min at RT, in the dark), the reaction was stopped using stop solution. The 
color change was quantified by measuring the optical density of each well using the BioTek 
Synergy HT Multi-mode Plate Reader (BioTek Instruments, Winooski, VT) at 450 nm wavelength. 
Plates were washed (3X) with wash buffer in between each step.  
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4.4.3 Release of PLGF and VEGF-A by platelets 
 The effect of shear stress on PLGF and VEGF-A release by platelets was measured using 
the commercial DuoSet ELISA development kit (R&D Systems, McKinley Place, MN). Platelets 
were initially incubated with 200 ng/mL recombinant human PLGF or 120 ng/mL recombinant 
human VEGF-A (R&D Systems, McKinley Place, MN) for 1 hr at RT on a rocker. In some 
experiments, EDTA (2 mg/mL), beraprost-sodium (120 ng/mL), or 250 mg/dL glucose were 
included in the incubation along with PLGF or VEGF-A. Post-incubation, platelets were 
centrifuged at 1,100×g for 5 min and the supernatant (containing free recombinant protein) was 
aspirated. The platelet pellet was then resuspended in HBMT and sheared under normal and 
elevated dynamic shear waveforms for 1 hr. At the end of shear, the platelet-containing fluid 
medium was centrifuged at 1,100×g for 5 min. The supernatant was collected, then applied to the 
micro-titer plates of the ELISA kit following the steps described in the previous section (uptake of 
PLGF and VEGF-A by platelets) to observe the effects of calcium inhibitors and hyperglycemia 
on shear-induced release of growth factors (PLGF and VEGF-A) by platelets. 
4.5 Specific aim 4: The goal of this aim was to quantify the effect of diabetes-associated major 
metabolic dysfunction on the expression level of PLGF and vascular endothelial growth 
factor receptor 1 (VEGFR1, the receptor for PLGF) in mouse and human cell.   
 Previously conducted studies, in our lab, have demonstrated that, mice consuming Western 
diet for 24 weeks become diabetic and have reduced PLGF expression in heart and skeletal muscle. 
Since diabetes has many risk factors such as hyperlipidemia, hyperglycemia, hyperinsulinemia, and 
oxidative stress associated with it, in vitro studies were needed to be conducted to identify which 
of these risk factors has the greatest impact on PLGF expression inhibition. To achieve this goal 
and to translate the applicability of the mouse study, mouse and human coronary artery EC (CAEC), 
cardiac muscle cells (CM), and skeletal muscle cells (SKMC) were subjected to various treatments. 
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Post treatment, samples were collected for cell synthesized PLGF expression and cell surface 
VEGFR1 (corresponding PLGF receptor) expression assessment. 
4.5.1 Advanced Glycation End Product (AGE) preparation  
Glycating bovine serum albumin (BSA) protein in presence of D-(+) glucose or DL-
glyceraldehyde, AGE was formed in 8 weeks and 1 week respectively. Glucose derived AGE was 
prepared dissolving 50 mg/mL BSA (Sigma-Aldrich) and 45 mg/mL D-(+) glucose (Sigma-
Aldrich) in phosphate buffered saline (PBS, pH 7.4) and incubating the solution at 37˚C for 8 weeks 
for full albumin glycation. Glyceraldehyde derived AGE was prepared incubating 25 mg/mL BSA 
in presence of 20 mM DL-glyceraldehyde (Sigma-Aldrich) in PBS at 37˚C for 1 week. 
Corresponding controls were prepared incubating 50 mg/mL and 25 mg/mL BSA in PBS at 37˚C 
for 8 weeks and 1 week respectively. Afterwards, prepared AGE solutions were extensively 
dialyzed in cold fresh PBS (4˚C, every 2 hr, 4X changes) to remove any free AGEs. To ensure that 
the solutions were gram-negative bacterial contamination free, endotoxin level was quantified 
using LAL chromogenic Endotoxin Quantitation Kit (Life Technologies Corporation). If the 
endotoxin concentration came below 1.0 EU/mL, the solution was considered endotoxin free and 
used to treat the cells. Protein concentration of the BSA and AGE samples were measured, before 
treatment, using BCA protein assay kit (Pierce).  
4.5.2 Treatments of cells 
After confluency was reached, all the cell types (HCAEC, HSKMC, MSKMC, HCM, and 
MCM), prior to treatment exposure, were serum starved in serum reduced media for 24 hr. To 
induce diabetes-associated metabolic dysfunctions including hyperlipidemia, hyperglycemia, 
hyperinsulinemia, and oxidative stress, initially, HCAEC were treated with 50 - 200 µg/mL LDL 
(Alfa Aesar ) or oxidized LDL (ox-LDL, Alfa Aesar), 5 - 20 mM glucose (Sigma Aldrich) or 300 
- 1000 µg/mL AGE (glucose or glyceraldehyde derived), 100 - 500 mU/L insulin (Sigma Aldrich), 
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or 0.05 - 0.3 mM hydrogen peroxide (H2O2, vWR International) respectively for 24 hr. Treatments 
were directly added to the cell culture medium and post treatment, medium supernatant were 
collected at 4, 8, and 24 hr in protease inhibitors containing microcentrifuge tubes. Along with 
treatments, untreated cells medium was also collected to use as control sample. Since, cells release 
synthesized PLGF protein into the medium, only the medium was collected for PLGF protein 
quantification using sandwich ELISA technique. The most effective concentrations of the 
metabolic molecules tested were then used to treat the other cell types (HSKMC, MSKMC, HCM, 
and MCM). After 24 hr time point medium collection, cells were washed (3X with PBS), 
trypsinized (using 1% TrypleE, Life Technologies Corporation), collected, and lysed using lysis 
buffer (RIPA buffer containing protease inhibitors) for VEGFR1 quantification. Post 1 hr ice 
incubation of cells in lysis buffer, sample containing tubes were centrifuged at 14,000×g for 5 min 
to get rid of any cell debris. The supernatants were then collected and used for running VEGFR1 
ELISA experiments.  
4.5.3 PLGF and VEGFR1 protein quantification 
 Level of PLGF protein and VEGFR1 protein, produced and expressed on cell surface 
respectively by different treatment exposed cells, were quantified using solid phase sandwich 
ELISA technique. Mouse DuoSet ELISAs and human DuoSet ELISAs (R&D Systems) for PLGF 
and VEGFR1 were purchased for corresponding mouse and human proteins expressions. After 
exposing cells to different treatment conditions for 24 hr, media samples were collected 4, 8, and 
24 hr post treatment and stored at -80°C to use later. At 24 hr, rest of the media were aspirated out 
and the cells were washed, trypsinized, and lysed using 4°C, protease inhibitor added RIPA lysis 
buffer. Lysed cells were also stored at -80°C until use. To prepare the plates for protein detection, 
96-well microplates were coated and incubated overnight at RT with corresponding capture 
antibodies on a slow moving shaker. The next day, washing off the capture antibodies, the wells 
were blocked with reagent diluent (1% BSA, 1 hr, RT) followed by standard/sample incubation (2 
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hr, RT). Proteins were captured from samples and detected using detection antibody (2 hr, RT), 
streptavidin HRP (20 min, RT, dark), and substrate solution (20 min, RT, dark). After stopping the 
reaction using stop solution, the optical density of each well was measured immediately using a 
Biotek Synergy HT multi-mode plate reader (BioTek Instruments Winooski, VT) at 450 nm 
wavelength. Values were normalized to total protein concentrations as determined by BCA protein 
assay (Pierce Biotechnology, Rockford, IL). 
4.6 Specific aim 5: The goal of this aim was to investigate the effects of glucose, advanced 
glycation end products (AGE), and the presence of smooth muscle cells (SMC) on dynamic 
shear stress-stimulated EC PLGF expression, and to identify the signaling pathways involved. 
 EC of the co-culture models were exposed to dynamic shear stress of coronary/peripheral 
collaterals using the cone-plate shearing device in presence/absence of glucose/advanced glycation 
end product (AGE) treatment to study how hyperglycemic conditions can modulate shear stress 
induced EC PLGF expression affecting the cell-cell communication. Signal pathways involved in 
PLGF modulation had also been assessed through quantification of several genes expression.   
4.6.1 EC produced PLGF expression 
 HCAEC/HIAEC (confluent) of the co-culture models were sheared directly, under 
conditions mimicking normal and elevated dynamic shear stress of healthy and diseased 
coronary/peripheral collateral artery respectively (as mentioned previously in collateral blood flow 
induced shear stress section), in the 6 well cone-plate shearing device for 2 hr in presence or absence 
of glucose/AGE treatments. Culture medium/supernatant samples were collected just pre-shear 0 
hr, and post-shear 0 hr, 8 hr, and 24 hr. Using the sandwich ELISA technique, mentioned in the 
previous section, EC produced PLGF expression was assessed.  
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4.6.2 EC mRNA expression  
 The effects of dynamic shear stress (elevated shear stress of coronary collateral arteries) 
and/or glucose (20 mM)/AGE (1000 µg/mL) on EC RAGE, Nox2, Nox4, HO-1, MCP-1, TNF-α, 
and β-actin mRNA expressions were examined using reverse transcription polymerase chain 
reaction (RT-PCR). At the end of 2 hr dynamic shear stress exposure and 24 hr static incubation, 
EC were gently washed, trypsinized, collected, and resuspended in 1% β-mercaptoethanol added 
RLT lysis buffer. RT-PCR was then conducted on the targeted genes (RAGE, Nox2, Nox4, HO-1, 
MCP-1, TNF-α, and β-actin) following the procedure described previously (“Platelet mRNA 
expression”) for the mRNA level quantification. Forward and reverse primer sequences used for 
targeted genes were: for human RAGE, 5'-ATTGGTGGTGGAGCCAGAAG-3' and 5'-
CAGGTCAGGGTTACGGTTCC-3'; for human Nox2, 5’-GGGAACTGGGCTGTGAATGA-3’ 
and 5’-CCAGTGCTGACCCAAGAAGT-3’; for human Nox4, 5’-
GGGGTTAAACACCTCTGCCT-3’ and 5’-ACACAATCCTAGCCCCAACA-3’; for human HO-
1, 5’-CTGCGTTCCTGCTCAACATC-3’ and 5’-GGCAGAATCTTGCACTTTGTTG-3’; for 
human MCP-1, 5'-TGCTCATAGCAGCCACCTTC-3' and 5'-GGGCATTGATTGCATCTGGC-
3'; for human TNF-α, 5'-GAATCGGAGCAGGGAGGATG-3' and 5'-
AAGTTGGGGACACACAAGCA-3'; and for human β-actin, 5'-
AGTTCGCCATGGATGACGAT-3' and 5'-TGCCGGAGCCGTTGTC-3' respectively.  
4.7 Specific aim 6: The goal of this aim was to discover the key underlying molecular 
mechanisms by which a Western diet induces dysfunctional PLGF expression in mouse 
skeletal muscle. 
 To understand the underlying molecular mechanisms for the dysfunctional PLGF 
expression in skeletal muscle tissues of Western diet fed diabetic mice, the protein level of AGE 
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was quantified (using sandwich ELISA) along with the mRNA level of RAGE, Nox2, Nox4, HO-
1, MCP-1, TNF-α, and β-actin (using RT-PCR) in the tissues. 
4.7.1 Animals, diets, and metabolic phenotyping 
 Two different mouse strains (C57BL/6J and ApoE-/-) were fed with control diet (TD 
120336, Harlan, containing 13% Kcal from fat and cholesterol, 67.9% Kcal from carbohydrate, and 
19.2% Kcal from protein) or Western diet (TD 88137, Harlan, containing 3X more sucrose than 
control diet, 42% Kcal from fat and cholesterol, 42.7% Kcal from carbohydrate, and 15.2% Kcal 
from protein) to induce healthy/diabetic conditions. The diet program was started at the age of 6-8 
weeks of the mice and continued until their sacrifice at 24 weeks. Body weight was recorded weekly 
for every mouse. Prior to sacrifice, blood samples were collected for total plasma cholesterol and 
triglyceride level, and plasma 8-isopreostance (biomarker of oxidative stress) level quantification. 
Plasma level of glucose and insulin level were also measured through intraperitoneal glucose 
tolerance testing (IPGTT) to confirm metabolic phenotyping. The mouse breeding, raising, feeding, 
and metabolic phenotyping were conducted by another lab member, Dr. Asitha T Silva. 
4.7.2 Tissue Collection 
 Post sacrifice, control/Western diet fed C57BL/6J and ApoE-/- mice were anesthetized 
using 5% isoflurane until they were totally sedated (confirmed applying pressure in toes to observe 
muscle twitch). The thoracic cavity was opened afterwards to ensure lung collapse. Removing the 
skin layer from the hindlimb, quadriceps femoris (QF) and gastrocnemius/plantaris/soleus (G-P-S) 
muscles were collected from the thigh and calf respectively. Tissues were divided into two pieces: 
one for tissue AGE level and the other for tissue mRNA level quantification of several targeted 
genes. Samples were immediately frozen in liquid nitrogen and then preserved in -80˚C for future 
use. 
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4.7.3 AGE protein quantification 
 Muscle tissues were homogenized, prior to AGE protein quantification, using the Bio-Gen 
Pro200 homogenizer (PRO Scientific). Submerging the tissues in ice cold 1 mL lysis buffer (RIPA 
buffer added with protease inhibitors), homogenization was done, three times, going from speed 1 
to 5 slowly and then back to speed 1 in 40 sec. A minute interval was given in between each 
homogenization step to reduce protein degradation due to overheating. The homogenates were then 
centrifuged at 700×g for 10 min to get rid of tissue debris. Collecting the tissue supernatant in fresh 
tubes, samples were then either stored in -80˚C or immediately used for running AGE ELISA. 
OxiSelect AGE competitive ELISA kit from Cell Biolabs was used for quantifying the AGE protein 
adducts following the manufacturer’s instructions. Briefly, the required number of wells of the 96 
well plate were coated with 1:1 ratio of AGE conjugate and conjugate diluent and incubated at 4˚C 
overnight. Next day, removing the AGE conjugate coating solution, the wells were washed and 
blocked with assay diluent for 1 hr at RT. Then the prepared AGE-BSA standards and unknown 
samples were added to the AGE conjugate absorbed wells in duplicate. After 10 min incubation on 
orbital shaker at RT, anti-AGE polyclonal primary antibody was added (1 hr, RT) followed by HRP 
conjugated secondary antibody (1 hr, RT). Substrate solution was then added for 2 – 20 min, and 
depending on the color change, the enzyme reaction was stopped adding stop solution to prevent 
color saturation. The optical density value of the color change was immediately read using the 
Biotek Synergy HT multi-mode plate reader (BioTek Instruments Winooski, VT) at 450 nm 
wavelength. Comparing with the AGE-BSA standard curve, the level of AGE protein adducts in 
the unknown samples were determined, which was normalized to the total protein concentration 
(quantified using BCA assay). The wells were washed three times and emptied properly in between 
each step. 
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4.7.4 mRNA expression of skeletal muscle tissues 
 Collected muscle tissue sections (QF and G-P-S) were weighed and diced/minced to the 
smallest pieces possible using very fine surgical scissors. The tissue holding tubes were kept in ice 
bucket all the time and 1-2 tissue sections were handled each time to reduce tissue mRNA 
degradation. RLT lysis buffer (1% β-mercaptoethanol added) was then added to the minced tissues 
at the ratio of 10 µL/mg of tissue. A Bio-Gen Pro200 homogenizer (PRO scientific) was used to 
homogenize the tissues (three times, 40 sec each), submerged in the RLT buffer, going slowly from 
low to high level and then back to low level giving interval in between every step. Homogenized 
tissue supernatants were then centrifuged at 2000×g for 10 min to get rid of any tissue debris and 
the clear supernatants were transferred in new tubes. Total RNA was collected using RNeasy 
Fibrous tissue mini kit (Qiagen) following the manufacturer’s instructions. RNA level of each 
tissue section was analyzed for quantity and purity using spectrophotometer, reverse transcribed to 
cDNA, and amplified for targeted genes (mouse RAGE, Nox2, Nox4, HO-1, MCP-1, TNF-α, and 
β-actin) employing RT-PCR technique mentioned previously in “Platelet mRNA expression” 
section. Used forward and reverse primer sequences for the targeted genes were: for mouse RAGE, 
5'-CAAGGAGGAACCACCCATCC-3' and 5'-CAACCAACAGCTGAATGCCC-3'; for mouse 
Nox2, 5'-CACACCGCCATCCACACAAT-3' and 5'-GTCACCGATGTCAGAGAGAGC-3'; for 
mouse Nox4, 5'-TGCCCCAGTGTATCAGCATTAG-3' and 5'-
CCGGAATCGTTCTGTCCAGTC-3'; for mouse HO-1, 5’- TCGTGCTCGAATGAACACTCTG-
3’ and 5’-AGCTCCTCAAACAGCTCAATGT-3’; for mouse MCP-1, 5′-
GGCTCAGCCAGATGCAGTTAA-3′ and 5′-CCTACTCATTGGGATCATCTTGCT-3′; for 
mouse TNF-α, 5'-GACGTGGAACTGGCAGAAGA-3' and 5'-GAGGCTGAGACATAGGCACC-
3'; and for mouse β-actin, 5′-AGTTCGCCATGGATGACGAT-3′ and 5'-
TGCCGGAGCCGTTGTC-3' respectively. Gene expressions were normalized to the expression of 
β-actin and the relative gene expressions were quantified using the comparative Ct, Ct method.  
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4.8 Statistical Analysis 
Statistical analysis was conducted using Student's t-test or ANOVA as appropriate for the 
experimental design. If a significant difference (P<0.05) was detected by ANOVA, the data were 
further analyzed for multiple comparisons using the Student-Newman-Keuls post hoc method. The 
non-parametric Kruskal-Wallis method was used if a large variance was present. “Primer of 
Biostatistics” and “Statistical Analysis System” (SAS) software were used for all the statistical 
analyses.
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CHAPTER V 
 
 
RESULTS 
 
5.1 Specific aim 1: The goal of this aim was to measure platelet and endothelial cell (EC) 
responses under physiologically relevant dynamic shear stress conditions in vitro, and to 
determine whether the presence of one cell type affects the responses of the other to shear. In 
addition, the effects of dynamic shear stress on endothelial cell responses ex vivo, in a rat 
aorta model, was also investigated.  
Washed platelets and confluent EC were sheared alone or together using the cone-plate 
shearing device. Dynamic shear stress conditions included normal shear stress, low pulsatile shear 
stress representing the recirculation zone, and elevated shear stress representing conditions at the 
stenosis throat of a left coronary artery. Post shearing, platelet responses to flow were measured by 
assessing platelet surface PECAM-1, GPIbα, and GPIIb expression, and platelet microparticle 
generation. EC responses to flow were measured by assessing EC surface and released vWF and 
TF expression, and endothelial microparticle generation.  
5.1.1 PECAM-1 expression on the platelet surface 
 Washed platelets (250,000/µl) were exposed to normal and low pulsatile shear stress for 
30 and 60 min with or without the presence of confluent EC. Afterwards, platelet surface PECAM-
1 expression was measured with flow cytometry using a PE conjugated anti-human PECAM-1 
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antibody. All mean fluorescence values were normalized to that of untreated platelets. Figure 5.1 
shows that neither shear stress magnitude nor presence of EC affected platelet surface PECAM-1 
expression after 30 min shear exposure (n=6/group). However, platelet surface PECAM-1 
expression was increased in the presence of EC under both flow conditions after 60 min shear 
exposure (n=7-8/group), although shear stress magnitude had no effect. Statistical analysis 
indicated that platelet surface PECAM-1 expression was significantly (P<0.05) up-regulated in the 
presence of EC under dynamic shear stress conditions after 60 min of shear exposure.  
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Figure 5.1: PECAM-1 expression of platelets exposed to normal and low pulsatile shear stress for 
30 min and 60 min in absence or presence of EC. All mean fluorescence intensity of PECAM-1 
expression was normalized to that of control platelets. Values are depicted as Mean+SD. Analysis 
(from three-way ANOVA) indicated significant increase (P<0.05) in PECAM-1 expression of 
platelets after 60 min of shear exposure when EC were incorporated into the system (n=7-8/group). 
However, no significant change in platelet PECAM-1 expression was observed under dynamic 
shear stress after 30 min of shear exposure even in the presence of EC (n=6/group). (NS: Normal 
shear, LS: Low shear, Plt: Platelet, *: P<0.05) 
 These results provided evidence that presence of EC can increase PECAM-1 expression on 
the platelet surface under dynamic shear stress conditions with prolonged shear exposure. 
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5.1.2 Platelet surface GPIbα expression 
Platelets were exposed to normal (NS), low (LS), and elevated (ES) pulsatile shear stress 
with or without the presence of EC for 60 minutes. Platelet surface GPIbα expression was then 
measured by flow cytometry using a FITC conjugated anti-CD42b antibody. All mean fluorescence 
intensity values were obtained and normalized to those of resting platelets. In the absence of EC, 
platelets expressed lower level of GPIbα under pathological flow conditions (low and elevated 
pulsatile shear stress) compared to the normal flow condition (Figure 5.2, n=6/group). In the 
presence of EC, platelet surface GPIbα expression was reduced under all three dynamic shear stress, 
significantly under NS and ES (P<0.05) conditions (n=6/group). However, no statistically 
significant difference was observed, in platelet GPIbα expression between the different dynamic 
shear stress conditions within each group (absence or presence of EC).  
 
Figure 5.2: Normalized platelet surface GPIbα expression (Mean+SD) under normal (NS), low 
(LS), and elevated (ES) shear stress conditions, when platelets were sheared (60 min) without or 
with EC. Normalized values were obtained from the ratio of all mean fluorescence GPIbα 
expression values of sheared platelets and the corresponding resting platelets (n=6/group). Platelet 
surface GPIbα expression decreased significantly under NS and ES conditions, when EC were 
incorporated into the system (*: P<0.05). 
 Results from these experiments indicated that the presence of EC decreases platelet surface 
GPIbα expression in response to dynamic flow. 
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5.1.3 Platelet surface GPIIb expression 
Platelets (250,000/μl) were exposed to constant (0.1 Pa, 0.3 Pa, 1 Pa, and 3 Pa) and dynamic 
shear stress (normal, low, and elevated shear stress) conditions in the presence or absence of 
confluent healthy or activated (by 1 ng/mL TNF-α) EC for 60 min. Timed sheared samples were 
collected every 15 min starting at time 0 min. Post-shear, platelet samples were incubated with a 
FITC conjugated anti-human CD41a antibody (30 min, RT, dark) and analyzed immediately using 
flow cytometry. All mean fluorescence intensity values were normalized with respect to the signal 
from non-sheared control platelets. Figure 5.3 shows the normalized mean fluorescence values of 
platelet GPIIb expression under both constant and dynamic shear stress conditions when platelets 
were sheared in the absence of EC (n=5-6/group). Platelet GPIIb expression increased slightly after 
15 min of constant shear stress exposure, then decreased with shear exposure time. After 60 min 
shear exposure, GPIIb expression decreased 7.5-20.7% across all shear conditions, compared to the 
15 min expression under the same conditions. This effect was strongest in the 3 Pa group, possibly 
indicating impairment of GPIIb expression under elevated shear condition. Two-way ANOVA 
analysis indicated that constant shear stress had a significant (P<0.05) effect in downregulation of 
platelet GPIIb expression. However, no significant change in GPIIb expression was observed under 
dynamic shear stress when platelets were sheared alone (Figure 5.3, bottom panel). Figure 5.4 
illustrates the effect of cellular interaction between platelets and healthy/activated EC on platelet 
surface GPIIb expression under normal, low, and elevated shear stress, respectively (n=6/group). 
A decreasing trend was observed in GPIIb expression in presence of EC. Two-way ANOVA 
analysis indicated that there was a significant difference in GPIIb expression under normal and 
elevated (P<0.05, in presence of healthy EC), and low and elevated (P<0.05, in presence of 
activated EC) shear stress conditions. 
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Figure 5.3: Platelets were activated under constant (0.1 Pa, 0.3 Pa, 1 Pa, and 3 Pa) and dynamic 
(normal, low, and elevated) shear stress for 60 min in a cone-pate shearing device. Platelet surface 
GPIIb expression was measured in samples collected every 15 min (n=5-6/group). Data are 
represented as normalized mean fluorescence value (ratio of GPIIb expression of treated timed 
sample and corresponding control) ± SD. Results indicated significant decrease in GPIIb expression 
under constant shear exposure (P<0.05), but, not under dynamic shear stress exposure. (Normal 
shear – NS, low shear – LS, elevated shear – ES). 
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Figure 5.4: Platelets were exposed to dynamic (normal, low, and elevated) shear stress waveforms 
using a cone-plate shearing device for 60 min in absence/presence of healthy/activated EC and 
samples were collected every 15 min (n=6/group). Normalized mean fluorescence values of GPIIb 
expression are represented as Mean±SD. Results indicated decreasing trend in presence of 
healthy/TNF-α activated EC. Significant difference was observed in GPIIb expression induced by 
normal and elevated shear stress (P<0.05) in presence of healthy EC, and by low and elevated shear 
stress (P<0.05) in presence of activated EC. 
99 
 
 Using normalized mean fluorescence values for platelet surface GPIIb expression when 
platelets were exposed to constant shear stress (0.1, 0.3, 1, 3 Pa), as a function of exposed shear 
stress and shear exposure time, a three dimensional plot (Figure 5.5) was developed using 
MATLAB. This mathematical model can be used for predicting platelet surface GPIIb expression 
for different shear stress and exposure time values. 
 
Figure 5.5: A 3D mathematical model for GPIIb expression. Using shear stress magnitude varying 
between 0 to 3 Pa for exposure duration varying between 0 to 60 min, corresponding platelet surface 
GPIIb expression can be predicted.  
 This model was validated using experimental data for platelet GPIIb expression following 
dynamic shear exposure. Plotting a graph in Excel (Figure 5.6) for GPIIb expression vs shear stress-
exposure time integral, a mathematical equation was obtained for constant shear (0.1, 0.3, and 1 
Pa) stresses up to 60 min. Since the shear stress-exposure time integral values for dynamic shear 
stress varies between 828-2088 Pa-s, the excel plot was drawn for 0.1, 0.3, and 1 Pa constant shear 
stress only. The equation was then used to predict GPIIb expression for dynamic shear stress-time 
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integral values. Experimental values were close to predicted values (Table 1) and comparison 
showed minimal % error (below 15%). 
 
Figure 5.6: Platelet surface GPIIb expression under different constant shear stress-exposure time 
integrals. 
Table 1: Mathematical model validation 
Shear Stress 
Shear Stress-time 
integral (Pa-s) Experimental value Predicted value % error 
NS 1980 1.039 0.906 12.84 
LS 828 1.021 0.924 9.52 
ES 2088 1.067 0.908 14.90 
 
 For easier comparison of data, normalized GPIIb expression of platelets exposed alone or 
together with healthy EC for 60 min under dynamic shear stress waveforms were put together in 
Figure 5.7. Platelet GPIIb expression was significantly decreased (P<0.05) in the presence of EC, 
under normal and elevated shear stress conditions. 
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Figure 5.7: GPIIb expression of platelets, sheared alone or together with EC for 60 min, under 
dynamic shear stress [normal (NS), low (LS), and elevated (ES)] conditions (n=5-6/group). Mean 
fluorescence values were normalized to those of resting platelets. A significant decrease in GPIIb 
expression was observed when platelets were sheared in presence of EC under normal and elevated 
(P<0.05) shear stress conditions. Data are presented as Mean+SD. 
 These results suggested that dynamic shear stress can decrease platelet surface GPIIb 
expression in the presence of EC. 
5.1.4 Platelet microparticle (PMP) and endothelial microparticle (EMP) generation  
Platelets were sheared in presence of EC under dynamic shear stress (normal, low, and 
elevated) for 30 min. Post shearing, platelet microparticles (PMP) and endothelial microparticles 
(EMP) were identified by flow cytometry as CD31+/CD42b+ and CD31+/CD42b- respectively. 
Flow cytometry results indicated an increase in EMP and PMP generation under all shear stress 
conditions, compared to control. The majority of the microparticles detected were EMP. Figure 5.8 
depicts EMP and PMP generation (n=4-6/group) normalized with respect to resting control. 
Results from the non-parametric Kruskal-Wallis test (used due to the large variance in the number 
of microparticles across samples) indicated that elevated dynamic shear stress significantly 
increased EMP (P<0.05) generation, though had no effect on PMP generation. Further comparison 
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for EMP and PMP generation indicates no significant difference in the generated microparticle 
numbers under different dynamic shear stress exposure.  
 
 
Figure 5.8: Box plot representing normalized (with respect to control) EMP and PMP generation 
when platelets and EC were co-sheared under dynamic shear stress (NS, LS, and ES) conditions 
(n=4-6/group). Data are presented as maximum and minimum values along with 75th and 25th 
percentile (black circles - outliers). 
These results indicated that EMP generation can be enhanced by exposure to dynamic shear 
stress. 
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5.1.5 EC surface vWF expression 
 Confluent EC were exposed to constant shear stresses (0.1, 0.3, 1, and 3 Pa) for 60 min. 
Post-shearing, EC surface vWF expression was measured using solid phase ELISA (n=4-6/group). 
Figure 5.9 represents the EC surface vWF expression following exposure to constant shear stress 
at 0.1, 0.3, 1 and 3 Pa. Different shear stress exposure could not induce any significant changes in 
EC surface vWF expression.  
 
Figure 5.9: Surface expression of sheared (0.1, 0.3, 1, and 3 Pa shear exposure for 60 min) EC vWF 
expression (n=4-6/group). There was no significant effect of shear stress on EC surface vWF 
expression. Data are presented as Mean+SD.  
EC were also sheared for 60 min in the absence (in a parallel study conducted in our lab) 
or presence of platelets using dynamic shear waveforms. After shearing, supernatant was removed 
and EC surface vWF expression was quantified using solid phase ELISA. Figure 5.10 demonstrates 
the surface vWF expression of EC co-sheared with platelets under dynamic shear exposure (n=5-
6/group). There was no significant effect of dynamic shear stress on EC surface vWF factor 
expression in the presence of platelets. However, compared to EC sheared alone (normal shear, 
Mean±SD value: 1.00±0.31; low shear, 1.11±0.27; elevated shear, 1.00±0.2), EC co-sheared with 
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platelets had increased expression of surface vWF (normal shear, 1.104±0.163; low shear, 
1.204±0.21; elevated shear, 1.244±0.187)221. 
 
Figure 5.10: vWF expression of EC co-sheared with platelets under normal, low, and elevated shear 
stress (n=5-6/group). No significant effect of dynamic shear stress on EC surface vWF level was 
observed. Data are presented as Mean+SD.  
Results from the vWF experiments indicated that EC surface vWF expression is unaffected 
by shear stress exposure.  
5.1.6 Soluble vWF expression  
The amount of soluble vWF released by EC and platelets following dynamic shear stress 
exposure was also measured (n=7-8/group). EC released significantly (P<0.05) more soluble vWF 
under elevated shear stress condition (Figure 5.11). Data analysis (two-way ANOVA) results 
demonstrated significantly increased soluble vWF expression under elevated shear stress (P<0.05) 
compared to the normal and low shear stress exposure.  
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Figure 5.11: Soluble vWF expression of EC in presence of platelets under normal (NS), low (LS), 
and elevated shear (ES) stress (n=7-8/group). A significantly (P<0.05) increased amount of soluble 
vWF is released under ES compared to the NS and LS. Data are presented as Mean+SD.     
 These results indicated that dynamic shear exposure enhance soluble vWF expression.  
5.1.7 EC surface TF expression 
The effect of shear stress on EC surface TF expression was measured by exposing EC to 
constant shear stress (0.1, 0.3, 1, and 3 Pa) and dynamic shear stress (normal, low, and elevated; in 
a parallel study conducted in our lab) for 60 min. The solid phase ELISA technique was utilized 
for TF measurement. Figure 5.12 represents EC surface TF expression after exposure to constant 
shear (n=6-7/group). No significant effect of constant shear or dynamic shear stress on EC surface 
TF expression was observed221. 
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Figure 5.12: TF expression of EC surface, when EC were exposed to 0.1, 0.3, 1, and 3 Pa shear 
stress waveforms for 60 min (n=6-7/group). No significant effect of constant shear on EC surface 
TF expression was detected (Data are presented as mean+SD).  
 
All these results indicated that dynamic shear exposure and platelet-EC communication 
can enhance platelet surface PECAM-1 expression, EC released soluble vWF expression, and EMP 
generation, and decrease platelet surface GPIbα and GPIIb expression. Overall, these results 
demonstrated that communication between platelets and EC can modulate functional responses of 
platelets and EC. 
5.1.8 Platelet adhesion to EC 
EC were exposed to dynamic (normal and low) shear stress waveforms for 60 min in 
presence of platelets. TNF-α treated EC were used as positive control. Post-shear exposure or 
positive control treatment, platelet adhesion to EC was observed using optical microscopy. Figures 
are attached in appendix which shows platelet-EC interaction under different treatment conditions 
(TNF-α or shear). Images were consistent with more interaction and attachment of platelets to EC 
under pathological low shear stress exposure than under normal shear conditions (based on n=2). 
However, more experiments were needed to be conducted for reaching a definite conclusion.  
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5.1.9 vWF, ICAM-1, and TF protein expressions of EC in rat aorta model 
Physiological relevance was further enhanced by investigating the effects of dynamic shear 
stress on EC responses in rat aorta model ex vivo. Freshly dissected rat abdominal aortas were 
perfused with physiological salt solution at different flow rates (2 hours at 37C) to achieve normal, 
low, and elevated shear stress (shown in Figure 4.2B) at the vessel wall. Cytoplasmic and 
membrane proteins were extracted from abdominal aortas to assess vessel wall vWF, ICAM-1, and 
TF expression through Western blot (n=9-13/group). Figure 5.13 represent Western blot results for 
cytoplasmic and membrane-bound vWF, ICAM-1, and TF for proteins extracted from sheared 
aortas. Data were first normalized to the total protein (obtained from BCA assay) in the sample, 
and then to the expression of the same marker in control (unsheared) aortas. Results from Western 
blots indicated that shear stress significantly reduced (P<0.05) vWF and ICAM-1 protein 
expressions compared to that of control aortas. Both vWF and ICAM-1 protein level were reduced 
in the cytoplasmic level of sheared aortas; whereas, ICAM-1 was also reduced in the membrane 
fraction compared to non-sheared aortas. However, no significant differences were observed in 
either cytoplasmic or membrane bound TF expression between non-sheared and shear exposed 
aortas or in vWF, ICAM-1 or TF levels across the three shear stress exposures.  
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Figure 5.13: Western blot results for cytoplasmic and membrane proteins expression of vWF, 
ICAM-1, and TF obtained from shear (normal, low, and elevated) exposed aortas (2 hr at 37ºC by 
perfusing physiological salt solution). Dynamic shear exposure reduced vWF and ICAM-1 
expression, compared to the same protein levels in control aortas (n=9-13/group). (* - significantly 
different compared to non-sheared control aortas’ expressions. P<0.05, one-way ANOVA). 
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In parallel, after shearing, the aorta was removed and fixed in 4% paraformaldehyde 
overnight. The sample was then embedded in paraffin and sectioned (5 µm thickness). Hematoxylin 
and eosin (H&E) staining was conducted to examine tissue morphology at the vessel wall, and 
immunostaining against vWF, ICAM-1, and TF was conducted to examine EC activation and 
injury. Figures are attached in appendix which shows representative H&E and immunostained 
images of tissue cross-sections of non-sheared (control) and shear stress treated aorta, obtained 
using a digital camera interfaced with an optical microscope. H&E images of tissue sections from 
shear stress treated vessels appeared similar to sections from untreated vessels, indicating that shear 
exposure did not cause tissue damage or affect vascular wall cell morphology. However, 
immunostained tissue section images were needed to be analyzed for statistical analysis to decide 
if these changes were significant.  
These results indicate that dynamic shear stress can modulate EC responses ex vivo, as 
decrease in cytoplasmic and membrane vWF and ICAM-1 expressions were observed. 
5.2 Specific aim 2: The goal of this aim was to study signaling pathways involved in 
endothelial cell responses to dynamic shear stress. 
EC were exposed to various dynamic shear stress (normal and low) of left coronary artery, 
and MAPK pathway activation was assessed by measuring, ERK1/2, JNK, and p38 
phosphorylation levels. Along with the MAPK pathway, NF-κB activation was also quantified. The 
effect of EC-platelet interaction on MAPK pathway and NF-κB activation was further investigated 
co-shearing EC with platelets. 
5.2.1 Levels of ERK1/2, JNK, and p38 phosphorylation 
Level of ERK1/2 phosphorylation under normal (NS) and low (LS) pulsatile shear stress 
treated EC was measured using Western blot. EC were sheared using the cone-plate shearing device 
for 2, 5, 15, 30, or 60 min. Band intensity of expressed proteins (obtained from the blots using spot 
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densitometry) was normalized to that of non-sheared EC. Figure 5.14 shows the band intensity and 
normalized level of ERK1/2 phosphorylation of EC after 0-60 min exposure to normal and low 
pulsatile shear stresses. Level of ERK1/2 phosphorylation increased significantly after exposure to 
shear stress, with a peak at 5 min (P<0.05), and then decreased significantly (P<0.05) with longer 
shear exposure compared to the non-sheared EC (n=3-4/group).  
 
 
Figure 5.14: Quantification of level of ERK1/2 protein phosphorylation using Western blot. EC 
were exposed to normal and low shear stress conditions for 0, 2, 5, 15, 30, or 60 min. A) Actin 
expression and ERK1/2 phosphorylation in EC exposed to normal shear stress (top panel) and low 
shear stress (bottom panel) respectively. B) Bar graph plot of normalized level of ERK1/2 
phosphorylation (normalized to that of non-sheared EC) in EC exposed to normal shear (NS) or 
low shear (LS) stress (n=3-4/group). Data are presented as Mean+SD. (*- significantly different 
than the level of phosphorylation of non-sheared control EC. P<0.05, one-way ANOVA). 
A) 
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Phosphorylated ERK1/2 levels were also quantified in EC exposed to normal and low 
pulsatile shear stresses in the presence of platelets for 2, 5, 15, 30, or 60 min using Western blot. A 
similar pattern (initial increase and then gradual decrease) in phosphorylated ERK1/2 level 
following shear exposure was observed in the presence of platelets. An increase in phosphorylated 
ERK1/2 level was observed at all time points in EC exposed to shear in the presence of platelets vs 
EC sheared without platelets. However, more experiments were needed for reaching a complete 
conclusion. Figures are attached in appendix which demonstrated phosphorylated ERK1/2 levels 
in EC exposed to normal (NS) or low (LS) pulsatile shear stress for 0-60 min in the absence and 
presence of platelets.   
Phosphorylation level of p38 and JNK (two other members of the MAPK family) were also 
quantified by Western blot in EC exposed to dynamic shear waveforms for 30 min or 60 min in 
absence (n=3/group) or presence of platelets. Normalized level of p38 and JNK phosphorylation in 
EC sheared, for 30 min or 60 min, in absence and presence of platelets are presented in Figure 5.15 
and in appendix respectively. Significant (P<0.05) decrease in phosphorylated p38 level was 
observed under low shear exposure at 60 min compared to that of non-sheared control EC. 
However, no significant change was observed in phosphorylated JNK protein level following 
exposure to shear stress. Presence of platelets induced increase in phosphorylated p38 and JNK 
levels of EC, compared to that of EC not sheared with platelets (similar to results of phosphorylated 
ERK1/2 level). However, more experiments were needed for a definite conclusion. 
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Figure 5.15: Normalized phosphorylated p38 (top panel) and JNK (bottom panel) levels in EC 
exposed to normal shear (NS) or low shear (LS) stress for 30 min (left panel) or 60 min (right panel) 
(n=3/group). No significant effect of shear stress on phosphorylated p38 and JNK levels were 
observed after 30 min shear exposure. Though phosphorylation level of p38 significantly reduced 
under 60 min LS exposure, such effect was not observed for JNK phosphorylation level at that time 
point (after 60 min shear exposure). Data are presented as Mean+SD. (*- significantly different 
than the level of phosphorylation of non-sheared control EC. P<0.05, one-way ANOVA). 
Immunocytochemical staining for phosphorylated ERK1/2 
Phosphorylated ERK1/2 level was measured using immunocytochemical staining, after 
exposing EC to normal (NS) or low (LS) shear stress conditions (Figure 5.16). After 60 min of 
shearing, control and sheared EC were fixed, blocked, permeabilized, and incubated with primary 
antibody against phosphorylated ERK1/2 (n=4-5/group). Qualitative evaluation of the intensity of 
phosphorylated ERK1/2 indicated that its level decreased following exposure to both NS and LS, 
compared to control EC phosphorylation level (matching what was observed at 60 min time point 
from the Western blot experiments). However, the phosphorylated ERK1/2 intensity appeared 
similar under both shear stress conditions. Quantitative analysis, using a Matlab program, indicated 
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that dynamic shear exposure for 60 min could not induce any significant difference in level of 
ERK1/2 phosphorylation between the two shear stress conditions. 
 
Figure 5.16: Immunocytochemical staining for phosphorylated ERK1/2 (n=4-5/group). Images 
were taken at 40X magnification. Bars represent 100 μm. 
5.2.2 Phosphorylated NF-κB (p65) activation 
 Level of NF-κB phosphorylation was measured using a sandwich ELISA after exposing 
EC without/with platelets to normal (NS) or low shear (LS) stress waveforms for 2, 5, 15, 30, and 
60 min. Figure 5.17 represents phosphorylated NF-κB levels (normalized to the phosphorylation 
level of control EC) of EC exposed to dynamic shear waveforms (n=4-5/group). Level of NF-κB 
phosphorylation followed a similar time course to level of ERK1/2 phosphorylation, but was 
slightly delayed, with peak level at 30 min post-shear exposure. It began to increase at 15 min 
(significant for NS exposure, P<0.05) and then decreased significantly (P<0.05) with prolonged 
shear exposure. Statistical analysis (ANOVA) indicated significant difference (P<0.05) in NF-κB 
activation level between normal and low shear exposed EC at 30 and 60 min. In the presence of 
platelets, quick increase in phosphorylation level was observed within 2 min of shear exposure, 
which then decreased with time (Figure shown in appendix). However, more experiments were 
needed for reaching a conclusion.  
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Figure 5.17: Normalized phosphorylated NF-κB level in EC exposed to normal (NS) or low (LS) 
shear stress (n=4-5/group). Significant difference in NF-κB activation level was observed between 
normal and low shear exposed EC at 30 min and 60 min time points. Phosphorylation of NF-κB 
level started to increase significantly at 15 min, reached the peak at 30 min, and then decreased 
significantly with longer shear exposure duration for shear exposed EC compared to non-sheared 
control EC. (Data are presented as Mean+SD). (*, ^ - significantly different than the level of 
phosphorylation of non-sheared control EC and normal shear exposed EC respectively. P<0.05, 
one-way ANOVA).  
All these results indicated that dynamic shear stress and platelet-EC communication can 
modulate activation of MAPK pathway and NF-κB, i.e, signaling pathways. 
5.3 Specific aim 3: The goal of this aim was to characterize the uptake/release of endothelial 
growth factors by platelets, and to test the effect of dynamic shear stress on these processes. 
5.3.1 PLGF and VEGF-A mRNA expression by platelets  
Platelets were exposed to elevated dynamic shear stress (simulating conditions in a 
remodeling coronary collateral artery) for 1 hr. Total RNA was isolated from control (unsheared) 
and shear exposed platelets and RT-PCR was performed for PLGF and VEGF-A quantification to 
determine whether platelets contain PLGF and VEGF-A mRNA. Results indicated that platelets do 
not contain PLGF mRNA (undetermined), but do contain VEGF-A mRNA (Average Ct value = 
30.8213). A non-significant increase in VEGF-A gene expression in response to dynamic shear 
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exposure was detected (average RQ value = 1.824) compared to control (average RQ value = 1) 
platelets. 
5.3.2 Uptake of PLGF and VEGF-A by platelets  
To characterize the uptake of PLGF and VEGF-A by platelets, platelets were incubated 
with different concentrations (12, 18, 30, 60, and 120 ng/mL) of recombinant human PLGF or 
VEGF-A for 1 hr. Platelets were then pelleted, washed gently, lysed, and applied to micro-titer 
plates to quantify the uptake of the proteins using sandwich ELISA (n=4-5/group). Figure 5.18 
depicts PLGF and VEGF-A uptake by platelets. Results indicated that platelets can take up both 
PLGF (A) and VEGF-A (B) proteins in a dose-dependent manner (P<0.05). 
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Figure 5.18: PLGF (A) and VEGF-A (B) uptake by platelets after 1 hr incubation with the 
recombinant proteins (12, 18, 30, 60, and 120 ng/mL). Data (Mean±SEM) are shown as fold 
increase in the protein concentration relative to 12 ng/mL of the corresponding recombinant protein 
treatment. Result indicated a significant dose-dependent uptake of the proteins by platelets (n=4-
5/group, P<0.05).   
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5.3.3 Effect of beraprost-sodium on uptake of growth factors 
 The effects of beraprost sodium (a prostacyclin analogue) on uptake of PLGF and VEGF-
A by platelets was assessed to determine whether growth factor uptake is passive or an active, Ca2+-
dependent process. Beraprost sodium can bind to the G-protein coupled receptors on platelet 
surface that activate platelet adenyl cyclase to synthesize cyclic adenosine monophosphate 
(cAMP). cAMP production can inhibit increase in intracellular Ca2+ level which plays a major role 
in most of the platelet activities. Figure 5.19 shows that the presence of beraprost sodium did not 
affect uptake of either of the growth factors by platelets (n=3/group). 
 
Figure 5.19: Platelets were incubated with recombinant PLGF or VEGF-A for 1 hr with or without 
beraprost sodium (a prostacyclin analogue). No significant change in the uptake of PLGF or VEGF-
A by platelets was observed in the presence of beraprost sodium (n=3/group). Data (Mean±SEM) 
are presented as fold increase in protein uptake of PLGF or VEGF-A by platelets compared to that 
of control. 
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5.3.4 Effect of hyperglycemia on uptake of growth factors 
 Since diabetes is associated with poor collateral artery growth, we next tested the effect of 
hyperglycemia (250 mg/dL glucose treatment) on platelet uptake of PLGF and VEGF-A. Results 
indicated that hyperglycemia did not affect platelets’ growth factor uptake (Figure 5.20, 
n=3/group). However, an increasing trend was observed for platelet PLGF and VEGF-A uptake in 
presence of hyperglycemic treatment. 
 
Figure 5.20: Platelets were co-incubated with recombinant PLGF or VEGF-A and 250 mg/dL 
glucose for 1 hr. Results indicated no significant effect of hyperglycemia on uptake of PLGF or 
VEGF-A by platelets (n=3/group). Data (Mean±SEM) are presented as fold increase of PLGF or 
VEGF-A protein uptake compared to that of control.  
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5.3.5 Combined effects of dynamic shear stress and calcium chelation on uptake of growth 
factors 
 To assess the combined effects of dynamic shear stress (simulating conditions within 
coronary collaterals) and a calcium chelator (ethylenediaminetetraacetic acid, EDTA) on the uptake 
of growth factors by platelets, platelets were exposed to either normal or elevated shear stress in 
the absence or presence of EDTA along with either recombinant PLGF or VEGF-A for 1 hr. Figure 
5.21 shows PLGF (A) and VEGF-A (B) uptake by platelets following exposure to shear stress 
with/without EDTA (n=3-5/group). Presence of EDTA could not also induce any significant effect 
on growth factors uptake by dynamic shear stress exposed platelets. 
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Figure 5.21: Single and combined effects of dynamic shear exposure and calcium chelation 
(EDTA) on uptake of PLGF or VEGF-A were tested by exposing platelets to normal (NS) and 
elevated (ES) coronary collateral shear stress for 1 hr in the presence of recombinant PLGF and 
VEGF-A ± EDTA. Data (Mean±SEM) are presented as normalized (with respect to resting platelet 
uptake level) PLGF (A) and VEGF-A (B) concentration. Results indicated no significant effect of 
single or combined treatment of dynamic shear exposure and EDTA on platelets PLGF or VEGF-
A uptake (n=3-5/group). 
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5.3.6 Release of exogenous PLGF and VEGF-A by platelets 
Combined effects of dynamic shear stress and beraprost-sodium on release of exogenous 
growth factors following uptake 
 Combined effects of dynamic shear stress and beraprost-sodium on release of the growth 
factors taken up by platelets was also investigated after exposing PLGF/VEGF-A and beraprost-
sodium treated platelets to normal and elevated dynamic shear stress (NS and ES) for 1 hr using 
the cone-plate shearing device. PLGF release had a decreasing trend and VEGF-A release had an 
increasing trend following dynamic shear stress exposure in the presence of beraprost-sodium 
(Figure 5.22, n=4/group). 
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Figure 5.22: Release of PLGF (A) and VEGF-A (B) were observed by exposing PLGF/VEGF-A 
and beraprost-sodium treated platelets to normal (NS) and elevated (ES) shear stress waveforms. 
Results indicated no significant effect of beraprost-sodium on shear induced platelet PLGF or 
VEGF-A release (n=4/group). Released growth factor concentration was normalized to the 
corresponding value from resting platelets. Data: Mean±SEM. 
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Combined effects of dynamic shear stress and hyperglycemia on release of growth factors 
 Recombinant human PLGF or VEGF-A ± 250 mg/dL glucose treated platelets were 
exposed to normal and elevated shear stress for 1 hr to assess the combined effects of dynamic 
shear stress and hyperglycemia on release of growth factors previously taken up by platelets. A 
decreasing trend was observed in PLGF release in presence of hyperglycemic condition. However, 
no significant change in either of the growth factors (PLGF/VEGF-A) release was observed (Figure 
5.23) under dynamic shear and hyperglycemic treatment exposure (n=4/group).  
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Figure 5.23: PLGF/VEGF-A and/or 250 mg/dL glucose treated platelets were stimulated with 
dynamic shear (normal and elevated) and the release of PLGF (A) and VEGF-A (B) was quantified 
using sandwich ELISA. PLGF and VEGF-A protein release was normalized to that of resting 
platelets release, and presented as Mean±SEM. Combined exposure of platelets to dynamic shear 
and hyperglycemia did not induce any significant change in PLGF/VEGF-A release by platelets 
(n=4/group). NS – normal shear stress, ES – elevated shear stress.  
 All these results indicated that platelets do take up both PLGF and VEGF-A. We were not 
able to demonstrate a significant effect of Ca2+ chelation or hyperglycemia on this process or on 
release of the growth factors following uptake. However, 1 hr of dynamic shear stress and/or 
treatment with EDTA, beraprost-sodium, or 250 mg/dL glucose may not be sufficient to induce 
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significant changes in PLGF/VEGF-A uptake and release. Thus, the short experimental time frame 
represents one limitation of this study. Low number of experiments (n=3-5) could be another 
limitation of the study.  
5.4 Specific aim 4: The goal of this aim was to quantify the effect of diabetes-associated major 
metabolic dysfunction on the expression level of PLGF and vascular endothelial growth 
factor receptor 1 (VEGFR1, the receptor for PLGF) in mouse and human cell. 
5.4.1 PLGF and VEGFR1 protein quantification  
 We wished to identify mechanisms by which diabetes inhibits PLGF expression in heart 
and skeletal muscle. We utilized both human and mouse cell types for these in vitro studies. Cell 
types tested were human coronary artery endothelial cells (HCAEC), human cardiac muscle cells 
(HCM), mouse cardiac muscle cells (MCM), human skeletal muscle cells (HSKMC), and mouse 
skeletal muscle cells (MSKMC). Cells were subjected to different treatments [low density 
lipoprotein (LDL), oxidized LDL (ox-LDL), glucose, advanced glycation end products (AGE), 
hydrogen peroxide (H2O2), or insulin] to mimic various aspects of diabetes-associated metabolic 
dysfunction, and cell-produced PLGF protein was quantified. Cell surface VEGFR1 (PLGF 
receptor) expression was measured as well. 
5.4.2 PLGF and VEGFR1 protein expression of HCAEC 
 Initially, confluent HCAEC were exposed to each of the following for 24 hr: LDL (50-200 
g/mL) or ox-LDL (50-200 g/mL) to mimic hyperlipidemia; glucose (5-20 mM) to mimic acute 
hyperglycemia; AGE (glucose or glyceraldehyde derived, 300-1000 g/mL) to mimic long-term 
hyperglycemia; hydrogen peroxide (H2O2, 0.05-0.3 mM) to simulate oxidative stress, or insulin 
(100-300 mU/L) to mimic the hyperinsulinemia environment. Post-treatment, cell culture media 
samples were collected at 4, 8, and 24 hr to quantify PLGF and total protein using commercially 
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available PLGF ELISA kits and the BCA assay, respectively. The most effective concentrations of 
the metabolic molecules tested was determined from this HCAEC dose study. These concentrations 
were then used to treat HCM, MCM, HSKMC, and MSKMC, and media samples were probed for 
PLGF and total protein as mentioned previously. Cell surface PLGF receptor (VEGFR1) was also 
quantified post 24 hr treatment using VEGFR1 ELISA. Both PLGF and VEGFR1 protein were 
normalized to corresponding media and cell total protein respectively, and data analysis was 
conducted using ANOVA. Figure 5.24 illustrates the PLGF expression of HCAEC treated with 
LDL (5.24A, n=6/group) or ox-LDL (5.24B, n=4-6/group), figure 5.25 illustrates the PLGF 
expression of HCAEC treated with glucose (5.25A, n=6/group) or glucose derived-AGE (5.25B, 
n=4-6/group) or glyceraldehyde derived-AGE (5.25C, n=6/group), and figure 5.26 illustrates the 
PLGF expression of HCAEC treated with H2O2 (5.26A, n=5-6/group) or insulin (5.26B, n=6/group) 
respectively. Results showed that LDL, ox-LDL, or insulin treatment failed to induce any 
significant changes in HCAEC PLGF expression. However, glucose, AGE (both glucose and 
aldehyde derived), and 0.3 mM H2O2 significantly (P<0.05) reduced PLGF expression. Cell surface 
expression of VEGFR1 in HCAEC (Figure 5.27, n=4-5/group) exposed to ox-LDL, glyceraldehyde 
derived-AGE, or H2O2 is shown in Figure 5.27A, 5.27B, and 5.27C respectively. Ox-LDL and H2O2 
treatment did not induce any significant changes in VEGFR1 levels. However, glyceraldehyde 
derived-AGE significantly (P<0.05) increased HCAEC VEGFR1 expression. 
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Figure 5.24: PLGF expression level (normalized to total protein), at 4, 8, 24 hr post-treatment, of 
HCAEC exposed to (A) low density lipoprotein (LDL, 50-200 g/mL, n=6/group) or (B) oxidized 
LDL (ox-LDL, 50-200 g/mL, n=4-6/group) treatment for 24 hr. Data are presented as 
Mean±SEM. Neither of the treatments had any significant effect on PLGF expression of HCAEC.  
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Figure 5.25: Normalized PLGF expression (to total protein) of HCAEC after 4, 8, 24 hr treatment 
exposure to (A) glucose (5-20 mM, n=6/group), or (B) glucose (n=4-6/group)/(C) glyceraldehyde 
derived-AGE (300-1000 g/mL, n=6/group). Treatment with higher concentrations of glucose and 
AGE all significantly (P<0.05) reduced PLGF expression by HCAEC (Data: Mean±SEM). [*-
significantly lower compared to corresponding time point control (Ctr), based on ANOVA 
analysis]. 
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Figure 5.26: Effect of hydrogen peroxide (H2O2) and insulin treatment on HCAEC PLGF 
expression. HCAEC were exposed to (A) 0.05-0.3 mM H2O2 (n=5-6/group) or (B) 100-300 mU/L 
insulin treatment (n=6/group), and media samples were collected and probed for PLGF expression 
4, 8, and 24 hr post-treatment. Data are presented as mean normalized PLGF expression (with 
respect to total protein). Results indicated a significant (P<0.05) reduction in PLGF expression in 
the presence of 0.3 mM H2O2. However, insulin treatment failed to induce any significant effect. 
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Figure 5.27: Cell surface expression of HCAEC VEGFR1, after 24 hr of (A) ox-LDL (50-200 
g/mL, n=5/group), (B) glyceraldehyde derived AGE (300-1000 g/mL, n=5/group), or (C) H2O2 
(0.05-0.3 mM, n=4-5/group) treatment. VEGFR1 expression was normalized to total protein and is 
represented as Mean±SEM. Glyceraldehyde derived AGE significantly (P<0.05) increased 
HCAEC surface VEGFR1 expression. The other two treatments (ox-LDL and H2O2) had no 
significant effect.  
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5.4.3 PLGF and VEGFR1 protein expression of HCM and MCM 
Next, HCM and MCM were treated with 200 g/mL of LDL or ox-LDL, 1000 g/mL of 
glucose or glyceraldehyde derived-AGE, or 0.1/0.3 mM of H2O2 for 24 hr, and media and cell 
samples were probed for PLGF and surface VEGFR1 expression respectively, as previously 
described. Figure 5.28 represents HCM PLGF expression in the presence of LDL/ox-LDL (A), 
AGE (B), and H2O2 (C) treatment (n=5/group). Figure 5.29 illustrates VEGFR1 expression of HCM 
cells after 24 hr of treatment. Results indicated that LDL treatment had no significant effect on 
HCM PLGF expression (n=5/group). However, AGE treatment significantly (P<0.05) reduced 
PLGF expression, whereas 0.3 mM H2O2 significantly increased PLGF expression. There was no 
significant effect of any of the treatments on VEGFR1 expression (n=5/group).  
We also compared results from HCAEC and HCM to determine the relative abundance of 
PLGF in endothelial cells and cardiac myocytes. Figure 5.30 shows that untreated HCAEC 
produced a significantly higher amount of PLGF (~10-15 times more) than HCM. 
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Figure 5.28: Effect of (A) LDL/ox-LDL (200 g/mL), (B) glucose/glyceraldehyde derived AGE 
(1000 g/mL), or (C) H2O2 (0.1/0.3 mM) on PLGF production by HCM (n=5/group). PLGF 
expression was normalized to total protein at 4, 8, and 24 hr post treatment and represented as 
Mean±SEM. Both of the AGE treatments significantly (P<0.05) reduced PLGF expression at all 
time points, whereas 0.3 mM H2O2 treatment significantly increased HCM produced PLGF level. 
However, LDL/ox-LDL treatment had no effect. (Ctr – PLGF expression of control cells without 
any treatment). 
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Figure 5.29: Cell surface expression of VEGFR1 by HCM exposed to 200 g/mL LDL/ox-LDL, 
1000 g/mL glucose/glyceraldehyde derived AGE, or 0.1/0.3 mM H2O2 (n=5/group). No 
significant effect of any of the treatments was found on HCM VEGFR1 expression. (Ctr – VEGFR1 
expression of control cells without any treatment). 
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Figure 5.30: Comparative analysis of PLGF expression of untreated HCAEC and untreated HCM. 
Results identified HCAEC as the major source of PLGF in the heart, as untreated HCAEC produced 
a significantly (P<0.05) higher amount of PLGF than untreated HCM. 
 Figure 5.31 and 5.32 represent the produced PLGF level and VEGFR1 expression 
respectively of MCM exposed to the same treatments as HCM (n=5/group). Results from the MCM 
study indicated that MCM are more sensitive to the different metabolic treatments, compared to 
HCM. Both LDL/ox-LDL (5.31A) and glucose/glyceraldehyde derived-AGE (5.31B) significantly 
(P<0.05) reduced MCM produced PLGF level at different time points (4, 8, and 24 hr), whereas 
H2O2 treatment (5.31C) significantly increased PLGF expression. For VEGFR1 (Figure 5.32), 
glucose derived-AGE significantly (P<0.05) increased expression, and 0.3 mM H2O2 significantly 
(P<0.05) reduced expression compared to non-treated control (Ctr). However, the other treatments 
did not produce any significant effects on MCM VEGFR1 expression. 
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Figure 5.31: PLGF expression (normalized to total protein of corresponding treatment and time 
point) of MCM exposed to (A) hyperlipidemic (LDL/ox-LDL, 200 g/mL), (B) long-term 
hyperglycemic (glucose/glyceraldehyde derived AGE, 1000 g/mL), or (C) oxidative stress (H2O2, 
0.1/0.3 mM) environment for 4, 8, or 24 hr (n=5/group). Hyperlipidemic and long-term 
hyperglycemic treatment significantly (P<0.05) reduced, and oxidative stress treatment 
significantly (P<0.05) enhanced PLGF expression of MCM. 
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Figure 5.32: VEGFR1 expression (normalized to total protein) of MCM treated with LDL/ox-LDL, 
glucose/glyceraldehyde derived AGE, or H2O2 (n=5/group). Glucose derived AGE and 0.3 mM 
H2O2 significantly increased and decreased cell surface VEGFR1 expression, respectively, by 
MCM. However, other treatments failed to elicit any significant effect on MCM VEGFR1 
expression. 
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5.4.4 PLGF and VEGFR1 protein expression of HSKMC and MSKMC 
 Since a previous in vivo study conducted in our lab on mouse models of Western diet 
induced metabolic dysfunction showed that the diet inhibited PLGF expression in skeletal muscle 
tissue, we treated HSKMC and MSKMC with different compounds as described above to mimic 
diabetes-associated metabolic dysfunction. Both confluent HSKMC and MSKMC were exposed to 
200 g/mL LDL/ox-LDL (n=6/group), 1000-1500 g/mL glucose or glyceraldehyde derived-AGE 
(n=5-10/group), 0.1-0.3 mM H2O2 (n=6/group), 5-20 mM glucose (n=6/group), and 100-300 mU/L 
insulin (n=6/group) for 24 hr. Media samples were assessed for PLGF expression after 4, 8, and 24 
hr and cell samples were probed for VEGFR1 expression after 24 hr of treatment using sandwich 
ELISA. The effects of LDL/ox-LDL (A), glucose/glyceraldehyde derived-AGE (B and C), 0.1/0.3 
mM H2O2 (D), and glucose/insulin (E) on HSKMC PLGF production is shown in Figure 5.33. 
LDL/ox-LDL, 0.1/0.3 mM H2O2, and insulin treatment had no effect on PLGF expression. The 
higher concentration (1500 g/mL) of both glucose and glyceraldehyde derived-AGE significantly 
reduced PLGF expression at all time points (post 4, 8, and 24 hr); whereas the lower concentration 
(1000 g/mL) of glucose and glyceraldehyde derived-AGE reduced PLGF only at 24 hr post 
treatment. The higher concentrations of glucose (15-20 mM) also inhibited PLGF production by 
HSKMC. However, none of the treatments elicited any effect on cell surface VEGFR1 expression 
(n=6/group), as shown in Figure 5.34.  
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Figure 5.33: PLGF expression in HSKMC following exposure to (A) 200 g/mL LDL/ox-LDL 
(n=6/group), (B) 1000-1500 g/mL glucose or glyceraldehyde derived-AGE (n=5-10/group), (C) 
0.1-0.3 mM H2O2 (n=6/group), (D) 5-20 mM glucose (n=6/group), or (E) 100-300 mU/L insulin 
(n=6/group) for 24 hr. Data are presented as Mean±SEM. Results indicated a significant (P<0.05) 
reduction in PLGF expression in the presence of AGE and glucose, but not in the presence of other 
treatments. 
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Figure 5.34: Effect of LDL/ox-LDL, glucose/glyceraldehyde derived AGE, and H2O2 on HSKMC 
surface VEGFR1 expression (n=6/group). There was no significant effect of any of the treatments 
on VEGFR1 expression. 
 Figure 5.35 illustrates the effect of similar treatments on MSKMC PLGF expression. As in 
HSKMC, MSKMC were treated with LDL/ox-LDL (A, n=6/group), glucose/glyceraldehyde 
derived-AGE (B, (n=6/group), 0.1/0.3 mM H2O2 (C, n=6/group), or glucose/insulin (D, n=5/group) 
followed by assessment of PLGF expression. Results indicated a significant change in MSKMC 
PLGF expression in response to all the treatments except insulin. LDL/ox-LDL, AGE, and H2O2 
treatment significantly (P<0.05) reduced PLGF expression, whereas glucose induced a significant 
(P<0.05) increase in PLGF expression in MSKMC. Again, there was no significant effect of any 
of the treatments on MSKMC surface VEGFR1 expression (Figure 5.36, n=5/group). 
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Figure 5.35: Effect of LDL/ox-LDL (A, n=6/group), glucose/glyceraldehyde derived-AGE (B, 
n=6/group), 0.1/0.3 mM H2O2 (C, n=6/group), or glucose/insulin (D, n=5/group) on MSKMC 
PLGF expression (normalized to total protein) assessed 4, 8, 24 hr after treatment exposure. 
MSKMC PLGF expression was significantly (P<0.05) downregulated by LDL, ox-LDL, AGE, and 
H2O2 treatment, and significantly (P<0.05) upregulated by glucose treatment.  
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Figure 5.36: Normalized MSKMC cell surface VEGFR1 expression after 24 hr of treatment in the 
presence of LDL/ox-LDL, glucose/glyceraldehyde derived AGE, or H2O2 (n=6/group). None of the 
treatments could induce any significant change in VEGFR1 expression. 
 All these results indicated that hyperglycemia and long-term hyperglycemia resulting in 
AGE formation may be the major contributors to impaired PLGF expression and thus impaired 
arteriogenesis in diabetic heart and skeletal muscle, as treatment with high concentrations of 
glucose and AGE had the greatest negative impact on PLGF expression.  
5.5 Specific aim 5: The goal of this aim was to investigate the effects of glucose, advanced 
glycation end products (AGE), and the presence of smooth muscle cells (SMC) on dynamic 
shear stress-stimulated EC PLGF expression, and to identify the signaling pathways involved. 
 Human iliac artery EC (HIAEC), co-cultured with human coronary artery SMC (SMC), 
were exposed to normal (NS) and elevated (ES) shear stress simulating conditions in healthy and 
remodeling peripheral collateral arteries, and HIAEC PLGF expression was measured.  
 Human coronary artery EC-SMC co-cultures were exposed to elevated (ES) dynamic shear 
stress of remodeling coronary collateral artery in the presence or absence of 20 mM glucose or 
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1000 µg/mL of glucose derived AGE, and EC secreted PLGF was quantified. To identify AGE 
affected signaling pathways, the gene expression level of EC RAGE, Nox2, Nox4, HO-1, MCP-1, 
TNF-α, and β-actin were also quantified 24 hr post-elevated shear (ES) exposure.  
5.5.1 EC PLGF expression  
To investigate how altered dynamic shear stress of diseased peripheral arteries can 
modulate EC PLGF expression, HIAEC-SMC co-cultures were exposed to normal (NS) and 
elevated (ES) dynamic shear stress as found in healthy and remodeling peripheral collateral arteries 
(Figure 4.4) respectively, using the cone-plate shearing device, for 2 hr. Media samples were 
collected (from HIAEC side) immediately pre-shear and post shear, and also 8 and 24 hr post shear. 
Samples were assessed for PLGF and total protein level using a PLGF sandwich ELISA and the 
BCA assay, respectively. The PLGF protein level at the various post-shear time points was double 
normalized to total protein and to the normalized (to pre-shear total protein) pre-shear value of 
PLGF expression. Results (Figure 5.37) indicated that ES induced a significant (P<0.05) increase 
in EC PLGF production compared to NS exposure at 8 hr and a non-significant increase at other 
time points (at 0 hr, P=0.068; at 24 hr, P=0.089, n=5/group). 
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Figure 5.37: Normalized PLGF protein expression by HIAEC exposed to normal (NS) and elevated 
shear (ES) stress simulating conditions in healthy and remodeling peripheral collateral arteries 
respectively for 2 hr (n=5/group). ES enhanced PLGF expression significantly at 8 hr and non-
significantly at 0 (P=0.068) and 24 hr (P=0.089) time points compared to NS. Data are presented 
as Mean±SEM. 
 The study next focused on how hyperglycemic conditions (simulated by glucose and AGE 
treatment) could affect shear stress mediated PLGF expression in EC. EC were co-cultured with 
SMC on two opposite sides of a cell culture insert membrane. EC-SMC co-cultures were then 
exposed to elevated (ES) pulsatile shear stress mimicking conditions in remodeling coronary 
collateral arteries for 2 hr in the presence or absence of glucose (20 mM) or glucose derived AGE 
(1000 µg/mL). Media samples were collected from the EC side immediately pre-shear and again 0, 
8, and 24 hr post-shear to assess EC PLGF and total protein using a PLGF sandwich ELISA and 
the BCA assay, respectively. Data analysis was conducted on PLGF protein normalized to total 
protein and to the normalized (to pre-shear total protein) pre-shear PLGF protein value using two-
way ANOVA. A 2 hr shear exposure time was chosen, as a previously conducted study in our lab 
had demonstrated that 1 hr shear exposure did not significantly effect PLGF expression. EC-SMC 
static co-cultures not exposed to any treatment were used as controls (Ctr). Additionally, static co-
cultures exposed to 20 mM glucose or 1000 µg/mL of glucose derived AGE were also analyzed to 
distinguish between the effects of shear stress and metabolic treatments. Figure 5.38 shows the 
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normalized level of PLGF protein (represented as fold of pre-shear value, n=5/group). 
Compared to Ctr, AGE treatment significantly (P<0.05) reduced PLGF expression in static culture. 
Exposure of EC-SMC co-cultures to ES stress significantly (P<0.05) increased PLGF production 
(~24%). This effect of ES was significantly (P<0.05) blocked by glucose and AGE treatment, with 
AGE having a greater effect.  
 
Figure 5.38: Fold change in PLGF expression (with respect to pre-shear PLGF expression) of EC 
co-cultured with SMC and exposed to elevated (ES) pulsatile shear stress, for 2 hr (n=5/group). ES 
significantly (P<0.05) enhanced EC PLGF expression. However, this effect was significantly 
(P<0.05) blocked in the presence of glucose and AGE. AGE treatment, compared to control (Ctr), 
significantly reduced PLGF expression in static culture. (Data: Mean±SEM, *- significantly 
different based on ANOVA analysis). 
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5.5.2 EC mRNA expression  
 The gene expression level of RAGE, Nox2, Nox4, HO-1, MCP-1, TNF-α, and β-actin in 
EC was also assessed in shear and glucose/AGE exposed co-cultures using RT-PCR. Twenty-four 
hr after EC-SMC co-culture exposure to the ES waveform ± 20 mM glucose or 1000 µg/mL AGE 
treatment, EC were collected, lysed, and probed for the above-mentioned target genes. Figure 5.39 
shows gene expression of RAGE, Nox4, HO-1, MCP-1, and TNF-α normalized to β-actin mRNA 
expression (n=3-5/group). Nox2 gene expression level could not be determined. Results indicated 
that there was no significant effect of shear, glucose, or AGE treatment on expression of any of the 
genes, with the exception of TNF-α.  
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Figure 5.39: Effect of elevated shear stress (ES) ± glucose (20 mM) or advanced glycation end 
product (1000 µg/mL) treatment on RAGE (A), Nox4 (B), HO-1 (C), MCP-1 (D), and TNF-α (E) 
gene expression of EC in co-culture (n=3-5/group). Shear, glucose, or AGE treatment had no 
significant effect on expression of any of the genes except TNF-α. The TNF-α mRNA level was 
significantly reduced in the presence of glucose + ES treatment, but significantly increased in AGE 
treated static culture. Data are shown as Mean±SEM. (P<0.05; * - represents significant difference). 
 These results demonstrated that elevated dynamic shear stress is a major stimulus for PLGF 
upregulation whose effect can be blocked by glucose and AGE treatment, suggesting that acute and 
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long term hyperglycemia might inhibit PLGF expression and arteriogenesis by promoting AGE 
formation17. 
5.6 Specific aim 6: The goal of this aim was to discover the key underlying molecular 
mechanisms by which a Western diet induces dysfunctional PLGF expression in mouse 
skeletal muscle. 
 To better understand the mechanisms by which a Western diet reduces PLGF expression 
in skeletal muscle, quadriceps femoris (QF) and gastrocnemius/plantaris/soleus (G-P-S) muscles 
from C57BL/6J and ApoE-/- mice fed a Western diet for 6 mo were collected and probed for levels 
of advanced glycation end products (AGE) and RAGE, Nox2, Nox4, HO-1, MCP-1, TNF-α, and 
β-actin mRNA. 
5.6.1 AGE protein level quantification 
 AGE protein level was measured in Western diet fed C57BL/6J and ApoE-/- mouse QF and 
G-P-S muscle tissues using the sandwich ELISA technique. After homogenizing the tissues, tissue 
lysate supernatants were collected and added to specially prepared ELISA plates for AGE protein 
quantification. The AGE protein level was normalized to the total protein level for data analysis. 
Figure 5.40 shows the normalized AGE protein level of QF and G-P-S muscle tissues of Western 
diet fed C57BL/6J and ApoE-/- mice (n=8-10/group). Results indicated that the Western diet (WD) 
significantly (P<0.05) increased the AGE protein level in both QF and G-P-S muscle tissues of 
C57BL/6J and ApoE-/- mice, compared to control diet (CD) fed mice, with AGE deposition being 
greater in C57BL/6J mice than in ApoE-/- mice.  
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Figure 5.40: Tissue AGE protein quantification in control diet (CD) and Western diet (WD) fed 
C57BL/6J and ApoE-/- mouse quadriceps femoris (QF) and gastrocnemius/plantaris/soleus (G-P-S) 
muscles as determined using sandwich ELISA (n=8-10/group). Mouse were fed the diets for 6 mo 
before sacrifice. AGE protein was normalized to total protein for both QF (A) and G-P-S (B) 
muscles. Data are presented as Mean±SEM. Results indicated that the WD significantly (P<0.05) 
increased AGE protein level in QF and G-P-S muscle tissues of both strains, compared to the CD. 
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5.6.2 mRNA expression of skeletal muscle tissues 
 To begin defining the pathways through which Western diet induced metabolic dysfunction 
inhibits skeletal muscle PLGF expression, RAGE, Nox2, Nox4, HO-1, MCP-1, TNF-α, and β-actin 
mRNA was quantified using RT-PCR. Total RNA was collected from CD and WD fed C57BL/6J 
and ApoE-/- mouse skeletal muscle tissues (both QF and G-P-S), and was reverse transcribed and 
amplified for determination of the target gene expression. Target gene expression was normalized 
to the β-actin level in the corresponding same strain and diet fed tissues. Figure 5.41 and 5.42 show 
the normalized mRNA level of the target genes in C57BL/6J and ApoE-/- mice QF and G-P-S 
muscle tissues, respectively (n=3-5/group). Results indicated that in C57BL/6J QF muscle, the WD 
significantly (P<0.05) reduced the Nox4 mRNA level and increased the RAGE mRNA level; 
whereas in ApoE-/- QF muscle, the WD significantly reduced (P<0.05) the Nox2 and MCP-1 
mRNA level. In C57BL/6J G-P-S muscle, WD consumption was found to significantly (P<0.05) 
increase the Nox2 and HO-1 mRNA level; whereas in ApoE-/- G-P-S muscle, the WD significantly 
(P<0.05) reduced the MCP-1 and TNF-α mRNA level compared to CD feeding. No other 
significant effects of the diets on gene expression were observed. 
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Figure 5.41: mRNA quantification of Nox2, Nox4, HO-1, RAGE, MCP-1, and TNF-α genes using 
RT-PCR. QF muscle was collected from CD and WD fed C57BL/6J and ApoE-/- mice (n=3-
5/group). Gene expression (Data: Mean±SEM) was normalized to the corresponding β-actin 
mRNA expression. The results demonstrate that Nox4 and RAGE mRNA level was significantly 
(P<0.05) decreased and increased, respectively, in QF muscle of C57BL/6J mice; whereas, Nox2 
and MCP-1 mRNA expression was significantly (P<0.05) reduced in QF muscle of ApoE-/- mice.      
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Figure 5.42: Quantification of Nox2, Nox4, HO-1, RAGE, MCP-1, and TNF-α mRNA level in G-
P-S skeletal muscle of CD and WD fed C57BL/6J and ApoE-/- mice (n=3-5/group). Target gene 
expression was normalized to the corresponding β-actin expression value for the same diet and 
strain. Results indicated that the Nox2 and HO-1 mRNA level was significantly (P<0.05) increased 
in C57BL/6J mice, and that the MCP-1 and TNF-α mRNA level was significantly (P<0.05) 
decreased in ApoE-/- mice.      
 
 Considered together, these results suggest that the presence of chronic hyperglycemia 
resulting in AGE formation is one underlying cause for reduced PLGF expression in skeletal 
muscle of WD fed mice. Along with RAGE, other AGE receptors may play role in AGE-AGE 
receptor mediated signaling. Our signaling pathway study results may indicate that our hypothesis 
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of Nox mediated oxidative stress generation and subsequent inflammatory response induction may 
not be the pathway inducing dysregulated PLGF expression in WD fed mouse skeletal muscle. 
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CHAPTER VI 
 
 
DISCUSSION 
 
The onset and pathological progression of cardiovascular disease (CVD), especially 
coronary artery disease (CAD) and peripheral artery disease (PAD), is greatly modulated by 
biochemical and biomechanical stimuli. Biomechanical stimuli, such as altered shear stress induced 
by disturbed blood flow, act as an important regulator of platelet and EC functions. Since EC are 
the innermost layer of blood vessels, and platelets are freely circulating through the blood, both EC 
and platelets are continuously exposed to shear stress. Any change in local shear stress may alter 
their functions and activities significantly. Changes in the shear environment trigger activation of 
various signaling pathways, resulting in alteration of EC and platelet functional responses (e.g. 
over-expression of inflammatory and adhesion molecules, and expression of cytokines and growth 
factors). Activated platelets communicate with the activated EC through various receptor-ligand 
interactions that can positively or negatively affect each cell type’s function.  
One of the major goal of this project was therefore to investigate how physiologically 
relevant dynamic shear stress, along with platelet-endothelial cell interactions, affects function and 
activation of platelets and endothelial cells. For this purpose, in vitro studies were conducted to 
measure the effects of dynamic shear stress on functional responses of EC through the measurement 
of cell surface and released von Willebrand factor (vWF) levels and tissue factor (TF) expression,
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as well as EC microparticle (EMP) generation. Platelet responses were also monitored under 
dynamic shear stress conditions by measuring cell surface PECAM-1, GPIb, and GPIIb 
expression and platelet microparticle (PMP) generation. In addition, platelets and EC were co-
sheared to investigate the combined effects of shear stress and platelet-EC interaction on activation 
of platelets and EC (Aim 1). Different dynamic (normal, low, and elevated shear stress) shear 
waveforms were applied for 1 hr to platelets and/or EC (cultured in petri dishes/6 well plates) using 
a cone-plate viscometer. The shear stresses were obtained through computational fluid dynamics 
(CFD) modeling conducted previously in our lab that replicated the shear waveforms sensed by EC 
and platelets in a physiologically realistic left coronary artery (LCA) model under healthy and 
diseased conditions46;220. The LCA was chosen as it is vulnerable to atherosclerotic plaque 
development due to its complex geometrical structure. In vitro studies were further extended to ex 
vivo animal studies to enhance the physiological relevance of the in vitro findings. For the ex vivo 
study, freshly harvested rat aortas were exposed to dynamic shear stress (same time average value 
of shear waveforms as used in the in vitro study) and EC activation and inflammatory responses 
were assessed in terms of ICAM-1, TF, and vWF protein expression (Aim 1). Our goal was to 
combine in vitro and ex vivo experimental studies to achieve a better understanding of the role of 
platelets and EC in the development of cardiovascular diseases. To further evaluate the downstream 
signaling pathways, involved in modulation of cell functions and various gene expressions, MAPK 
and NF-κB pathway activation level was quantified through p38, JNK, and ERK1/2, and NF-κB 
p65 protein phosphorylation after shearing EC under normal and low pulsatile shear stress for 1 hr 
using the cone-plate shearing device (Aim 2).  
Along with contributing to the pathogenesis of cardiovascular diseases, activated platelets 
and EC also play important roles in the body’s compensatory response mechanism to arterial 
occlusion through arteriogenesis. During arteriogenesis, small arterioles bypassing the obstruction 
enlarge to accommodate additional blood flow, a process mediated by uptake and release of growth 
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factors and modulation of growth factor receptor levels. Therefore, the other major goal of the 
project was to investigate how dynamic shear stress, as found in remodeling coronary collaterals, 
as well as various metabolic parameters associated with type 2 diabetes, affects platelet and EC 
behavior related to arteriogenesis. CVD progression (i.e. the presence of atherosclerotic plaque in 
major arteries) can stimulate arteriogenesis by increasing blood flow and shear stress in collateral 
arteries. However, as diabetes can inhibit arteriogenesis, diabetes may affect how the shear signal 
is sensed and/or transduced into an arteriogenic stimulus. Therefore, we focused on studying how 
platelets, EC, cardiac muscle cells, and skeletal muscle cells take up/release PLGF (an 
arteriogenesis-specific growth factor) and the related protein VEGF in response to dynamic shear 
and/or diabetes-associated metabolic parameters. The effect of shear stress and hyperglycemia on 
PLGF/VEGF uptake/release by platelets was measured after incubating platelets with recombinant 
PLGF/VEGF protein (Aim 3). Whether the uptake/release of growth factors by platelets is a passive 
or an active Ca2+ signaling dependent process was also assessed in studies using calcium chelators. 
To identify which type 2 diabetes-associated metabolic parameter has the greatest negative impact 
on PLGF expression at the cellular level, we exposed coronary artery EC, cardiac muscle cells, and 
skeletal muscle cells to various simulated metabolic conditions (hyperlipidemia, hyperglycemia, 
hyperinsulinemia, and oxidative stress) by treating them with low density lipoprotein (LDL), 
oxidized LDL, glucose, advanced glycation end products (AGE), insulin, and hydrogen peroxide. 
Following these treatments, PLGF and cell surface VEGFR1 were quantified (Aim 4). To further 
enhance the physiological relevance of these studies by more completely reproducing conditions 
within the vascular wall, we tested the effects of simulated acute hyperglycemia (elevated glucose) 
and long term hyperglycemia (advanced glycation end products AGE) on dynamic shear stress 
mediated PLGF expression in EC. For these studies, EC from coronary/peripheral vessels were co-
cultured with smooth muscle cells (SMC) and exposed to shear stress in the presence or absence of 
glucose/AGE, followed by quantification of PLGF expression (Aim 5). In addition, underlying 
signaling mechanisms by which these metabolic parameters could modulate PLGF expression were 
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assessed through measuring expression of several relevant genes. These in vitro studies were again 
extended to an ex vivo animal study, in which skeletal muscle tissues from the thigh and calf of 
control and Western diet fed mice of two strains were harvested and probed for AGE protein and 
associated signaling pathway genes. The goal of these experiments was to begin identifying key 
underlying mechanisms modulating dysfunctional PLGF expression in skeletal muscle in response 
to feeding of a Western diet (Aim 6). 
6.1 Effect of dynamic shear stress and platelet-EC interaction on platelet and endothelial cell 
responses in vitro and ex vivo 
 Since platelets travel through flowing blood and EC are continually exposed to blood flow, 
both platelets and EC are susceptible to any changes in the blood flow induced shear stress. 
Therefore, to investigate how these two cell types behave under conditions of dynamic shear 
exposure, cone-plate shearing devices (Figure 4.1) were used to apply shear stress on platelets and 
EC. Previous studies have utilized simple constant shear stress to stimulate these cell types; whereas 
physiologically relevant dynamic shear (physiological and pathological) stress was utilized in this 
study (shown in Figures 4.2)21. Also, to enhance the physiological relevance of the findings, 
platelets and EC were co-sheared to observe the effects of platelet/EC cross-talk on cellular 
responses. Using the cone-plate shearing device, platelets and confluent EC were sheared 
alone/together for 1 hr and activation responses were quantified, for platelets: through cell surface 
PECAM-1, GPIb, and GPIIb expression, and platelet microparticle (PMP) generation, and for 
EC: through cell surface and released von Willebrand factor (vWF) levels, tissue factor (TF) 
expression, and EC microparticle (EMP) generation. 
 Platelet endothelial cell adhesion molecule-1 (PECAM-1) is a surface glycoprotein 
expressed on both platelets and EC. A dual role of PECAM-1 has been reported, in which PECAM-
1 acts as an initiator of EC activation but an inhibitor of platelet activation115;124. On platelets, 
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PECAM-1 reduces platelet adhesion or aggregation regulating integrin activation (through 
inhibition of GPIbα mediated GPIIb activation)127. Hence, PECAM-1 can be considered as a 
potential therapeutic target. Though, several studies have reported activation of PECAM-1 on EC 
under static shear stress exposure, no studies have yet examined the effect of dynamic shear stress 
on platelets PECAM-1 expression31;222. Therefore, in this study, we quantified the platelet surface 
PECAM-1 protein after exposing platelets to dynamic shear waveforms (normal and pathological 
low shear) in either the absence or presence of EC. Interestingly, the presence of EC significantly 
enhanced platelet PECAM-1 expression (Figure 5.1) after 60 min of shear exposure. Jones et al. 
have shown negative co-relation between platelet surface PECAM-1 expression and platelet 
function, as expression and clustering of PECAM-1 inhibited multiple signaling pathways resulting 
in reduced thrombus formation223. Therefore, our observations may indicate that platelets which 
become activated under dynamic shear exposure express more surface PECAM-1, which then acts 
as a negative regulator to inhibit further platelet activation. 
 GPIbα, the main binding component of GPIb-IX-V complex, facilitates firm adhesion of 
activated platelets to suebdothelium through vWF-GPIbα interaction135. It has been reported that 
this interaction can lead to GPIIb/IIIa mediated platelet aggregation as aggregation was attenuated 
blocking vWF using anti-vWF antibody under high shear stress (10.8 Pa) exposure224. Hence in 
this study, we wanted to see whether dynamic shear exposure (for 1 hr) and EC-platelet 
communication can affect GPIbα expression of platelets. Our results (Figure 5.2) showed that 
dynamic shear stress did not have any significant effect on platelet GPIbα expression indicating 
pulsatile shear stress may initiate some negative regulatory mechanism (such as proteolytic 
cleavage of GPIbα) that attempts to reduce platelet activation225. Another reason could be the 
variation in shear stress magnitudes over time that has lower shear stress-time integral value, 
compared to similar level of constant shear stress, that may not be enough to induce any significant 
effect on platelet GPIbα expression. Exposing platelets to 1-38.8 Pa for 90 s, Leytin et al. found no 
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significant changes in GPIbα expression under low shear stress (1, 4.4, and 11.7 Pa); whereas, 
found significant downregulation under high shear (20.4 and 38.8 Pa) exposure226. When EC were 
incorporated into our system, dynamic shear (normal and elevated) stress exposure reduced platelet 
surface GPIbα expression significantly demonstrating role of platelet-EC communication in 
modulation of platelet responses.  
 GPIIb is another platelet surface membrane glycoprotein that contributes to platelet 
aggregation. Upon platelet activation, GPIIb undergoes conformational changes and transforms 
from inactive state to active state. Reduction in GPIIb expression can decrease shear stress induced 
pro-coagulant granule secretion and spreading of platelets227;228. Though it is unclear how shear 
stress can affect GPIIb expression, decreased GPIIb expression would mean reduced platelet 
aggregation eventually132;229. In this study, platelets were exposed to constant and dynamic shear 
stress for 60 min either with or without healthy or activated EC (through TNF-α treatment), and 
platelet surface GPIIb expression was measured every 15 min (Figure 5.3). Platelet GPIIb responses 
were observed to vary with different shear loading environments. Platelets were more sensitive in 
presence of constant shear stress as significant reduction in GPIIb expression was observed under 
elevated (3 Pa) shear exposure. Time study demonstrated that both normal and elevated constant 
shear stress (1 and 3 Pa) increased platelet surface GPIIb expression within 15 min of shear 
exposure that reduced with longer exposure duration (after 60 min). However, dynamic shear stress 
had no significant effect on platelet GPIIb expression further suggesting that pathological dynamic 
shear exposure may not necessarily cause damage or activation of platelets. These results indicated 
that platelets’ response to shear stress is dependent on shear stress (constant or dynamic) nature. 
Platelets tend to have different level of activation under constant shear stress as they are constantly 
exposed to same level of shear magnitude over a certain period of time. Therefore, they do not get 
a chance to recover from exposed shear stimulation. However, as dynamic shear stress varies over 
time, it seems to have a protective effect on platelets230. Interestingly, in the presence of healthy 
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and activated EC, a significant reduction in platelet surface GPIIb expression (Figure 5.4) was 
observed under dynamic elevated shear exposure, suggesting cross-talk between platelets and EC 
may have initiated a protective mechanism to reduce aggregation. 
 Upon activation, platelets and EC also release small vesicles (0.1 to 1.5 µm) known as 
microparticles that contain most of the platelet and EC surface glycoproteins (PECAM-1, GPIbα, 
GPIIb), negatively charged surface phospholipids, and binding sites for coagulation factors. 
Microparticles can induce activation of platelets and EC, facilitating adhesion and platelet 
aggregation. After exposing platelets to dynamic shear stress in the presence of EC, both platelet 
(PMP) and EC (EMP) microparticles were quantified in this study based on their size and positive 
binding for PECAM-1 and GPIbα (Figure 4.6)231. PMP are positive for both PECAM-1 and GPIbα; 
whereas EMP are positive for PECAM-1 and negative for GPIbα. Our results (Figure 5.8) showed 
an increase in EMP and PMP production under all the dynamic shear exposure conditions compared 
to static control. Between the two, EMP represented the majority of the detected microparticle 
population. Further analysis showed that elevated shear exposure significantly increased EMP 
generation that may have enhanced platelet sensitivity to dynamic shear stress exposure in presence 
of EC. Applying 1.2 and 10.8 Pa shear stress using a cone plate shearing device for 5 min, Miyazaki 
et al. have found significantly high PMP generation under 10.8 Pa, but, not under 1.2 Pa indicating 
PMP generation is dependent upon shear stress magnitude as high level of shear stress can enhance 
PMP release232. A positive relationship has been reported to exist between hemodynamic shear 
stress and EMP generation as both PMP, EMP had been reported to increase during pulmonary 
hypertension, but only EMP level was associated with the hemodynamic severity of the disease233. 
vWF is a multimeric glycoprotein that is synthesized exclusively by EC and 
megakaryocytes. vWF is either expressed on the cell surface or released in soluble form into the 
plasma. Because it is a dimer, vWF can form a bridge between two cells (two platelets or one 
platelet and one EC) facilitating their interaction and platelet-EC adhesion. vWF binding to GPIbα 
160 
 
plays vital role for activated platelets to adhere to damaged sub-endothelium, whereas GPIIb-vWF 
interaction for platelet aggregation28. Since shear-induced interaction between platelet GPIbα and 
immobilized vWF can cause GPIbα ectodomain shedding under shear stress exposure, we wanted 
to see how dynamic shear stress can affect EC vWF expression225. Hence, EC were exposed under 
different constant and dynamic shear exposure, and EC surface and released vWF expression was 
quantified. Tissue factor (TF) is another membrane bound glycoprotein which has a major role in 
blood coagulation. During injury, TF forms a complex with coagulation factor (factor VII), 
resulting in insoluble fibrin formation to stop bleeding. TF is reported to induce an increase in 
thrombin generation which can down regulate GPIbα expression234;235. Therefore, we also 
investigated the change in TF expression under constant and dynamic shear exposure. Both surface 
vWF and TF expressions on EC and released soluble vWF was quantified using solid phase and 
sandwich ELISA technique respectively. Results showed that there was no significant change in 
EC surface vWF (Figure 5.9 and 5.10) or TF (Figure 5.12) expression under constant or dynamic 
shear exposure. No change in observed EC surface vWF expression could be due to the applied 
shear stress magnitude or shear stress exposure duration, or due to the rapid (within seconds to 
minute) cleavage of EC surface vWF by EC produced metalloproteases (such as ADAMTS13). 
ADAMTS13 cleaves off the cell surface vWF and reduces the ultra large size of the multimers 
resulting in soluble vWF expression54. Similar result, i.e. no change in EC surface vWF expression, 
has also been reported in a previous study, when EC were exposed to 1.2 Pa for 6 hr57. Interestingly, 
they found significant increase in vWF expression when EC were sheared for longer duration (15 
hr) which demonstrates shear exposure duration as a major modulator of EC surface vWF 
expression. For TF expression, as EC produce both TF and TF pathway inhibitor (TFPI), no change 
in EC surface TF expression could be attributed to simultaneous TFPI secretion. Grabowski et al., 
activating HUVEC under 0.068 and 1.32 Pa shear stress for 3 hr, have found direct diminishing 
effect of flow mediated shear stress on EC TF generation through upregulation of TFPI236. In our 
study, when EC were exposed to dynamic shear stress in the presence of platelets, elevated shear 
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stress induced a significant increase in soluble vWF expression (Figure 5.11) indicating soluble 
vWF may be a mediator of enhanced platelet activation under dynamic shear stress exposure. 
Galbusera et al. has also reported significant shear stress magnitude dependent increase in EC 
released soluble vWF expression after applying 0.2-1.2 Pa shear stress for 6 hr on HUVEC57. 
Interaction between platelets and EC can greatly modulate their functions during 
physiological and pathological conditions. Both platelets and EC can release different substances 
that can enhance or inhibit activation of the other cell type. Platelets and EC also communicate via 
cell surface glycoproteins. To investigate the level of platelet-EC interaction on responses to shear 
stress, platelets were exposed to dynamic shear stress in the presence of EC. Optical microscopy 
images showed that dynamic shear exposure enhanced interaction between platelets and EC, as 
more platelets were observed to adhere to sheared EC. However, more experiments were needed 
to reach a definite conclusion. 
 Our results indicated that platelet and EC activation by shear stress is sensitive to the nature 
of the shear exposure. Constant and dynamic shear can both modulate platelet and EC function, but 
in different ways. Constant shear stress induced a greater change in protein expression than 
dynamic shear stress (when compared for platelet surface GPIIb expression). One possible 
explanation for this observation is that platelets do not get any recovery time from shear stimulation 
when exposed to constant shear. Another explanation is that the shear stress-exposure time integral 
value is much higher for constant shear stress (360, 1080, 3600, and 10800 Pa-s for 0.1, 0.3, 1, and 
3 Pa shear stress respectively) compared to the dynamic shear waveforms (1980, 828, and 2088 Pa-
s for normal, low, and elevated shear stress respectively). Therefore, pathological (low or elevated) 
dynamic shear stress may not induce as great of a change in expression as constant shear stress. 
Also, platelet-EC communication plays a vital role in platelet and EC activation237. Our results 
showed that, in the presence of platelets, pathological dynamic shear can induce EC activation (as 
seen by a significant increase in soluble vWF and EMP generation). Activated EC may engage in 
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signaling crosstalk with platelets to return activation towards equilibrium levels by 
increasing/decreasing platelet surface glycoproteins or PMP generation. We conjecture that the 
increase in platelet surface PECAM-1 (negative modulator for platelets) and decrease in GPIbα and 
GPIIb and PMP generation which we observed following dynamic shear exposure serves to 
counteract EC activation by shear stress exposure.   
Physiological relevance of in vitro EC study has been further enhanced through ex vivo 
animal study. In ex vivo study, we have examined activation and injury level of EC, of aorta freshly 
harvested from rats, following dynamic shear (normal, low, and elevated) exposure in a perfusion 
flow chamber (Figure 4.5 and 4.7). Total protein expression of vWF, ICAM-1, and TF expression 
was measured through Western blot. Results from Western blots (Figure 5.13) showed no 
significant difference in either of the proteins expression (vWF, ICAM-1, or TF) in cytoplasmic or 
membrane level under different dynamic shear exposure. However, compared to the non-sheared 
aortas, dynamic shear stress induced significant reduction (P<0.05) in vWF and ICAM-1 
expression in cytoplasmic level, as well as significant reduction in ICAM-1 expression in 
membrane protein level. As it has been reported that only ~5% of the synthesized vWF remains 
stored in the Weibel-Palade bodies of the EC and the remainder gets secreted as soluble vWF, this 
can cause reduced cytoplasmic vWF expression under dynamic shear exposure238. Studies have 
shown that shear stress magnitude and exposure duration play important role on EC ICAM-1 
expression, as significantly increased ICAM-1 level was observed in vitro (when HUVEC were 
subjected to 0.25-4.6 Pa for 48 hr) in time-dependent manner and in vivo [when carotid arteries of 
rabbits were ligated to induce low (0.326±0.058 Pa) and elevated (3.05±0.46 Pa) shear stress for 5 
days]13 in shear stress magnitude-dependent manner239. Reduction in vWF, ICAM-1 expression 
might also indicate to a potential protective mechanism that inhibits EC activation. No significant 
change in either cytoplasmic or membrane TF level was observed under dynamic shear exposure. 
This could be due to variable expression of EC TF as TF has been identified on activated static 
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cultured EC surface in vitro, whereas has not been found on endothelium in vivo indicating the 
protective effect of flow dependent shear stress on cell synthesized protein expression/release240;241. 
All together the results indicate that dynamic shear stress induce higher activation of EC in vitro 
compared to ex vivo. Differences between our in vitro and ex vivo results could be attributed to 
some facts: a) EC were exposed to dynamic shear stress in vitro for 1 hr, but for 2 hr in ex vivo 
study, b) in vitro EC were coronary artery endothelial cell from human (HCAEC); whereas ex vivo 
study EC were abdominal aorta EC of rat, c) total EC lysates were used for in vitro study, but tissue 
lysates were separated as cytoplasmic and membrane protein extracts in ex vivo study, and d) the 
ex vivo study is more physiologically relevant than the in vitro study. Expression level of a 
particular protein in EC has been reported to vary not only in different species, but, from different 
origins as well196.   
6.2 Signal pathways involved in endothelial cell responses to dynamic shear stress 
 Signal pathways are part of a complex communication system that can modulate different 
cellular functions such as differentiation, proliferation, and migration. Signals are sensed and 
converted to intracellular biochemical signals that are passed through the cytoplasm by various 
signaling pathways. The MAPK pathway is one such pathway (composed of ERK1/2, JNK, and 
p38 members) that passes the intracellular signal to the nucleus through phosphorylation of its 
signaling cascade components. NF-κB is an important transcription factor that translocate to the 
nucleus upon activation and plays an important role in regulating expression of growth factors, 
cytokines, and other proteins (ICAM-1, E-selectin). Studies have shown that MAPK pathway 
activation can activate NF-κB and induce its translocation into the nucleus93;94. Most studies of the 
role of shear stress in regulating MAPK and NF-κB activity have utilized constant shear stress to 
activate EC79;242. Therefore, this study was designed to observe the effects of the more physiological 
stimulus of dynamic shear exposure, as well as platelet-EC interaction, on activation of the MAPK 
and NF-κB pathway. EC were exposed to normal or low dynamic shear exposure of left coronary 
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artery, for 1 hr using the cone-plate shearing device, in the absence or presence of platelets, and 
MAPK and NF-κB pathway activation level was observed through Western blotting. 
Immunocytochemical staining was also conducted for quantification of ERK1/2 activation. Results 
from the Western blot (Figure 5.14 and 5.15) experiments indicated that there was no significant 
effect of dynamic shear exposure on EC MAPK pathway activation (measured through level of 
ERK1/2, JNK, and p38 phosphorylation) after 30 min, but a significant reduction (P<0.05) in 
ERK1/2 and p38 phosphorylation level was observed after 60 min shear exposure compared to non-
sheared EC (control). Results from immunocytochemical (Figure 5.16) staining images (ERK1/2, 
60 min shear exposure, qualitative analysis) were consistent with the Western blot data. In the 
presence of platelets (more experiments were needed), level of MAPK phosphorylation (ERK1/2, 
JNK, and p38) of EC increased compared to that of EC sheared in absence of platelets. In the 
absence of platelets, a significant decrease (P<0.05) in phosphorylated ERK1/2 was observed after 
60 min shear exposure (compared to 30 min). Therefore, further experiments were conducted to 
see whether a shorter dynamic shear exposure duration (2, 5, and 15 min) could activate ERK1/2. 
As ERK1/2 plays the most prominent role in modulation of cellular and physiological activities 
among the three members of MAPK family (ERK1/2, JNK, and p38), we were more interested on 
ERK1/2 activation level. Significant phosphorylation of ERK1/2 occurred during this short 
exposure duration, with a peak within 5 min followed by a significant decrease with continued 
shear exposure (at the end of 60 min). Exposing HUVEC to 0.42 Pa shear stress for 0-120 min in 
a parallel plate flow chamber, Cheng et al. also reported increased ERK1/2 phosphorylation level 
within 10 min of shear exposure that returned to basal level after 60 min79. Surapisitchat et al. 
applied 1.2 Pa constant shear stress on HUVEC for 60 min and have found significant increase in 
ERK1/2 activation within 10 min of shear stress exposure that sustained till the end; whereas, p38 
activation level increased slowly reaching the peak after 60 min shear exposure243. Their study also 
indicated no significant effect of shear stress on activation of JNK, similar to what we have found. 
In the presence of platelets, a similar trend (initial increase followed by a gradual decrease) in 
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ERK1/2 phosphorylation of EC was observed in our study. Interestingly, an overall higher 
activation level was observed in the presence of platelets, suggesting that platelet-EC 
communication enhanced sensitivity of EC to shear stress (more experiments were needed) and 
activated EC MAPK pathway.  
Level of NF-κB phosphorylation was also quantified after exposing EC to dynamic shear 
stress (normal and low) in the absence or presence of platelets. We observed (Figure 5.17) a similar 
trend (significant initial increase and gradual decrease, P<0.05) in NF-κB phosphorylation as seen 
for phosphorylation level of ERK1/2. However, the NF-κB response was delayed, as the highest 
level (P<0.05) of phosphorylation reached after 15-30 min of shear exposure. This result suggests 
that dynamic shear stress first affects MAPK activation, which in turn modulates NF-κB activation. 
Conducting a time course study on cardiac myocytes, treated with septic plasma, Yang et al. found 
that activation of MAPK members (p38, after 2 min) precedes activation of NF-κB (after 5 min)244. 
Blocking p38 MAPK activity, they also found inhibition of NF-κB phosphorylation and 
translocation that confirmed the role of MAPK in modulation of NF-κB activities. Therefore, in 
our study, further investigations were required with MAPK inhibitors in order to test the possibility 
of dynamic shear stress in such modulation. Other studies have also demonstrated involvement of 
different MAPK members regulating NF-κB activities93;245. Liang et al. have reported significantly 
increased NF-κB staining in nuclei after 30 or 60 min of shear exposure to 0.42 Pa, suggesting 
activation and translocation of NF-κB from cytoplasm to nuclei under steady shear stress 
exposure96. Interestingly, in our study, the peak activation of NF-κB was observed within 2 min of 
shear exposure in the presence of platelets, followed by a gradual decrease (more experiments were 
needed to reach a definite conclusion). However, no significant difference was observed in either 
ERK1/2 or NF-κB phosphorylation level in response to low shear stress exposure, compared to 
normal shear. Results from specific aim 1 also indicated that pathological low shear stress does not 
induce any significant EC activation. Taken together, these data suggest that low dynamic shear 
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stress may not be harmful for EC, or that low shear exposed EC recovers quickly from shear 
exposure as the time averaged value of this shear stress waveform is quite low.  
6.3 Effect of dynamic shear stress on uptake/release of endothelial growth factors by platelets  
PLGF and VEGF-A are two important endothelial growth factors that can contribute to 
arteriogenesis by modulating various cellular functions (such as cell permeability, survival, 
proliferation) directly or indirectly (through attraction of inflammatory cells towards EC). Upon 
activation, EC and SMC produce an abundant amount of PLGF and VEGF-A, respectively196. Non-
EC secreted VEGF-A then acts on EC in a paracrine manner246. However, the mitogenic effect of 
VEGF-A requires the presence of PLGF to make the greatest impact on EC functions199. Studies 
have shown that PLGF alone does not induce EC migration, but VEGF-A requires PLGF for 
modulating this function, and PLGF deficiency can hamper responses to VEGF-A198. For 
enhancing the mitogenic response of EC to VEGF-A, a high level of PLGF expression is not 
necessary; rather, the presence of a low level of PLGF is sufficient to exert the effect196. PLGF and 
VEGF-A bind to their corresponding growth factor receptors (VEGFR1 and VEGFR2) to send 
different intracellular signals that modulate EC responses195;212. Since platelets circulate throughout 
the body and can take up or release proteins upon activation, platelets can act as effective 
transporters for carrying PLGF and VEGF-A from the site of protein synthesis to their site of 
action247;248. Therefore, this study investigated the role of platelets in uptake and release of PLGF 
and VEGF-A. The effects of dynamic shear exposure (simulating conditions in remodeling 
coronary collateral arteries; Figure 4.3), calcium ion inhibitors (beraprost sodium and EDTA), and 
metabolic dysfunction (hyperglycemia) on the uptake and release of PLGF and VEGF-A by 
platelets were also assessed. 
Initially, an RT-PCR analysis was conducted to determine whether platelets contain mRNA 
for PLGF and VEGF-A. Results showed that platelets do contain VEGF-A mRNA. In contrast, no 
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PLGF mRNA was detected in platelets. The presence of VEGF-A mRNA in platelets has been 
reported previously, but, no prior studies have reported whether platelets contain PLGF mRNA249. 
We next conducted an uptake study using exogenous PLGF and VEGF-A. Results of this study 
demonstrated a dose-dependent uptake of both PLGF and VEGF-A by platelets (Figure 5.18), 
indicating that platelets can take up arteriogenesis-mediating growth factors. Similar to our results 
for PLGF and VEGF-A, Klement et al. also found dose-dependent increase in bFGF uptake by 
platelets by incubating platelets with different concentrations (0-600 ng/mL) of endostatin and 
basic fibroblast growth factor (bFGF) for 1 hr248.  
Since most platelet functions are modulated by calcium signaling, and since beraprost 
sodium (a stable prostacyclin analogue) can inhibit calcium efflux by binding to corresponding 
prostacyclin receptors present on the platelet surface, we next tested the effect of beraprost sodium 
on PLGF and VEGF-A uptake by platelets250. Beraprost sodium did not affect uptake of PLGF or 
VEGF-A protein (Figure 5.19), indicating that either the concentration of beraprost sodium or the 
short treatment duration (1 hr) was insufficient to induce any effect on calcium signaling. A dose-
dependent and time-dependent effect of beraprost sodium has been reported by Nony et al251. The 
lack of effect of beraprost sodium could also indicate that uptake of the growth factors by resting 
platelets may not be a calcium dependent process.  
Since type 2 diabetes (characterized by insulin resistance of cells) is associated with poor 
arteriogenesis, we next tested the effect of simulated hyperglycemia on platelet PLGF and VEGF-
A uptake252. In studies by other groups, induction of hyperglycemia in platelets collected from both 
non-diabetics and diabetics resulted in increased platelet activation and reactivity in vitro253;254. 
Since platelets are known to be hyperreactive in diabetics, we hypothesized that exposure of 
platelets to simulated hyperglycemic conditions (250 mg/dL glucose treatment) would significantly 
increase platelet uptake of growth factors. However, acute hyperglycemia (250 mg/dL glucose; 1 
hr) had no effect on PLGF and VEGF-A uptake by platelets (Figure 5.20), though an increasing 
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trend was observed for both the growth factors uptake. The increasing trend suggested that the 
treatment exposure time frame was probably short to induce any significant effect on platelet 
growth factor uptake, which is a potential limitation of this study. Another limitation of the study 
could be low number of experiments. As type 2 diabetes is also characterized by a variety of other 
abnormal metabolic features (hyperlipidemia, hyperinsulinemia, and oxidative stress) in addition 
to hyperglycemia, the presence of these conditions could possibly induce defective growth factor 
uptake by platelets contributing to poor arteriogenesis in diabetics. These conditions were not tested 
in our present studies. Administration of lipoprotein in diabetic patients has been found to promote 
calcium efflux leading to reduced platelet activation and aggregation255. Hwang et al. has reported 
that hyperinsulinemia induces magnesium efflux in platelets, leading to an increased cAMP level 
and reduced platelet activation256. Therefore, the effects of these parameters on platelet uptake of 
growth factors should also be examined in future studies.  
The effect of a calcium ion chelator (EDTA) on uptake of growth factors by dynamic shear 
exposed platelets was also assessed. The results showed (Figure 5.21) no significant effect of 
dynamic shear stress exposure on platelet growth factor (PLGF and VEGF-A) uptake. EDTA 
treatment also had no significant effect on uptake of growth factors by dynamic shear stress exposed 
platelets. These results may demonstrate that growth factor uptake by platelets is a process 
independent of calcium signaling, consistent with what we observed in the beraprost sodium study. 
The effect of dynamic shear stress and beraprost-sodium on platelet release of exogenous 
PLGF and VEGF-A was analyzed by exposing recombinant PLGF/VEGF-A and beraprost-sodium 
treated platelets to dynamic shear. A decreasing trend for PLGF release and an increasing trend for 
VEGF-A release was observed under the combined treatment of dynamic shear stress and 
beraprost-sodium (Figure 5.22). Studies have shown that different types of stimulation 
(biochemical vs. biomechanical) induce release of angiogenic proteins from activated platelets at 
different levels based on their release kinetics247;257. Since our data analysis indicated no significant 
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effect of the shear stress or beraprost treatment on growth factor release, these results again suggest 
that uptake/release of growth factors by platelets is not probably an active Ca2+ signaling dependent 
process.  
Next, the combined effect of dynamic shear stress and hyperglycemia on release of PLGF 
and VEGF-A by platelets was assessed. Results indicated (Figure 5.23) no significant effects of 
combined exposure to dynamic shear stress and hyperglycemia on growth factor release by 
platelets. Further studies are necessary to test the effect of other diabetes-associated metabolic 
features on platelet PLGF and VEGF-A uptake/release. Also, longer dynamic shear stress exposure 
with/without different metabolic treatments should be considered for future experimental designs.  
6.4 Effects of diabetes associated major metabolic dysfunction on PLGF and VEGFR1 
expression by human and mouse cardiac and skeletal muscle cell types 
 PLGF, a major modulator of arteriogenesis, is produced in heart, lungs, skeletal muscles, 
and abundantly by placenta. PLGF exerts its arteriogenic function through activating VEGFR1 (the 
PLGF receptor), which is present on the cell surface of EC, SMC and inflammatory cells and sends 
intracellular signals that modulate EC responses, SMC growth and proliferation, and inflammatory 
cell migration. Although PLGF has been established as one of the key arteriogenic growth factors, 
modulation of the PLGF expression level and the mechanisms behind this regulation is not well 
characterized during disease conditions such as diabetes. Diabetics have a much higher risk of 
cardiovascular events, as they are more susceptible to develop athero-thrombotic vascular disease 
and to have impaired angiogenesis/arteriogenesis. These effects are seen in both the cardiac and 
the peripheral circulation. Together, the increased risk of disease development and the decreased 
ability to compensate for the disease result in a high risk of heart attack or limb amputation. 
Therefore, we were interested in studying PLGF expression by myocytes from both cardiac and 
peripheral origins. We focused on heart and skeletal muscle cells, as diabetic CAD and PAD affect 
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arteriogenesis in these two regions the most. A previously conducted study in our lab has 
demonstrated that mice consuming a Western diet for 6 mo exhibit metabolic dysfunction similar 
to that found in type 2 diabetics (as determined by metabolic phenotyping) and express a reduced 
level of PLGF in both heart and skeletal muscle. Chou et al. reported reduced collateral formation 
in cardiac tissues of diabetic rats and identified reduced VEGF and VEGFR1/R2 expression as one 
basis for this impairment18. However, diabetes is a complex metabolic disorder characterized by 
many abnormal metabolic parameters such as hyperlipidemia, hyperglycemia, hyperinsulinemia, 
and oxidative stress. Therefore, further in vitro studies were required to investigate the effect of 
each of these parameters on PLGF expression and to identify which parameter has the greatest 
impact on PLGF258. Also, we wished to determine the relevance of the mouse study to human 
physiology. To fulfil this purpose, both human and mouse cell types from heart (human coronary 
artery endothelial cells, HCAEC and human cardiac myocytes, HCM; and mouse cardiac myocytes, 
MCM) and skeletal muscle (human skeletal muscle cells, HSKMC and mouse skeletal muscle cells, 
MSKMC) were subjected to various diabetes-associated treatment conditions mimicking 
hyperlipidemia (low density lipoprotein, LDL and oxidized LDL, ox-LDL), hyperglycemia 
(glucose and advanced glycation end products, AGE), hyperinsulinemia (insulin), and oxidative 
stress (hydrogen peroxide, H2O2), followed by PLGF and VEGFR1 quantification. Along with 
glucose derived AGE, glyceraldehyde derived AGE has been used to treat cells. Glyceraldehyde 
has the advantage of more rapidly forming AGE than glucose but can evoke similar endothelial cell 
dysfunction259. Endothelial cells form the inner lining of the cardiac chambers and blood vessels 
and cardiac myocytes constitute the heart wall. Therefore, to identify which of these two major cell 
types of the heart is the primary source of PLGF in heart, HCAEC and HCM were chosen for the 
study. Initially, the effect of different metabolic molecules at various concentrations (chosen based 
on literature survey) was tested on PLGF production by HCAEC. The most effective concentrations 
were then used to treat the other cell types.  
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 Results from the initial HCAEC dose study showed that hyperlipidemia (LDL/ox-LDL 
treatment; Figure 5.24) and hyperinsulinemia (insulin treatment; Figure 5.26B) failed to have any 
effect on HCAEC PLGF expression. No effect of 0.1 mM H2O2 (Figure 5.26A) treatment on PLGF 
production level was expected, as this is considered to be a physiological concentration level for 
normal cellular activities in vivo176. However, 0.3 mM H2O2 (Figure 5.26A) reduced HCAEC PLGF 
levels significantly, demonstrating that a pathophysiological level of oxidative stress can inhibit 
PLGF production by HCAEC. Growth factors such as members from VEGF family appear to be 
subjected to redox regulation as reduced growth factor (VEGF) expression in the setting of 
oxidative stress has been reported in epithelial cells that can promote the development of pulmonary 
disorders260. A redox-window hypothesis exists for collateral artery growth, and states that an 
optimal level of oxidative stress is required above which growth factor dependent signaling and 
corresponding collateral growth is corrupted. Oxidative stress below the optimal level also results 
in impaired collateral growth. The results of our oxidative stress study are consistent with this 
hypothesis185.  
During diabetes, an excess level of glucose is present in the blood. If this condition is 
maintained for a long duration, the excess glucose begins to interact with proteins, forming AGE. 
In rodent studies, the presence of high glucose and AGE has been reported to impair angiogenic 
potential, and this impairment can be reversed by inhibiting AGE’s interaction with its receptor 
(RAGE)261;262. Therefore, we next set out to investigate whether PLGF production by HCAEC was 
inhibited by AGE treatment. Our results indicated that both glucose and AGE significantly reduced 
PLGF expression (Figure 5.25) demonstrating that acute hyperglycemia and chronic 
hyperglycemia are both major negative modulators of HCAEC PLGF production. Dose dependent 
and time dependent effects of glucose and AGE on PLGF were also observed, as the most 
significant reduction was observed at the highest concentration and the longest treatment duration 
(24 hr).  
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Interestingly, lower concentrations of AGE (300-500 µg/mL) significantly and H2O2 (0.05 
µM) non-significantly increased HCAEC surface VEGFR1 expression after 24 hr of treatment 
(Figure 5.27), but expression returned to basal levels in the presence of higher concentrations 
(AGE: 1000 µg/mL and H2O2: 0.3 mM). Although PLGF expression was significantly reduced in 
the presence of AGE and 0.3 mM H2O2, a similar level of inhibition was not observed for VEGFR1. 
This could be due to the reason that VEGFR1 is also a receptor for VEGF-A and the level of VEGF-
A was found to be increased in diabetic patients297. Therefore, PLGF expression may not correlate 
with its receptors’ (VEGFR1) expression. Another reason could be the generation of soluble variant 
of VEGFR1 receptor (sVEGFR1) that can bind to PLGF, reducing availability of free and active 
PLGF protein. Hornig et al. has reported sVEGFR1 release by both human microvascular and 
macrovascular EC298. Therefore, along with cell surface VEGFR1, sVEGFR1 level also need to be 
quantified during different treatment conditions. 
Similar to what we observed in the HCAEC study, the results of the HCM study 
demonstrated that LDL or ox-LDL treatment (Figure 5.28) had no significant effect on HCM PLGF 
expression. Therefore, hyperlipidemia alone may not be a major contributor to impaired PLGF 
expression in the heart during diabetes. However, it is possible that hyperlipidemia may act 
additively or synergistically with other metabolic parameters. Treatment with AGE (Figure 5.28) 
significantly reduced PLGF, whereas 0.3 mM H2O2 (Figure 5.28) significantly increased PLGF 
expression by HCM. The inhibitory effect of AGE on PLGF inhibition in cardiac cells (both 
HCAEC and HCM) further supports our hypothesis that AGE formation during long-term 
hyperglycemia is a key contributor to impaired coronary arteriogenesis during diabetes. The 
opposite effect of 0.3 mM H2O2 on HCAEC (significant decrease) and HCM (significant increase) 
PLGF expression could be attributed to the metabolic difference of the two cell lines. HCM are the 
most physically active and highly specialized oxygen content rich cells in the body. Therefore, 
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though 0.3 mM H2O2 level tend to be pathophysiological for HCAEC, the same level of H2O2 may 
be necessary for normal physiological function of HCM.  
Comparison of PLGF production by untreated HCAEC and untreated HCM identified 
HCAEC as the major source of PLGF in the heart, as HCAEC produced ~10-15 times more PLGF 
than HCM (Figure 5.30). Therefore, although oxidative stress (0.3 mM H2O2) induced an increase 
in PLGF protein by HCM, reduced expression by HCAEC may lead to an overall decrease in 
cardiac PLGF protein level in the presence of oxidative stress.  
Interestingly, PLGF expression was found to be more sensitive to metabolic parameters in 
MCM than HCM, as a significant change in PLGF expression was observed in response to all of 
the treatment conditions in MCM (Figure 5.31). In contrast, PLGF levels were affected only by 
AGE and 0.3 mM H2O2 in HCM (Figure 5.28). The various metabolic compounds tested (glucose, 
AGE, and 0.3 mM H2O2), affected MCM VEGFR1 as well (Figure 5.32). This finding suggests 
that results obtained from mouse studies/cell types should be carefully interpreted, and validated in 
human tissues and cells. 
To investigate the effect of different diabetes-associated metabolic parameters on PLGF 
expression by skeletal muscle cells (SKMC), HSKMC and MSKMC were also exposed to 
simulated hyperlipidemic, hyperglycemic, hyperinsulinemic, and oxidative stress conditions as 
described above. Results from the HSKMC study indicated that skeletal muscle cells were less 
sensitive to different metabolic treatments, as compared to cardiac cells. This finding could be 
attributed to the cell-specific differences in protein expression based on the different origins of the 
cells. For example, even within one species (such as rat), VEGF protein expression and its 
corresponding receptors have been reported to decrease in cardiac tissue and increase in retina 
during diabetes18. In our study, only the hyperglycemia-associated treatments (glucose and AGE) 
were able to induce a significant reduction in HSKMC PLGF production (Figure 5.33). Tamarat et 
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al. showed that diabetes associated AGE formation impairs ischemia induced angiogenesis 
(induced by femoral artery ligation) which was rescued by prohibiting AGE formation using 
aminoguanidine263.  
A higher sensitivity of mouse skeletal muscle cells (compared to human cells) to the 
metabolic factors has also been observed. MSKMC PLGF levels were significantly attenuated in 
the presence of simulated hyperlipidemia, long-term hyperglycemia, and oxidative stress (Figure 
5.35). Interestingly, glucose treatment significantly increased PLGF levels in MSKMC. This 
disparity in results (from mouse and human cells) could be due to the species differences, as mice 
and humans have many morphological, genetic, and metabolic differences.  
No significant change in cell surface VEGFR1 expression was observed under any 
treatment condition in either HSKMC (Figure 5.34) or MSKMC (Figure 5.36). Summarizing all 
these results, it can be concluded that hyperglycemia and long-term hyperglycemia resulting in 
AGE formation may be the major contributors to impaired arteriogenesis in diabetic skeletal muscle 
as well as in heart; however, other metabolic parameters may also play a role.  
A brief overview of the results of this aim is shown in table 2. 
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Table 2: Effects of different diabetes associated (type 2) metabolic molecules on PLGF expression 
by different cell types. (N.E. means no effect) 
Cell type Treatments 
 Simulated 
Hyper-
lipidemia 
Simulated 
Hyper-
glycemia 
Simulated 
Long-term 
Hyperglycemia 
Simulated 
Hyper-
insulinemia 
Simulated 
Oxidative 
Stress 
HCAEC N.E.   N.E.  
HCM N.E. -  -  
MCM  -  -  
HSKMC N.E.   N.E. N.E. 
MSKMC    N.E.  
 
6.5 Effects of glucose, AGE, and EC-SMC communication on dynamic shear stress-
stimulated EC PLGF expression and related signaling pathways 
 Increased shear stress is considered to be a major stimulus for arteriogenesis. It is well 
established that arterial occlusion can increase blood flow induced shear stress in the connecting 
collateral arteries of proximal areas, affecting EC activation, monocyte adhesion, and subsequent 
growth factor production by EC in the collaterals264;265. Diabetes, a major risk factor for 
cardiovascular complications, limits both the adaptive response due to arterial obstruction and the 
number of collaterals that develop. However, the mechanism(s) through which diabetes suppresses 
arteriogenesis are still not well defined. Our study has identified diabetes associated acute 
hyperglycemia and chronic hyperglycemia as two of the major modulators that negatively influence 
the key arteriogenic growth factor PLGF. As experimental hyperglycemia consistently reduced 
PLGF expression in all of the cell types tested (in the previous specific aim 5), and EC were 
identified as the major source of PLGF in the heart, the study next focused on how hyperglycemia 
could affect shear stress mediated PLGF expression in EC. This goal was achieved by exposing 
176 
 
human coronary artery endothelial cells (EC) co-cultured with human coronary artery smooth 
muscle cells (SMC) to glucose/AGE and/or elevated dynamic shear waveforms mimicking shear 
stress of coronary collateral arteries undergoing remodeling due to the presence of a 60% blockage 
in the main artery. Previous studies have shown that co-culturing EC with SMC can affect SMC 
density and proliferation, as well as EC and SMC gene/protein expression266;267. Therefore, we used 
a co-culture model that mimicked the vascular wall more physiologically due to the presence of 
direct communication between EC and SMC, allowing them to modulate each other’s functions. 
Also, the co-culture model allowed us to single out the effect of specific treatments on EC PLGF 
expression since the two cell types can be collected and analyzed separately. Our results (Figure 
5.38) indicated that AGE treatment can significantly reduce PLGF production by EC even in co-
culture model. Elevated shear stress significantly increased PLGF production ~24% by EC in co-
culture. Effects of shear stress on other growth factors have been reported by Gloe et al., who found 
an increase in EC proliferation and differentiation by enhanced basic fibroblast growth factor 
(bFGF) release during shear exposure268.  
Next, we hypothesized that the increase in PLGF in response to shear stress would be 
reduced by experimental hyperglycemia. Our results demonstrated that the increase in PLGF 
expression following exposure to elevated shear stress was blocked by both glucose and AGE 
treatment, the effect of AGE being greater, suggesting that acute and long term hyperglycemia 
might inhibit PLGF expression and arteriogenesis by promoting AGE formation during diabetic 
CAD. Overall, our results are in agreement with previous in vivo findings demonstrating that 
diabetes inhibits arteriogenesis186;269.   
 To determine the signal transduction pathway involving AGE-mediated PLGF reduction 
in the presence of dynamic shear stress, the gene expression level of RAGE, Nox2, Nox4, HO-1, 
MCP-1, and TNF-α was (Figure 5.39) assessed in EC 24 hr post shear exposure. Our hypothesis 
was that AGE treatment would inhibit PLGF expression through a RAGE-Nox2/4-TNFα pathway. 
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RAGE is a receptor for AGE and is present on EC, SMC, and inflammatory cells such as 
leukocytes. Generally, a low level of RAGE is expressed on quiescent cells, and is upregulated at 
the site of AGE accumulation270. AGE-RAGE interaction has been reported to enhance the 
activities of NADPH oxidase (Nox) enzyme family members271. In presence of AGE, both Nox2 
and Nox4 mRNA have been found to be upregulated that can induce sustained ROS production in 
rat cardiac myocyte and human EC respectively272;273. Channon et al.’s group has reported 
increased Nox2 and Nox4 expression in the vascular system (in arteries and veins) of patients 
suffering from CAD and/or diabetes274;275. Nox2 and Nox4 are the major sources of intracellular 
oxidative stress that generate ROS through superoxide (O2.-) and H2O2 production276. When 
produced at low levels (in the µM range; the optimum level for arteriogenesis), H2O2 plays an 
important role in physiological cellular signaling. However, increased levels of H2O2 have been 
found to amplify ROS generation in vascular cells, increasing iron uptake and enhancing Nox and 
xanthine oxidase activities. This acts as a positive feedback mechanism to further enhance and 
sustain H2O2 production277. Increased pathological level of H2O2 can then lead to dysregulated 
cellular functions through instigation of inflammatory responses (cytokine production such as 
TNF-α). Valen et al. reported that treatment of HUVEC with 0.2 mM H2O2 (which is considered 
as pathological level of oxidative stress for cultured HUVEC) enhances TNF-α mRNA level about 
four-fold, which can induce an inflammatory environment277;278. An increased serum level of TNF-
α has been associated with endothelial dysfunction in type 2 diabetic patients279. Chen et al. has 
reported that Nox generated H2O2 can potentiate TNF-α induced MCP-1 gene expression in EC280. 
MCP-1 is a chemoattractant protein that plays an important role in arteriogenesis by mediating 
monocyte recruitment. An increased level of MCP-1 has been found in plasma of type 2 
diabetics281. Though MCP-1 had been reported to modulate expression of growth factors such as 
VEGF-A, the effect of MCP-1 on PLGF levels in diabetes has not been defined yet282. Therefore, 
we also analyzed MCP-1 gene expression in this study. Gene expression of HO-1 was studied as 
well. HO-1 protects cells from oxidative stress injury by controlling iron metabolism, which is a 
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potential source of oxidative stress. Interestingly, HO-1 can generate H2O2 during its catalytic 
reaction. If present at high concentration levels, this H2O2 can inhibit iron degradation by HO-1283.  
 Our results indicated that the Nox2 gene expression was below detection level in EC. 
Previous studies also have demonstrated that Nox4 is the most abundant Nox isoform present in 
the EC and the level of Nox2 is very low (~1000 times) compared to Nox417;284. The results from 
our other gene expression study demonstrated that there was no significant effect of shear stress, 
glucose or AGE treatment on expression of any of the genes studied, except for TNF-α. One 
possible explanation for this finding could be that gene expression was quantified 24 hr post shear. 
Results from previously conducted studies in our lab have indicated that EC PLGF gene expression 
in response to shear stress was transient, as the PLGF mRNA expression level increased 
significantly within 4 hr but had returned to basal levels by post 24 hr shear exposure. Though the 
change in PLGF protein level was detected 8 hr post-shear exposure, there was no change in gene 
expression at a similar time point (10 hr). Also, PLGF upregulation was found to be dependent on 
the Nox4 signaling pathway, and Nox4 gene expression was elevated within 4 hr of shear 
exposure17. Therefore, to more conclusively identify the involvement of different signaling 
molecules, expression of the target genes should have been quantified at earlier time points (at 0-2 
hr).  
6.6 Underlying molecular mechanisms inducing dysfunctional PLGF expression in skeletal 
muscle of Western diet fed mice  
Diabetes can impair arteriogenesis through inhibition of growth factor production and 
release. From the results of our two previous specific aims, we concluded that advanced glycation 
end products (AGE) formed during long-term hyperglycemia reduces placental growth factor 
(PLGF) expression in vitro. To further enhance the physiological relevance of these findings, we 
next studied whether these results could be confirmed in an animal model. We focused on the 
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quadriceps femoris (QF, from thigh) and gastrocnemius/plantaris/soleus (G-P-S, from calf) skeletal 
muscle tissues, where two distinct types of vascular remodeling occur that are relevant to disease 
conditions such as PAD. Arteriogenesis is the main type of remodeling in the QF, whereas 
angiogenesis (capillary growth) is predominant in the G-P-S. Mice of two strains (C57BL/6J and 
ApoE-/-) were fed a Western diet (WD, high fat diet) for 6 mo to mimic diet-induced type 2 diabetes, 
followed by collection of the QF and G-P-S muscles285. In previously conducted studies in our lab, 
PLGF expression was found to be down-regulated in both the muscle types of both the strains. 
Therefore, based on these findings and the results of our in vitro experiments on skeletal muscle 
cells, we set out to determine whether tissue AGE could account for the reduced PLGF expression 
in skeletal muscle of WD fed mice. Our ex vivo study results (Figure 5.40) demonstrated that the 
WD did significantly increase AGE protein levels in both QF and G-P-S muscle tissues of 
C57BL/6J and ApoE-/- mice, compared to the control diet fed mice, with AGE deposition being 
greater in C57BL/6J mice than in ApoE-/- mice. Similar results showing increased level of AGE 
following high fat/high sugar diet feeding have been reported in aorta and skeletal muscle by 
different groups, and linked to aortic stiffening and muscle fiber atrophy, respectively286;287. AGE 
has also been reported to modulate the expression level of growth factors such as VEGF288. 
Therefore, these results are consistent with our hypothesis that AGE deposition could be the 
underlying cause of dysfunctional PLGF expression in skeletal muscle tissues of WD fed mice. 
 We next tried to further identify underlying molecular mechanisms by which AGE could 
induce dysfunctional PLGF expression. We hypothesized that the RAGE-Nox2/4-TNFα pathway 
mentioned in the discussion section of the previous specific aim could be involved in AGE 
mediated signaling in skeletal muscle. We were interested in MCP-1 and HO-1 gene expression as 
well for the same reasons mentioned in the previous specific aim’s discussion section. Though we 
investigated gene expression in both muscles (QF and G-P-S), we were primarily interested in the 
QF, since vascular growth in the QF in response to vascular occlusion happens primarily by 
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arteriogenesis (whereas the G-P-S mainly undergoes angiogenesis). Our results indicated that the 
Nox4 mRNA level was significantly reduced, while the RAGE mRNA level was significantly 
increased in QF muscle of WD fed C57BL/6J mice (Figure 5.41A). However, in QF muscle of WD 
fed ApoE-/- mice (Figure 5.41B), the only significant change was a reduction in both Nox2 and 
MCP-1 mRNA. A non-significant increase in RAGE mRNA was observed as well. In the G-P-S 
muscle of C57BL/6J mice (Figure 5.42A), the Nox2 and HO-1 mRNA level was significantly 
increased, whereas in the G-P-S muscle of ApoE-/- mice (Figure 5.42B), the MCP-1 and TNF-α 
mRNA level was significantly reduced following long-term WD consumption.  
Though we were expecting an increase in RAGE mRNA in all the muscle types, due to the 
observed increase in tissue AGE level, we found a significant increase in RAGE only in the QF 
muscle of C57BL/6J mice, with a non-significant increase in ApoE-/- mice. Since there are several 
other receptors for AGE, one possible reason for this result could be that one or more of these other 
receptors (which were not examined in our study) was affected by the diet. Though RAGE is the 
most studied AGE receptor, several studies have also reported the existence of other cellular AGE 
receptors, such as oligosaccharyl transferase-48 (AGE-R1), protein kinase C (AGE-R2), and 
substrate galectin-3 (AGE-R3) whose expression level may have varied with the WD 
consumption169;289. The lack of change in RAGE expression in G-P-S muscle is consistent with 
possible involvement of other AGE receptors in our model.  
As described above, the Nox2, Nox4, and MCP-1 mRNA level was significantly reduced, 
while the expression of other genes (HO-1, TNF-α) was not significantly changed in QF muscle of 
either of the mouse strains. This results may indicate that our proposed signaling pathway of Nox 
mediated oxidative stress generation leading to inflammatory cytokines (TNF-α and MCP-1) 
production does not mediate dysregulated PLGF expression in WD fed mice QF muscle. AGE has 
been found to modulate the activities of xanthine oxidase (XO) and uncoupled endothelial nitric 
oxide synthase (eNOS) through AGE receptor interaction, both of which are other potential sources 
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of oxidative stress171;172. AGE also induces expression of several other inflammatory molecules and 
chemokines such as interleukin (IL)-6, -8, CCL-3, and -4290;291. IL-6 and CCL-4 have been reported 
to modulate expression of growth factors such as VEGF292;293. Therefore, the involvement of other 
signaling pathways not tested in the current study could be a possibility.  
In G-P-S muscle of C57BL/6J mice, although expression of pro-oxidant Nox2 increased, 
anti-oxidant HO-1 expression also increased. HO-1 is a cytoprotective enzyme that can inhibit Nox 
activity, thereby reducing oxidative stress294;295. In G-P-S muscles of ApoE-/- mice, neither Nox2 
nor Nox4 gene expression was affected, but expression of mRNA for the inflammatory molecule 
TNF-α and chemoattractant protein MCP-1 was significantly reduced after WD consumption, 
compared to CD. These results of G-P-S muscle may indicate the existence of an inhibitory 
pathway that acts to limit Nox generated oxidative stress and subsequent inflammation.  
The differing results from QF and G-P-S muscle are consistent with the different types of 
vascular growth that occur within each tissue in response to vascular occlusion. QF is composed of 
four muscles, whereas G-P-S consists of three separate muscles. The capillary distribution or 
vascular growth is different in each section of these muscles. This could be a reason for differing 
gene expression in QF and G-P-S muscle. Another possible reason could be the low number of 
experiments (n=3-5/group) conducted for gene analysis. However, as it was difficult to identify a 
clear pattern of gene expression overall, analysis of protein levels for the target factors could 
provide more clear insights into the involvement of these factors in mediating WD-induced 
inhibition of PLGF expression. Further studies are also needed to examine other candidate signaling 
pathways that could contribute to this response. 
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CHAPTER VII 
 
 
CONCLUSION 
 
The major goals of this study were to investigate the effects of physiologically relevant 
dynamic shear stress, cell-cell communication, and type 2 diabetes-associated metabolic factors on 
platelet and EC activities. This study was divided into two parts: study 1 and study 2. Study 1 
focused on understanding how changes in platelet and EC behavior (expression of adhesion ligands 
and inflammatory molecules) during dynamic shear exposure can contribute to CAD progression. 
Study 2 focused on the role of platelets and EC in arteriogenesis during diabetic CAD/PAD (in 
terms of their production, uptake, and/or release of key arteriogenic growth factors). Associated 
signaling pathways and the underlying molecular mechanisms modulating these processes were 
investigated as well.  
Results from in vitro and ex vivo study of stimulation of endothelial cells (EC) in the 
absence/presence of platelets under physiologically relevant dynamic shear stress (simulating 
conditions in both healthy and diseased left coronary arteries) showed that presence of both the cell 
types can greatly affect each other’s activities. Our results further demonstrated that shear stress 
type (constant or dynamic), magnitude (low or elevated), and exposure duration are important 
modulators of the cellular activation level. Platelet surface PECAM-1 expression was increased in 
the presence of EC, while platelet surface GPIbα and GPIIb expression was decreased by dynamic 
shear exposure. The presence of platelets significantly increased EC soluble vWF expression and
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microparticle (EMP) generation. Overall, these results demonstrated that platelet-EC interaction 
can modulate platelet and EC activation level in vitro. Platelets enhance dynamic shear induced EC 
activation, which then through platelet-EC signaling crosstalk tries to return the activation level 
towards the equilibrium level by modulating platelet activation. This result was further confirmed 
through an ex vivo study, where EC activation (vWF, ICAM-1) was found to be modulated by 
dynamic shear exposure compared to non-sheared controls.  
Next, the study addressed the question of whether the EC activation response was mediated 
through MAPK and NF-κB pathway activation. Our findings indicated the involvement of the 
MAPK and NF-κB pathways modulating EC responses to dynamic shear exposure. However, 
further experiments with inhibitors are needed to confirm the involvement of the MAPK pathway 
in modulation of NF-κB activities.  
In study 2, the first goal was to characterize the uptake/release of key endothelial growth 
factors (PLGF and VEGF) by platelets, and to test whether these processes could be modulated by 
dynamic shear (simulating conditions in quiescent and remodeling coronary collateral arteries) 
exposure. Our results indicated that platelets do take up endothelial growth factors. However, we 
could not demonstrate any effect of dynamic shear stress, calcium chelation, or hyperglycemia on 
platelet uptake or release of exogenous growth factors. The relatively low concentration level of 
these treatments, low number of experiments, and/or the relatively short time frame are potential 
limitations of this study.  
The next aim was to quantify the effect of major metabolic dysfunctions associated with 
type 2 diabetes (such as hyperlipidemia, acute hyperglycemia, chronic hyperglycemia, 
hyperinsulinemia, or oxidative stress) on modulation of PLGF and VEGFR1 expression by mouse 
and human cardiac and skeletal muscle cells. The goal of these studies was to identify which of the 
tested metabolic parameters had the greatest negative influence on PLGF expression at the cellular 
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level. Results from this study identified acute hyperglycemia and chronic hyperglycemia (resulting 
in AGE formation) as the major contributors to impaired PLGF expression in diabetic cardiac and 
skeletal muscle cells, suggesting that this phenomenon could contribute to impaired arteriogenesis 
in diabetic patients. Also, this study identified human coronary artery endothelial cell (EC) as the 
major source of PLGF in the heart. Based on our results, we hypothesized that oxidative stress 
could lead to an overall PLGF reduction in heart, since oxidative stress reduced PLGF expression 
in EC. In type 2 diabetics, this decrease could be additive to the decrease in PLGF produced by 
hyperglycemia/AGE. Lastly, comparison between mouse and human cell results yielded the 
interesting observation that PLGF expression is more sensitive to metabolic dysfunction in mouse 
cells than in human cells.  
Next, the effect of acute and chronic hyperglycemia (simulated by glucose and AGE 
administration) on dynamic shear stress stimulated EC PLGF expression was assessed. We also 
attempted to identify signaling pathways involved in this response. Results from this aim 
demonstrated that elevated shear stress of coronary collateral arteries significantly increases PLGF 
production by co-cultured EC and the presence of glucose or AGE negatively modulate dynamic 
shear stress enhanced PLGF expression, further supporting our hypothesis that glucose and AGE 
are the major inhibitors of cardiac arteriogenesis through inhibition of PLGF expression. However, 
the involvement of the specific signaling pathway which we hypothesized would contribute to this 
effect (RAGE-Nox2/4-TNF-α) could not be confirmed through gene expression analysis.  
In the final part of our study, validation of the above in vitro study results was taken to the 
next level through an ex vivo study. The goal of this aim was to discover underlying mechanisms 
that contribute to dysfunctional PLGF expression in Western diet (WD) fed mouse skeletal muscle. 
Based on in vitro results, we quantified the AGE protein level in skeletal muscle tissues. Our 
findings showed a significantly increased level of AGE in skeletal muscle tissues of WD fed mice, 
compared to control diet (CD) fed mice. Assessment of pathways potentially involved in AGE 
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mediated signaling suggested that AGE receptors not tested in the present study (such as AGER1 
and AGER2) may act in conjunction with RAGE to mediate activation of downstream AGE-
induced signal transduction pathways leading to decreased PLGF expression. Our gene expression 
results testing potential involvement of Nox2, Nox4, TNF-α, and MCP-1 were inconsistent and 
study of these factors at the protein level, along with investigation of additional possible signaling 
mechanisms, is needed.  
Summarizing all these results, it can be concluded that platelet and EC interaction under 
conditions of dynamic shear stress exposure can modulate both platelet and EC functions. Dynamic 
shear exposure can increase platelet surface PECAM-1 expression in the presence of EC, which 
can initiate an inhibitory mechanism that reduces platelet surface GPIbα and GPIIb expression. 
Activated platelets can enhance shear-induced EC activation, as an increased level of EC-released 
soluble vWF and EMP generation was observed in the presence of platelets. Our ex vivo study 
showed downregulation of EC activation through reduced EC vWF and ICAM-1 expression 
following dynamic shear exposure. In addition, dynamic shear stress has been found to modulate 
EC signaling pathways, i.e. the MAPK and NF-κB pathways. All these results demonstrate that 
dynamic shear stress exposure and platelet-EC crosstalk can induce platelet activation, which in 
turn enhances shear induced EC activation. Activated platelets and EC then work together to 
attempt to return the activation level towards its equilibrium level by inhibiting each other’s 
activation. These interactions may contribute to CAD development. Additionally, activated 
platelets and EC can also modulate arteriogenesis. Platelets can take up growth factors (PLGF and 
VEGF-A) in a dose-dependent manner, making them potential transporters of growth factors. 
Activated EC can produce PLGF, as shear stress stimulated EC were found to express a 
significantly higher level of PLGF compared to static control EC. However, the presence of 
conditions simulating type 2 diabetes was found to reduce PLGF production by stimulated EC. 
Among the different metabolic dysfunctions (hyperlipidemia, hyperglycemia, hyperinsulinemia, 
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and oxidative stress) associated with diabetes, simulated acute (glucose treatment) and chronic 
(AGE treatment) hyperglycemia, and oxidative stress were found to be the major negative 
modulators of EC PLGF production. Along with EC, these metabolic parameters (acute and chronic 
hyperglycemia) also modulated PLGF expression by cardiac myocytes and skeletal muscle cells 
(both mouse and human). These findings suggest that hyperglycemia and long-term hyperglycemia 
resulting in AGE formation can contribute to impaired arteriogenesis in both diabetic cardiac and 
skeletal muscles through reduction of PLGF expression during CAD/PAD. Ex vivo study of mouse 
skeletal muscle tissues (QF and G-P-S) further supports our hypothesis that deposition of AGE is 
the underlying reason for dysfunctional PLGF expression in diabetic skeletal muscle. 
Overall, the results obtained from this study have advanced our knowledge of how platelets 
and EC interact with each other in various physiological and pathophysiological settings, including 
dynamic shear stress and diabetes associated metabolic dysfunction. Our results suggest that these 
interactions can contribute to both CAD development and arteriogenesis. Thus, this study has the 
potential to lead to eventual therapeutic innovations. 
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APPENDICES 
 
 
 
Platelet adhesion to EC 
 
Figure: White light images of platelets adhering to EC. Platelets and EC were exposed to 
dynamic shear stress waveforms of left coronary artery and TNF-α treatment for 1 hr. Small 
black dots are the platelets. Images were taken in 40X magnification. Bars represent 100 
μm. 
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vWF, ICAM-1, and TF protein expression 
  
Figure: Top panel: H&E stained cross sections of control and sheared (exposed under 
dynamic shear stress waveforms of left coronary artery) aorta. Images indicate that shear 
stress exposure did not damage the aorta wall, as the vessel wall morphology looks intact. 
Bottom three panels: EC activation visualized through vWF, ICAM-1, and TF 
immunostaining on cross sections of control and shear stress (normal, low, and elevated) 
exposed (for 2 hr) aortas. All images were taken at 10X magnification. (Scale bar: 100 
µm).  
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Levels of ERK1/2, JNK, and p38 phosphorylation of EC in presence of platelets 
 
 
Figure: Normalized phosphorylated ERK1/2 levels in EC exposed to normal or low shear 
stress without (A) or with (B) platelets. Increased level of phosphorylated ERK1/2 was 
observed in the presence of platelets. A decreasing phosphorylation trend was also 
observed in the presence of platelets with increasing shear exposure time. Data are 
presented as Mean+SD. (*- significantly different than the level of phosphorylation of non-
sheared control EC. P<0.05, one-way ANOVA). 
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Figure: Normalized phosphorylated p38 (top panel) and JNK (bottom panel) levels in EC 
exposed to normal shear (NS) or low shear (LS) stress for 30 min or 60 min in presence of 
platelets. Presence of platelets increased p38 and JNK phosphorylation level in EC at both 
time points compared to the corresponding expressions of EC sheared in absence of 
platelets. Data are presented as Mean+SD. (*- significantly different than the level of 
phosphorylation of non-sheared control EC incubated in presence of platelets. P<0.05, one-
way ANOVA). 
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Phosphorylated NF-κB (p65) activation of EC in presence of platelets 
 
Figure: Normalized phosphorylation level of NF-κB of EC exposed to dynamic [normal 
(NS) or low (LS)] shear stress in presence of platelets (Plt). NF-κB phosphorylation level 
reached the peak within 2 min of shear exposure and decreased with further shear exposure 
duration. Data are presented as Mean+SD. More experiments were needed to reach a 
definite conclusion. 
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EC surface VEGFR1 and VEGFR2 expression 
 
 
Figure: VEGFR1 and VEGFR2 expression on EC surface following exposure to normal 
(NS) or elevated (ES) dynamic shear waveforms of coronary collateral artery for 1 hr. Post-
shear, samples were incubated for 0, 2, or 4 hr prior to quantification of VEGFR1 and 
VEGFR2 expression. All mean fluorescence intensity values were normalized to the 0 hr 
static control sample. Data are presented as Mean+SD.  
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Figure: Effect of normal (NS) and elevated (ES) dynamic shear stress of coronary collateral 
artery on EC surface VEGFR1 expression in the absence or presence of platelets (Plt), 
assessed 0, 2, or 4 hr after shear exposure. EC surface VEGFR1 expression was not 
upregulated by dynamic shear stress in the presence of platelets. Data were normalized to 
the 0 hr static control EC and are presented as Mean+SD.  
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Figure: Effect of normal (NS) and elevated (ES) dynamic shear stress of coronary collateral 
artery on EC surface VEGFR2 expression (normalized to 0 hr static EC expression) 
assessed 0, 2, or 4 hr after 1 hr shear exposure without or with platelets (Plt). EC surface 
VEGFR2 expression was not upregulated by shear in the presence of platelets. Data are 
presented as Mean+SD.
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